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Cellular iron and copper homeostasis is interdependent with mitochondrial iron
and copper homeostasis. Mitochondria must import iron to form iron-sulfur clusters and
heme, while it must import copper for usage and storage. These cofactors are
incorporated into mitochondrial proteins that support essential functions, including
cellular respiration and maintaining redox homeostasis. In turn, mitochondria also
provide heme to the cell and enables the biogenesis of cytosolic iron-sulfur cluster
containing proteins, while also providing copper when needed. Due to both metals (and
their modified species) reactivity, iron and copper are stored and trafficked within the
mitochondria carefully. Although these cofactors are crucial for mitochondrial
homeostasis, mechanistic details are lacking regarding the meticulous process of iron and
copper transport.
With the goal in mind to determine the mitochondrial factors necessary for proper
heme biosynthesis and transport within the mitochondrion, our lab investigated the
physical and genetic interactions of the terminal heme biosynthetic enzyme
ferrochelatase, Hem15. These analyses revealed a dynamic association between Hem15
and the core component of the mitochondrial contact site and cristae organizing system

(MICOS) Mic60. The loss of Mic60 negatively impacts Hem15 activity, affects the size
of the Hem15 high mass complex, and results in the accumulation of reactive and toxic
tetrapyrrole precursors. Furthermore, using fluorescent heme sensors, our lab determined
that heme is trafficked to the nucleus approximately 25% faster than to the cytosol and
mitochondrial matrix. We, also, discovered that mitochondrial heme efflux to the nucleus
is regulated by the initial heme biosynthetic enzyme and GTPases that control
mitochondrial dynamics and endoplasmic reticulum contact sites.
Lastly, we probed the copper cofactor site assembly within cytochrome c oxidase.
To this end, we determined that human cytochrome c oxidase copper chaperones form
macromolecular assemblies and cooperate with several twin-CX9C proteins to control
heme a biosynthesis and coordinate copper transfer to the CuA and CuB sites. Taken
together, these results provide insight for the meticulous transport of iron-containing
cofactors and its precursors and copper within the mitochondria.
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CHAPTER 1: INTRODUCTION

Note: Portions of this chapter are to be published with the citation:
Dietz, J.V., Fox, J.L., and Khalimonchuk, O. Down the Iron Path: Mitochondrial Iron
Homeostasis and Beyond. Cells, 2021, 10, 2198.

1.1 Cellular Homeostasis of Iron and Copper
1.1.1 The Role of Iron and Copper in Cells
The transition metals iron (Fe) and copper (Cu) are essential for life, from bacteria to
humans. Typically found as cofactors in proteins, these metals are indispensable for
enzymes involved in mitochondrial respiration, free radical scavenging, oxidative stress
response, DNA synthesis, gas sensing and transport, cell death, pigmentation, ion
homeostasis, cofactor biosynthesis, and neurotransmission (1-7). The ability of Fe and Cu
to participate in redox reactions and to exist at varying oxidation states permits the
versatility of these cofactors in biological settings. Moreover, Fe and Cu are highly
reactive and can participate in Fenton chemistry-like reactions in biological systems
which promotes the production of reactive oxygen species (2, 4, 8). Appropriately
balancing the redox reactivity of Fe and Cu is imperative to cellular and organismal
health. Perturbations in Fe and Cu homeostasis manifest in a vast spectrum of disorders.
Oftentimes these maladies result from mutations, which can occur in any one of a large
number of genes. The most common iron-related clinical manifestations result from Fe
deficiency and, in the most severe cases, are diagnosed as one of numerous anemias (6, 9,
10). Some Fe-related disease result from iron accumulation or overload, such as
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hemochromatosis and iron-loading anemias -- thalassemia, congenital dyserythropoietic
anemia, sideroblastic anemias, and myelodysplastic syndrome (11-15). Both iron
overload and deficiency are associated with adverse patient outcomes including
cardiovascular disease, cognitive impairment and neurodegeneration, organ failure,
diabetes mellitus, and various cancers (16-33). Defects in the biosynthesis of the ironcontaining heme causes hereditary porphyria diseases, while mutations in the genes
required for iron-sulfur cluster (ISC) biogenesis also result in human disease (34, 35).
Disturbances in Cu homeostasis are linked to Menkes’ disease, Wilson’s disease,
Alzheimer’s disease, Parkinson’s disease, anemias, myelopathy, neuropathy, diabetes,
and cardiovascular diseases and disorders (36-44). Due to these characteristic and the
importance of these cofactors, Fe and Cu transport and metabolism must occur in a
highly regulated and meticulous way.
1.1.2 Cellular import and trafficking of Fe and Cu
1.1.2.1 Fe import across the plasma membrane
Due to the reactivity of Fe through Fenton chemistry-like reactions, Fe metabolism
and transport are meticulously orchestrated by transport molecules (8). Fe acquired
through the diet is taken up by enterocytes via plasma membrane-bound divalent metal
transporter 1 (DMT1) or, in the case of heme, one of the plasma membrane heme
importers. Feline leukemia virus subgroup C receptor-related (FLVCR) protein 2 and
heme carrier protein 1 (HCP1) have been identified as heme importers in mammals, but
the roles in heme transport and heme transporting mechanisms are debated (45-47). Fe
not used by those enterocytes is exported into bodily fluids by the transporter ferroportin.
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In vertebrates, circulating ferric Fe (Fe3+) in the bloodstream is bound to the plasma
Fe-transport protein transferrin (Tf). To deliver Fe to tissues, Tf binds to the transferrin
receptor (Tfr) on the cellular membrane of the target cell. The Fe-loaded Tf-TfR
assembly is endocytosed, and Fe is released into the endosome, where it is reduced to the
ferrous (Fe2+) state (48-51). The plasma membrane metal ion transporter ZIP14 has been
shown to participate in he uptake of both transferrin-bound and non-transferrin-bound Fe
(52, 53). Plasma heme and hemoglobin serve as alternative Fe sources since they too can
be endocytosed from blood plasma. From the endosome, Fe relocates to the cytosol via
DMT1 (54).
In unicellular eukaryotes such as budding yeast, Saccharomyces cerevisiae, Fe is
imported through several pathways. Fe import can be mediated by the Fet3/Ftr1 complex
on the plasma membrane, which functions with high affinity for Fe and is Cu dependent
(55, 56), or by a low-affinity Fe import pathway, which involves the plasma membrane
proteins Smf1 and Fet4 (57, 58). Like some prokaryotes, budding yeast can also take up
Fe that is siderophore-bound in a process mediated by the ARN family transporters (59).
Unlike in metazoans, exogenous heme uptake pathways in S. cerevisiae are not efficient,
so heme supplies a negligible amount of Fe. Once within the cell, Fe is stored in the
vacuole until needed in the cytosol or other cellular compartments (60).
Fe in the cytosol forms the dynamic reservoir known as the cytosolic labile Fe pool
(CLIP). The CLIP consists of ferrous Fe either stored within the protein ferritin
(particularly in the liver in mammals) or chelated by low-molecular mass ligands to form
complexes. In S. cerevisiae and higher-order eukaryotes, small molecules such as citrate,
cysteine, and reduced glutathione have been proposed to serve as these ligands. To date,
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glutathione appears to be a strong candidate as an Fe ligand, based on in vitro studies and
studies in S. cerevisiae (61). Fe from the CLIP can be utilized in the cytosol to metalate
proteins or form ISCs, but most Fe is directed to mitochondria (62-64).
1.1.2.2 Cu import across the plasma membrane
Similar to Fe in vertebrates, diet is the primary source of Cu, and it is distributed
throughout the organism in a bound-state - to ceruloplasmin or albumin (65). Cu import
across the plasma membrane is mediated by the highly conserved, high-affinity plasma
membrane Cu transporter CTR1 (SLC31A1) (66). In serum, Cu is in the cupric state
(Cu2+) and CTR1 only binds to cuprous Cu (Cu1+) so the cofactor must be reduced prior
to binding to CTR1. The reduction of Cu is likely mediated by the plasma membranebound STEAP proteins which have been shown to exhibit Cu reductase activity (67).
Unlike the primary import mechanism for cellular Fe uptake, Cu bound to CTR1 is not
endocytosed. Instead, CTR1 accepts Cu from either ceruloplasmin or albumin and acts as
a pore for Cu to permeate through the plasma membrane (68). In addition to CTR1mediated import, Cu influx is mediated by other pathways. The CTR1 homolog, CTR2,
was originally characterized as a low-affinity plasma membrane Cu transporter, but
recent studies suggest that it participates in intracellular vesicular Cu transport (69-71).
DMT1 may also contribute to Cu import, as it does with Fe, but its role in Cu
homeostasis appears to be tissue- and condition-specific (72,73). In intestinal epithelial
cells and erythrocytes, anion exchange transporters are proposed to participate in Cu
transport across the plasma membrane. For Cu to utilize the anion exchange transporters,
it must be oxidized (Cu2+) and coordinated in an anionic low molecular weight complex
(66, 74, 75).
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Once Cu has crossed the plasma membrane, it is either bound to a cytosolic ligand or
accepted by the cytosolic Cu transporters ATOX1 and CCS and distributed to various
subcellular compartments (nucleus, mitochondria), other Cu chaperones (P-type ATPases
ATP7A and ATP7B), and cuproenzymes (Cu, Zn-superoxide dismutase) (76-81).
Cellular export pathways for Cu have been identified. Under high Cu concentrations,
ATP7A localizes to the plasma membrane to promote Cu efflux (82). Moreover, the
amyloid precursor protein has been hypothesized to contribute Cu efflux, but the
mechanism is currently unknown (83).
Cu internalization in S. cerevisiae is comparable to vertebrate Cu plasma membrane
import. In budding yeast, Cu is transported across the plasma membrane by Ctr1 and Ctr2
transporters, which are homologous to human CTR1 and functionally redundant (84, 85).
Furthermore, the low-affinity Fe transporters Fet4 and Smf1 also exhibit low-affinity
transport activity for Cu. The Cu permease Ctr2 can localize to the plasma membrane and
facilitate Cu import; however, this protein primarily localizes to the vacuole to
orchestrate vacuolar Cu export (84). The mammalian Cu metallochaperones ATOX1 and
CCS that accept Cu in the cytosol are also conserved in S. cerevisiae and are called Atx1
and Ccs1 respectively (79, 86). Cu bound to Atx1 is targeted to the P-type ATPase Ccc2
in the trans-Golgi network and to the Cu-ligand pool (86-88). Ccs1 specifically transfers
Cu to superoxide dismutase 1 (SOD1) (89). One of the primary targets and site of
utilization for ligand bound Cu and for Fe is the mitochondria, wherein it drives
mitochondrial function and homeostasis.
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1.2 The role of Fe and Cu in mitochondrial homeostasis
1.2.1 Fe and Cu utilization and function in mitochondria
Fe and Cu are required for the primary function of mitochondria – ATP production.
Working together, these two metals maintain and drive proper mitochondrial
bioenergetics and ion homeostasis. In mitochondria, Fe is primarily found in the form of
heme or ISC, which are both synthesized in the mitochondrial matrix. Heme and ISC are
prosthetic groups in electron-transfer flavoproteins, NADH:ubiquinone oxidoreductase,
Rieske ISC protein, subunits of succinate dehydrogenase, aconitase, lipoic acid synthase,
cytochromes bc1 and c, cytochrome c oxidase, and several other mitochondrial proteins.
Each of these enzymes is critical for mitochondrial energy production (64). Unlike Fe,
Cu-containing proteins are much less prevalent in the mitochondrial proteome as only
two are currently known – SOD1 and cytochrome c oxidase (CcO). SOD1 predominantly
localizes to the cytosol, but a small fraction of the total SOD1 pool functions in the
mitochondrial intermembrane space where it is responsible for the sequestration of
superoxide (90). In CcO, Cu cooperates with heme to transfer electrons from cytochrome
c to O2 producing H2O, ultimately contributing to the proton motive force which drives
ATP production by ATP synthase (91, 92). In addition to acting as cofactors for various
enzymes, Fe and Cu are also stored in the mitochondria within mitochondrial ferritin for
Fe or in low molecular weight complexes for Fe and Cu (80, 93, 94). Like the cellular
import and movement of Fe and Cu, mitochondrial Fe and Cu import and transport are
highly regulated, meticulous processes designed to limit unwanted reactivity of the metal
ions.
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1.2.2 Fe and Cu delivery to mitochondria
Mitochondria are one of the primary targets for Fe and Cu in cells. As mentioned
above, Fe can be found in ISC and heme (along with their biosynthetic pathway
machinery) or in storage (95, 96). Cu, on the other hand, is either stored in low molecular
weight anionic complex (CuL) in the mitochondrial matrix or within SOD1 and
cytochrome c oxidase subunits – Cox1 and Cox2 (80, 90-92, 94). Currently, no
mechanism is known for Cu delivery to mitochondria or for Cu transport across the outer
mitochondrial membrane (OMM) (Fig. 1.1). The mitochondrial Cu-chaperone Cox17 was
originally postulated to import Cu into mitochondria during protein import, but yeast
lacking COX17 exhibit no changes in mitochondrial Cu levels, and COX17 tethering to
the inner mitochondrial membrane (IMM) in yeast had no effect on mitochondrial Cu
homeostasis (80, 97-100). Furthermore, it is speculated that Cu diffuses across the OMM
in a low molecular weight anionic complex, bypassing the OMM ion channels that are
hypothesized to orchestrate Fe transport across the OMM (65).
In contrast to Cu, Fe delivery and transport across the OMM has been extensively
investigated (Fig. 1.1). In mammalian cells, several pathways have been identified,
including endosome-mitochondria “kiss and run”, fluid-phase endocytosis,
interorganellar contact sites, transport from cytosolic labile Fe sources, and
metallochaperone delivery. However, they remain poorly understood. The endosomemitochondria “kiss and run” interaction is primarily found in developing erythrocytes but
also demonstrated in epithelial cells. This method utilizes a direct, transient,
interorganellar interaction between Fe-loaded Tf-containing endosomes and mitochondria
to provide mitochondria with the excessive amounts of Fe required for hemoglobin and
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heme synthesis during erythropoiesis (101-103). This direct transfer of Fe from one
organelle to another bypasses cytosolic diffusion of Fe, preventing the production of
reactive oxygen species via Fenton chemistry.
Another method of Fe transfer to mitochondria that bypasses the cytosol and the
CLIP is fluid-phase endocytosis. This pathway, proposed to occur in cardiac cells,
occludes solvent from Fe to directly deliver non-Tf-bound Fe to mitochondria. The
limited effect of chelating cytosolic Fe on mitochondrial Fe uptake supports this fluidphase endocytosis model (104-106).
The lysosome (and lysosome-like vacuole in yeast) has recently been implicated in
mitochondrial Fe import and homeostasis. In erythrocytes, it appears that Fe is directly
conveyed to mitochondria at lysosome-mitochondria membrane contact sites to promote
heme biosynthesis during erythropoiesis (107). In yeast and mammalian cell culture,
disruptions to vacuolar and lysosomal homeostasis via an increase in alkalinity impairs
mitochondrial Fe uptake, solidifying the role of the lysosome and vacuole in
mitochondrial Fe import and homeostasis (108-111).
Mitochondria also obtain Fe from the CLIP. Low-molecular mass Fe complexes such
as Fe(ATP)2, Fe-citrate, Fe-glutathione, and Fe chelated by the mammalian siderophore
2,5-dihydroxybenzoic acid (112-114) may be imported into mitochondria, though the
impact of glutathione and 2,5-dihydroxybenzioc acid on mitochondrial Fe import has
been contested (106). The process of transferring Fe from the CLIP to mitochondria is
dependent on the mitochondrial membrane potential (115, 116).
Fe trafficking is proposed to involve the coordination of Fe to chaperone proteins.
This mode of transportation is not unprecedented since metallochaperones for Cu (CCS)
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and Atox1) have long been identified (117), as have several Fe-specific
metallochaperones. Two classes of chaperones, poly(rC)-binding proteins (specifically
PCBP1 and PCBP2) and monothiol glutaredoxins, which have been extensively studied
for their roles outside of Fe metabolism, have recently been the focus of Fe trafficking
research. PCBP1 and PCBP2 were initially identified as RNA-binding proteins required
for splicing, transcript stabilization, and translational regulation. More recently, they have
been shown to act as Fe chaperones to deliver Fe to ferritin and for metalation of
cytosolic proteins (118, 119). Glutaredoxins are glutathione (GSH)-dependent redox
enzymes necessary for DNA synthesis, protein folding, signal transduction, and reactive
oxygen species defense. In yeast, deletion of glutaredoxin 3 and glutaredoxin 4 results in
mitochondrial iron deficiencies and impairments in both ISC and heme biogenesis.
Additionally, the interaction between glutaredoxin and bovine lymphocyte antigen-like
protein is required for iron delivery to mitochondria (120, 121).
Once iron is delivered to mitochondria by one of the aforementioned pathways, it
must cross both the outer (OMM) and inner (IMM) mitochondrial membranes. The exact
mechanism for iron transport across the OMM remains undetermined, but some factors
have been speculated. Voltage-dependent anion channels (VDACs) are widely
hypothesized as mitochondrial iron channels throughout eukaryotes; however, their
proposed role in mitochondrial iron import relies entirely on their prevalence,
involvement in other energy-related metabolite channeling, and role in transport of other
divalent cations (122). Recent studies show that mitochondrial isoforms of DMT1
facilitate iron influx to mitochondria in several cell types, expanding the role of DMT1 in
iron homeostasis beyond enterocyte iron uptake and endosomal iron export (122, 123).
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The aforementioned iron chaperone PCBP2, which interacts with DMT1 and with
ferritin, may transport iron to other cellular compartments such as mitochondria (119).
1.2.3 Fe and Cu transport at the inner mitochondrial membrane
1.2.3.1 Fe transport at the inner mitochondrial membrane
Unlike import across the OMM, IMM Fe and Cu import is relatively well-studied
(Figure 1.2). Fe transport across the IMM is dependent on proper mitochondrial
membrane potential (115). Initial discoveries for the mechanism of Fe transport across
the IMM were completed in yeast, where the mitochondrial solute carrier proteins,
mitoferrins Mrs3 and Mrs4, are directly involved in IMM and matrix Fe supply (125,
126). Mrs3 and Mrs4 are highly conserved from fungi to mammals and are members of a
family of proteins required for IMM metabolite transport (127-136). Mitochondrial Fe
levels and heme and ISC biogenesis are directly dependent on Mrs3 and Mrs4 expression
(125, 126, 137, 138). Furthermore, genetic expression of Mrs4 is dependent on Fe
concentration and ISC synthesis (139, 140). However, the mechanism by which these two
proteins transport Fe across the IMM is presently unknown. Interestingly, it has been
posited that Mrs3 and Mrs4 may also transport Cu2+ into the mitochondrial matrix (141,
142).
Mrs3 and Mrs4 are non-essential proteins, while their deletion only being lethal in
low Fe conditions, suggesting that compensatory Fe uptake mechanisms must exist for
the IMM (125, 143). Genetic screens in yeast mutants with defective mitochondrial Fe
homeostasis identified the known pyrimidine transporter Rim2 as a low-affinity
mitochondrial Fe transporter (143-145). Overexpression of Rim2 recovers heme and ISC
biosynthesis deficiencies and growth defects exhibited in mrs3∆ mrs4∆ double mutants
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(143, 145-147). Whether Rim2 follows the trend of other mitochondrial carrier proteins
by co-transporting substrates remains to be determined (143, 145, 148, 149). Deletion of
Rim2 minimally affects mitochondrial Fe homeostasis, but deletion of RIM2 in parallel
with MRS3 and MRS4 deletions exacerbates ISC maturation defects (144, 145).
Additional genetics screens were performed to identified other IMM Fe transporters.
However, no candidates suppressed the phenotypes of Mrs3/Mrs4-deficient yeast like
Rim2, thus it was postulated that small levels of Fe nonspecifically enter mitochondria,
allowing triple deletion mutants to survive (150).
In mammalian cells, two paralogous proteins, mitoferrin 1 (MFRN1) and mitoferrin 2
(MFRN2), which are functionally complementary to and homologous to Mrs3 and Mrs4
(∼35% identity with Mrs4) (128, 151), are responsible for Fe transport across the IMM
(128, 132). MFRN1 is the primary IMM Fe transporter in differentiating erythrocytes,
partly due to its extended half-life (128, 132). Clinically, the loss of MFRN1 causes
erythropoietic protoporphyria due to its defects in heme biosynthesis (128, 152, 153).
While the exact mechanism it employs to transport Fe across the IMM remains elusive,
MFRN1 is stabilized by (and mitochondrial Fe import enhanced by) an interaction with
the IMM ATP-binding cassette (ABC) transporter ABCB10, which is likewise highly
expressed in erythroid cells (154). These two proteins associate with the final heme b
biosynthetic enzyme ferrochelatase (FECH), likely bolstering heme synthesis during
erythropoiesis by stabilizing MFRN1 and funneling Fe directly to FECH for integration
into protoporphyrin IX to produce heme b (155). Interestingly, in hepatocytes, ABCB10
has a very different role as a mitochondrial biliverdin exporter to promote the
regeneration of the antioxidant bilirubin (156).
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In contrast to MFRN1, MFRN2 is expressed in all vertebrate tissues (with highest
expression in heart, skeletal muscle, liver, and kidney) and is the primary IMM Fe
importer of non-erythroid cells (128, 151). MFRN2 levels are increased in mouse models
for Friedrich’s ataxia, the Fe dysregulation disease associated with mutations in the
mitochondrial protein frataxin (FXN), and in patients with muscle-specific mitochondrial
Fe accumulation in ISC deficiency-related human diseases (157-162).
In conjunction with the mitoferrins, the mitochondrial calcium uniporter (MCU) may
play a role in IMM Fe transport as well. Several studies have provided evidence that
inhibition of MCU-mediated calcium entry prevents mitochondrial Fe uptake (32, 116,
163).
Another group of mitochondrial proteins required for proper mitochondrial iron
homeostasis has recently been uncovered: the sideroflexins (SFXN). This family of five
IMM proteins is hypothesized to act as either channels or carrier proteins (164, 165).
Reduced sideroflexin expression (of SFXN4) or loss of sideroflexin function (of SFXN1)
results in impaired erythropoiesis (165, 166), but the precise roles of the sideroflexins in
erythropoiesis remain to be determined. While SFXN1 was initially identified as a serine
transporter, further analyses revealed it also participates in mitochondrial respiratory
complex III biogenesis, activity, and assembly (167, 168). SFXN4 deficiency impairs
respiration in zebrafish, and its role has been predicted to be related to mitochondrial
respiratory complex I assembly, with recent studies suggesting it is required for ISC
biogenesis (166, 169).
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1.2.3.2 Cu transport at the inner mitochondrial membrane
Cu transport across the IMM mediates Cu storage in the mitochondrial matrix since
Cu is predominantly used in the IMS (80, 90-92, 94). In budding yeast, Cu is transported
within mitochondria in complex with a low molecular weight molecule, termed CuL. The
phosphate carrier Pic2 was recently implicated in Cu mitochondrial matrix import. Pic2deficient cells were unable to grow and respire in the presence of Cu competitors and
exhibited lower mitochondrial Cu levels and uptake rates (170). Moreover, Pic2 deletion
does not completely ablate mitochondria matrix Cu uptake so an alternative pathway
must exist. Interestingly, the deletion of the Fe import factor Mrs3 also induces growth
defects under Cu-dependent growth conditions. Mrs3 overexpression in Pic2-deficient
yeast restores mitochondrial matrix Cu uptake and respiration. Together, these data
suggest that Mrs3 can import both Fe and Cu into the mitochondrial matrix (142).
In mammals, SLC25A3, an ortholog of Pic2, has been identified and investigated for
its role in Cu import (171, 172). In cells lacking SLC25A3, CcO and SOD1 activity were
significantly decreased. These effects were reversed when exogenous Cu was
supplemented. Furthermore, expressing SLC25A3 in yeast lacking Pic2 recovered CcO
defects and mitochondrial Cu uptake indicating that SLC25A3 mediates Cu transport
across the IMM. To date, SLC25A3 is the only known mammalian mitochondrial Cu
transporter (171, 172).
1.2.4 Mitochondrial Utilization of Fe and Cu
Fe and Cu are imperative for mitochondrial function, especially in mitochondrial
energy production. Mitochondria are also playing a key role in both Fe and Cu
homeostasis in the cell by serving as one of the main storage sites for these metals. Iron
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can be stored in mitochondrial ferritin (FTMT), a ferritin variant with high sequence
homology to the heavy chain ferritin subunit, H-ferritin (93). In humans, FTMT is
primarily expressed in testes and in sideroblasts of patients with sideroblastic anemia, but
immunohistochemical experiments have identified FTMT in the heart, spinal cord,
kidney, pancreas, and smooth muscle (93, 173-175). Like H-ferritin, FTMT also has
ferroxidase activity, but it occurs much slower than in its cytosolic paralog (176). The
expression of FTMT significantly impacts cellular iron homeostasis; increased FTMT
expression correlates to increased iron localization to mitochondria, causing
mitochondrial iron accumulation (96, 177). Iron sequestration by FTMT appears to be
protective against oxidative stress since it protects mitochondria from hydrogen peroxide,
antimycin A, and glucose-free conditions (178). Further experiments are needed to
determine the localization, mechanism of action, regulation, and role of FTMT in iron
homeostasis. In addition to storage in FTMT, iron can be sequestered in the
mitochondrial matrix within low-molecular-mass complexes to form the mitochondrial
labile iron pool (179). GSH might serve as a ligand for mitochondrial iron since it is
highly concentrated in mitochondria, is capable of chelating cytosolic ferrous iron, and
has been proposed to coordinate 2Fe-2S clusters within mitochondria (180-184). Citrate,
another highly concentrated metabolite in the mitochondrial matrix, has also been
hypothesized to function in mitochondrial iron coordination and sequestration (181, 185).
Similarly, Cu is also stored within the mitochondrial matrix liganded to an anionic
complex of unknown structure in eukaryotes such as yeast and mammals. This Cu pool is
necessary for cellular and mitochondrial Cu homeostasis (80, 94). In addition to storing
Fe, mitochondria are also the site for the synthesis and utilization of the Fe-containing
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cofactors ISC and heme. As for Cu, it is mainly used in the IMS wherein it is: (1) inserted
into the IMS-residing fraction of SOD1, and (2) assembled into CcO to form CuA and
CuB sites of the enzyme (86, 91, 92, 186, 187).
1.2.4.1 Mitochondrial Utilization of Fe – Iron-Sulfur Cluster Biogenesis and
Transport
In eukaryotes, mitochondria are essential for synthesis of all cellular ISC-containing
proteins and are the site for biogenesis of ISCs needed for mitochondrial proteins.
Composed of iron and sulfide ions, ISCs are commonly found with rhomboid [2Fe-2S] or
cubane [4Fe-4S] (and more rarely cuboidal [3Fe-4S]) geometries within ISC-containing
proteins, where the iron atoms are ligated to cysteine thiolates or nitrogen atoms from
residues such as histidine. The formation of this cofactor is critical for mitochondrial and
cellular homeostasis. ISCs are involved in electron transport (e.g., ISC-containing
subunits of the mitochondrial respiratory complexes I, II, and III), substrate binding and
enzymatic catalysis (e.g., aconitase), nucleic acid processing and repair (e.g., ISCcontaining enzymes required for DNA replication and mRNA translation), and metabolite
sensing (e.g., cytosolic regulation of iron metabolism) (188-195).
The formation of ISCs in eukaryotes occurs via two pathways, one responsible for
forming mitochondrial ISCs and one responsible for forming ISCs in the cytosol. Both
pathways are necessary for overall cellular health.
Mitochondrial ISC biogenesis entails synthesis of the ISC on a scaffold composed of
assembly proteins followed by transfer of the ISC to target apo-proteins (196). The ISC
assembly factor cysteine desulfurase (NFS1) abstracts sulfur from free cysteine in a
pyridoxal phosphate-dependent process that is activated by the binding of the protein
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ISD11 (197-200). This sulfur, held on a catalytic cysteine as a persulfide, is transferred to
the ISC scaffold protein ISCU, which directly interacts with NFS1, ISD11, and the
mitochondrial acyl carrier protein (ACP1) to form the ISC biogenesis scaffold (201, 202).
Electrons for the persulfide reduction, permitting formation of the ISC, are supplied by
ferredoxin (which is in turn reduced by ferredoxin reductase) (203-205) and iron is
supplied by an unknown mechanism (206, 207). The molecular mechanism of ISC
formation remains debated, but recent work suggests the mechanism may require iron to
bind to the scaffold before the sulfur is supplied (208, 209).
The most probable sources of the necessary iron are the mitochondrial labile iron pool
and frataxin, which can bind iron through acidic regions within the protein. Frataxin
interacts with the ISCU-NSF1-ISD11 complex and has been hypothesized to mediate iron
entry into the ISC biogenesis scaffold and/or act as a modulator for NFS1 that might
facilitate persulfide transfer to ISCU (179, 207, 210-217). Decreased expression of
frataxin impairs ISC biogenesis and iron metabolism, as seen in Friedreich's ataxia (218,
219).
Studies in yeast and bacteria have suggested additional roles for frataxin such as an
iron chaperone, an iron sensor and allosteric regulator of ISC biogenesis, or a metabolic
switch between ISC and heme synthesis. As an iron-sensor for ISC biogenesis, frataxin
acts as either a negative or positive regulator of ISC biogenesis depending on the
organism. Iron binding to frataxin in bacteria decreases the rate of ISC formation, while
eukaryotic frataxin enhances ISC formation by several mechanisms (212, 220-225). In
eukaryotes, frataxin also interacts with ferrochelatase and regulates heme biosynthesis
(226, 227). Evidence that frataxin may be acting as a metabolic switch between the
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formation of ISCs and heme cofactors includes its role in modulating both heme
synthesis and ISC biogenesis, its ability to bind to ferrochelatase and the yeast homolog
of ISCU with significantly different affinities, and its regulation by levels of
protoporphyrin IX, the precursor to heme b (228).
Following the coordinated assembly of the ISC, the cofactor is transferred from the
ISC biogenesis scaffold to target apo-proteins by a mechanism that entails a chaperone–
co-chaperone system. In higher eukaryotes, a member of the mitochondrial HSP70 family
(HSPA9), its J-type co-chaperone HSC20, and the glutaredoxin GLRX5 mediate the
transfer of ISCs to their targets. As an ATPase, HSPA9 utilizes the energy from ATP
hydrolysis to induce conformational changes in the ISC-loaded ISCU, allowing ISC
release from ISCU (188, 229, 230). The ISC is transferred to GLRX5, which in turn
transfers it to a recipient apo-protein, though in some cases apo-proteins may receive
ISCs without the intervention of GLRX5 (231, 232). Nucleotide exchange in the active
site of HSPA9 is facilitated by GRPEL1 to permit future catalytic cycles (231).
How the HSPA9-HSC20 system properly determines the targets for ISC delivery
remains to be determined. In some cases a conserved leucine-tyrosine-arginine (LYR)
motif in the recipient apo-protein or an accessory protein is recognized by HSC20 prior to
ISC loading. This appears to be the case for many of the ISC-containing electron
transport chain components (188, 233-235). The role of HSAP9 in ISC transport is still
debated, but HSC20 has been shown to directly interact with ISCU and FXN. Depletion
of this protein induces severe ISC deficits in both mitochondria and the cytosol (230,
236).

20
In addition to their use in maturation of [2Fe-2S] cluster-containing proteins, [2Fe2S] clusters can be used to produce [4Fe-4S] clusters. A dedicated complex composed of
ISCA1, ISCA2, and IBA57 is required to fuse two [2Fe-2S] clusters delivered by GLRX5
to form a [4Fe-4S] cluster in a process that requires ferredoxin and its reductase (237241). The proteins BOLA3, NFU1, and NUBPL have all been identified as ISC targeting
factors that assist in loading [4Fe-4S] clusters into particular mitochondrial proteins (232,
233, 240, 242-246). GLRX5 physically interacts with BOLA3 and BOLA1, and the yeast
homologs of both these BOLA family proteins have been shown to play a role in
maturation of [4Fe-4S] cluster proteins (247, 248).
In addition to producing ISCs for mitochondrial proteins, this mitochondrial ISC
biogenesis pathway directly enables its cytosolic counterpart, the CIA, which is required
to produce cytosolic and nuclear ISCs. The mitochondrial ISC pathway does this by
donating a sulfur-containing (and perhaps iron-containing) intermediate from the
mitochondrial matrix to the cytosol (249). Although the exact mechanism for the
transport of this intermediate is not fully understood, several studies in yeast have
provided insight into the factors involved. The ABC transporter Atm1 is postulated as the
IMM transporter of the sulfur-containing intermediate, and the intermembrane space
(IMS) sulfhydryl oxidase Erv1 facilitates Atm1-mediated transport (250, 251). In Atm1deficient yeast, cytosolic ISC biogenesis is disrupted, iron accumulates in mitochondria,
and cellular iron uptake is enhanced (249, 252). While the involvement of the human
ortholog of Atm1, ABCB7, in transporting the intermediate to the cytosol remains to be
clarified, ABCB7 has been implicated in several iron-related disorders, such as X-linked
sideroblastic anemia and ataxia (251, 253, 254). ABCB7 appears to be assisted in
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transporting the ISC intermediate by another ABC transporter, ABCB8, though the exact
nature of its involvement is presently unknown. Deletion of ABCB8 in murine heart
severely impairs cardiac function due to significant mitochondrial damage, mitochondrial
iron accumulation, and cytosolic ISC and heme deficiencies, which is a phenotype similar
to that caused by the absence of ABCB7 (253, 255-257). These ABC transporters share
similarity with the yeast mitochondrial peptide exporter Mdl1. Overexpression of Mdl1
partially rescues the phenotype of Atm1 deletion, but overall, Mdl1 is not implicated in
iron homeostasis (258-260). These data suggest that ABCB8, alongside ABCB7, may be
mediating the transfer of a sulfur-containing intermediate for cytosolic ISC biogenesis.
1.2.4.2 Mitochondrial Utilization of Fe – Heme Biosynthesis and Transport
Heme b, which is an iron ion ligated by the protoporphyrin IX tetrapyrrole, and its
biosynthetic derivatives heme c and heme a are the other vital iron-containing cofactors
produced by mitochondria and necessitating mitochondrial iron import. Hemes are
required for a plethora of processes, including oxygen transport and storage (e.g.,
hemoglobin and myoglobin), electron transfer (e.g., cytochrome c, respiratory complex
III, and respiratory complex IV), signal transduction (e.g., nitric oxide synthase), ligand
binding (e.g., horseradish peroxidase), transcriptional regulation (e.g., Rev-erbβ), and
xenobiotic detoxification (e.g., cytochrome P450) (261, 262).
The biosynthesis of heme b differs greatly from ISC biogenesis. In ISC biogenesis,
iron is present throughout much of the process, whereas in heme biosynthesis, iron is
only utilized in the final step wherein it is incorporated into protoporphyrin IX by
ferrochelatase. The process of heme biosynthesis has been studied extensively (45, 263266). Briefly, heme biosynthesis begins with the condensation of succinyl-CoA and
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glycine by aminolevulinic acid (ALA) synthase to produce ALA in the mitochondrial
matrix. ALA is exported to the cytosol and sequentially modified to create a cytosolic
porphyrin. This porphyrin, coproporphyrinogen III, is transported back into
mitochondria, where it is converted to protoporphyrin IX. Protoporphyrin IX and ferrous
iron are combined by ferrochelatase to produce heme b in the mitochondrial matrix (45).
Iron is proposed to be delivered directly to ferrochelatase via protein–protein interactions
with the mitoferrins (125, 126, 128, 137, 138, 155). Several enzymes in the heme
biosynthetic pathway have recently been shown to interact with each other and with
ABCB7, ABCB10, the protoporphyrinogen transporter TMEM14c, and the transferrin
receptor to form a complex termed the heme metabolon (267).
Once synthesized, heme b is used to form hemoproteins required for various
functions throughout mitochondria and other cellular compartments. The mechanism for
heme trafficking to these other locales remains unknown and the subject of ongoing
research. Recent studies using ratiometric heme sensors to study heme distribution
kinetics between cellular compartments in yeast revealed that the mitochondrial GTPases
Gem1, Mgm1, and Dnm1 modulate heme transport to the nucleus by regulating
mitochondrial architecture and endoplasmic reticulum–mitochondria contact sites (268).
Heme b destined for use within mitochondria is either added noncovalently to form
hemoproteins or covalently modified to produce heme c or heme a for use in
hemoproteins of the electron transport chain. Heme b is utilized by several mitochondrialocalized proteins, including the matrix protein neuroglobin (flavohemoglobin Yhb1 in
yeast), respiratory complex II, respiratory complex III, and yeast-specific proteins
(respiratory complex IV assembly factor Mss51, cytochrome c peroxidase Ccp1, and L-
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lactate cytochrome c oxidoreductase Cyb2) (45). To date, the mechanism of heme b
translocation to these proteins is unknown.
To form the covalently bound c-type heme found in cytochrome c (human CYCS or
yeast paralogs Cyc1/Cyc7) and the respiratory complex III subunit cytochrome c1 (human
CYC1 or yeast Cyt1), heme b is covalently bound to the hemoprotein via thioether bonds
with highly conserved cysteine residues (91, 269, 270). The process by which heme b is
transported to these heme c-containing proteins is partially understood. The mammalian
holocytochrome c synthase (HCCS) and the yeast cytochrome c heme lyases (Cyc3 and
Cyt2) are responsible for directly delivering and covalently attaching heme b to cysteines
in cytochrome c and cytochrome c1. However, the factors that mediate heme b transfer to
HCCS, Cyc3, and Cyt2 remain elusive (269, 271, 272).
In the heme a modification pathway, heme b is extensively modified via the addition
of a hydroxyfarnesyl group to one of its vinyl carbons by heme o synthase (COX10) and
the conversion of a methyl group to an aldehyde by heme a synthase (COX15). Heme a
is exclusively found in the COX1 subunit of respiratory complex IV, and heme
chaperones for delivering and installing the cofactor have not been identified. The
complex IV assembly factors SURF1 (Shy1 in yeast) and Coa2 have been posited as
heme chaperones for this pathway, but each protein appears to only be involved in the
hemylation of COX1 rather than heme trafficking to the site of complex assembly (273281).
1.2.4.3 Mitochondrial Utilization of Cu – Cytochrome c Oxidase and SOD1
Within the mitochondria, Cu participates in energy production and protection against
reactive oxygen species. CcO contains 3 Cu ions within the conserved subunits Cox1 and
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Cox2. In addition to Cu ions, Cox1 contains two heme a prosthetic groups (heme a and
a3). The Cu of Cox1 forms the CuB site of this subunit and interacts with the heme a3
moiety to create a heterometallic heme a3-CuB center. Cox2 utilizes the other two Cu ions
within CcO to produce the binuclear CuA site. Together, these two subunits and cofactors
make up the catalytic core of CcO (91, 92, 186). Cu insertion into Cox1 and Cox2 occurs
in the IMS via a series of Cu-binding chaperones and co-chaperones in the conserved
modular assembly of Cox1 and Cox2 which includes over 30 assembly factors (186). The
conserved IMS Cu chaperone Cox17 delivers Cu to the IMM-anchored Cox11 and
Sco1/2 to insert and assemble CuB and CuA site assemble, respectively (186, 282-284).
The current dogma is that CuB and CuA site assembly occur similarly in yeast and
mammalian. However, the mechanisms of how the CuB and CuA sites are assembled and
the roles of some CcO assembly factors – such as: Pet191, Cox19, Cox11 – are currently
obscure and yet to be completely understood and elucidated.
In the case of mitochondrial SOD1, Cu appears to be supplied by the mitochondrial
Cu pool. The conserved CCS/Ccs1 delivers Cu to the enzyme and facilitates the
metalation of SOD1 by physically interacting with SOD1 (86, 285-288). In mammals,
SOD1 metalation can occur in the absence of CCS and can accept Cu from glutathione
(289, 290). How Cu is loaded onto CCS/Ccs1 is currently unknown.
Fe, Fe-containing cofactors (heme and ISC), and Cu are pivotal in mitochondrial
function and in cellular and mitochondrial homeostasis. Together, these cofactors
facilitate energy production in mitochondria through ATP synthesis and protect the
organelle from reactive oxygen species. Furthermore, mitochondria are necessary for
maintaining and moderating Fe, heme, ISC , and Cu metabolism and homeostasis.
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Although these factors are critical to cellular wellbeing and survival, questions still
remain regarding substrate delivery to heme biosynthesis and ISC biogenesis machinery,
heme and ISC transport within mitochondria and to other subcellular compartments, and
the mechanisms necessary for cofactor site assembly in CcO. These questions will be
discussed, in part, in the following chapters.
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CHAPTER 2: MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING
SYSTEM (MICOS) MACHINERY SUPPORTS HEME BIOSYNTHESIS BY
ENABLING OPTIMAL PERFORMANCE OF FERROCHELATASE

Note: The results described in this chapter have been published and all text is modified
from the original version.

The citation is: Dietz, J.V., Willoughby, M.M., Piel III, R.B., Ross, T.A., Bohovych, I.,
Addis, H.G., Fox, J.L., Lanzilotta, W.N., Dailey, H.A., Wohlschlegel J.A., Reddi, A.R.
Medlock, A.E., Khalimonchuk, O. (2021) Mitochondrial contact site and cristae
organizing system (MICOS) machinery supports heme biosynthesis by enabling optimal
performance of ferrochelatase. Redox Biology. 46:102125.

2.1 ABSTRACT
Heme is an essential cofactor required for a plethora of cellular processes in eukaryotes.
In metazoans the heme biosynthetic pathway is typically partitioned between the cytosol
and mitochondria, with the first and final steps taking place in the mitochondrion. The
pathway has been extensively studied and its biosynthetic enzymes structurally
characterized to varying extents. Nevertheless, understanding of the regulation of heme
synthesis and factors that influence this process in metazoans remains incomplete.
Therefore, we investigated the molecular organization as well as the physical and genetic
interactions of the terminal pathway enzyme, ferrochelatase (Hem15), in the yeast
Saccharomyces cerevisiae. Biochemical and genetic analyses revealed dynamic

66
association of Hem15 with Mic60, a core component of the mitochondrial contact site
and cristae organizing system (MICOS). Loss of MICOS negatively impacts Hem15
activity, affects the size of the Hem15 high-mass complex, and results in accumulation of
reactive and potentially toxic tetrapyrrole precursors that may cause oxidative damage.
Restoring intermembrane connectivity in MICOS-deficient cells mitigates these cytotoxic
effects. These data provide new insights into how heme biosynthetic machinery is
organized and regulated, linking mitochondrial architecture-organizing factors to heme
homeostasis.
2.2 INTRODUCTION
Heme is an essential cofactor and signaling molecule required for diverse
physiological processes, from the mitochondrial electron transport chain to oxygen
transportation through the bloodstream (1-4). Most metazoans synthesize heme through a
highly conserved and well-characterized eight-step pathway (5). In the first step, the
mitochondrial enzyme aminolevulinic acid synthase (Alas; ALAS in humans; Hem1 in
yeast) catalyzes the condensation of glycine and succinyl-CoA to form aminolevulinic
acid (ALA), which is then transported out of the mitochondrion by an as-yetuncharacterized transporter. Once in the cytosol, two ALA molecules are condensed into
a monopyrrole, porphobilinogen, by the enzyme porphobilinogen synthase (Pbgs);
subsequently, four porphobilinogen molecules are joined together by
hydroxymethylbilane synthase (Hmbs) to form the linear tetrapyrrole
hydroxymethylbilane (HMB). HMB then undergoes cyclization to form
uroporphyrinogen III (catalyzed by uroporphyrinogen synthase, Uros) and
decarboxylation of its pyrrole acetate side chains (catalyzed by uroporphyrinogen
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decarboxylase, Urod) to yield coproporphyrinogen III. In Saccharomyces cerevisiae,
coproporphyrinogen III is converted to protoporphyrinogen IX by coproporphyrinogen
oxidase (Cpox) in the cytosol (6, 7), while in humans this reaction occurs in the
mitochondrial intermembrane space (IMS) (8, 9).
Protoporphyrinogen IX is transported into the mitochondrial matrix and converted
to protoporphyrin IX (PPIX) by the matrix-localized enzyme protoporphyrinogen oxidase
(Ppox) (10). How protoporphyrinogen IX is transported across the inner mitochondrial
membrane (IM) is currently unclear though evidence suggests that the porphyrinogen
transporter TMEM14C facilitates this process during erythroid cell maturation (11). The
final step of heme synthesis is catalyzed by ferrochelatase (Fech; FECH in humans;
Hem15 in yeast), which resides on the matrix side of the IM (12) and mediates the
insertion of ferrous iron into PPIX, thereby yielding heme (also known as protoheme or
heme b).
Even though the proteins involved in heme synthesis have been structurally
characterized and, in some cases, examined mechanistically (3, 13), the processes by
which the relative rates of heme synthesis are regulated remain obscure. Understanding
of this regulation is mainly limited to the transcriptional level in multicellular organisms
with erythrocytes. In these organisms, most heme production occurs in the developing
erythron, and specific transcription factors are known to play a role in regulating
expression of all the biosynthetic enzymes (14). The mechanisms of regulation of heme
synthesis for many other cells in these organisms and in unicellular eukaryotes like S.
cerevisiae, all of which require less heme, remain uncharacterized.
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In terms of enzyme activity, the rate-limiting step of the pathway in mammals is the first
step (catalyzed by ALAS), with the last step (catalyzed by FECH) being the second
regulatory point of the mammalian pathway (14). In S. cerevisiae, two other pathway
enzymes, Pbgs and Hmbs, have been proposed to catalyze the rate-limiting steps (7, 15).
Recent data suggest additional levels of regulation at the post-translational level (16, 17).
Proteomic studies in mammalian cells show that the mitochondrial heme
biosynthetic machinery exists as a large supercomplex, termed the heme metabolon (1719). FECH was identified as a component of a multimeric assembly that includes ALAS
and PPOX, the porphyrinogen transporter TMEM14C, and succinyl-CoA synthase (17,
18). The mitochondrial iron importer mitoferrin (20) and two ATP-binding cassette
proteins (ABCB7 and ABCB10) (20-22) have also been shown to bind to FECH.
Additional candidate interaction partners of FECH include factors that mediate IM
dynamics and ultrastructure (17, 19), most notably components of the conserved
mitochondrial contact site and cristae organizing system (MICOS). As suggested by its
name, MICOS maintains mitochondrial cristae and contact sites between the IM and the
outer mitochondrial membrane (OM) (23-25) and has been postulated to facilitate
bidirectional transport of hydrophobic molecules such as phosphatidic acid (26) and
coenzyme Q biosynthetic intermediates (27). However, the physiological significance of
its connection to FECH remains unaddressed.
Here a yeast genetic model was employed to investigate the putative molecular
interaction of Fech (Hem15 in yeast) with MICOS. Data from biochemical and genetic
analyses are consistent with a dynamic association of Hem15 with the core MICOS
component Mic60. Loss of MICOS negatively impacts Hem15 activity and results in
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accumulation of cytotoxic pathway intermediates. These data provide insights into how
the heme biosynthetic machinery is organized and supported, linking mitochondrial
architecture to heme homeostasis.
2.3 METHODS
2.3.1 Yeast strains, plasmids, and growth conditions
Yeast strains used in this work were of the W303-1B genetic background (MAT⍺
ade2-1 can1-100 his3-11,15 leu2-3 trp1-1 ura3-1), unless specified otherwise. Plasmids
for wild-type and variant Hem15 and human ferrochelatase expression in S. cerevisiae
were produced as previously described (28, 29). The HEM15 ORF with its 350-bp native
promoter region was subcloned into pRS424 and pRS426 vectors from the pRS316Hem15 plasmid described before (28). This plasmid also served as a template to generate
a pRS426-Hem15 vector in which the HEM15 ORF is under the control of the
heterologous MET25 promoter.
To generate a plasmid expressing Hem15-iFLAG, the mitochondrial targeting
sequence (MTS) of Hem15 (amino acid residues 1-31) with a flanking region containing
the FLAG epitope tag at the 3’-end was PCR-amplified from the pRS426-Hem15 plasmid
using primers 5’CGCGGATCCATGCTTTCCAGAACAATCCGTACACAAGGTTCCTTCCTAAGAA
GATCACAACTGACCATT-3’ and 3’CTTGTCGTCATCGTCTTTGTAGTCCTGCATGTTGAATGTAACCGAAAATGATC
TTGTAATGGTCAGTTGTGATCTTCT-5’. In a separate reaction, Hem15 excluding the
MTS (amino acid residues 31-393) containing the FLAG epitope tag at the 5’-end was
PCR amplified from the same plasmid using primers 5’-
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GACTACAAAGACGATGACGACAAGAATGCACAAAAGAGATCACCCACAGGA
ATTGTTTTGATGAACATGGGTGGC-3’ and 3’GCGCTCGAGTCAAGTAGATTCGTGATTGCCAAATACCAATGAAAGGTCCTTT
ACAGGATCATTGGACTT-5’. Gel-purified products of the reactions described above
were fused together by overlap extension PCR using 5’CGCGGATCCATGCTTTCCAGAACAATCCGTACACAAGGTTCCTTCCTAAGAA
GATCACAACTGACCATT-3’ and 3’GCGCTCGAGTCAAGTAGATTCGTGATTGCCAAATACCAATGAAAGGTCCTTT
ACAGGATCATTGGACTT-5’ including 5’-BamHI and 3’-XhoI restriction sites,
respectively. The obtained product was cloned into pRS423 vector under the control of
the MET25 promoter and CYC1 terminator.
The pRS424-Rnr1 plasmid was generated by subcloning a 2.8-kbp fragment from
the YEplac181-Rnr1 vector (30). The pCM185-Mrs3-FLAG plasmid has been described
previously (31). All plasmids were validated by DNA sequencing.
Depending on experiment, cells were cultured in yeast extract-peptone (YP) or
synthetic complete (SC) media lacking nutrients (amino acids or nucleotides) necessary
to maintain plasmid selective pressure (32) containing either 2% glucose, 2% galactose,
or 2% glycerol/2% lactic acid mix as the carbon source. To culture heme synthesisdeficient strains, cells were grown in the presence of either hemin or Tween80/ergosterol/methionine mix as described previously (33, 34). Growth tests to assess
respiratory capacity and quantify hydrogen peroxide sensitivity were carried out as before
(35, 36), except cells lacking functional Hem15 were cultured in 20 μM hemin. Cultures
used for growth tests were grown overnight (or two days in the case of cells lacking
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functional Hem15) in SC media lacking relevant nutrients to maintain plasmid selection
then normalized to OD600 of 1 and spotted onto SC plates with or without 20 μM hemin.
2.3.2 Heme and Porphyrin Analysis
Total cellular heme or protoporphyrin IX were measured using a previously
described porphyrin fluorescence assay (37). Briefly, 1×108 log-phase cells were
harvested, washed in sterile ultrapure water, resuspended in 500 μL of 20 mM oxalic acid
and stored at 4°C overnight (16–18 h) in the dark. The next day, 500 μL of 2 M oxalic
acid was added to the cell suspensions. Half the cell suspension was transferred to a heat
block set at 95°C and heated for 30 min to de-metallate the heme iron to yield fluorescent
protoporphyrin IX. The other half of the cell suspension was kept at room temperature for
30 min. All suspensions were centrifuged for 2 min on a table-top microfuge at 21,000 x
g and the porphyrin fluorescence spectra (excitation at 400 nm) or emission at 620 nm of
200 μL of each sample was recorded on a Synergy Mx multi-modal plate reader using
black Greiner Bio-one flat bottom fluorescence plates. The "boiled" sample provides a
measure of total heme and protoporphyrin IX in cells. The "room temperature" sample
provides a measure of total protoporphyrin IX in cells. When the "room temperature"
sample is subtracted from the "boiled" sample, "total" cellular heme is revealed.
Concentrations of heme or protoporphyrin IX are derived from standard curves of known
concentrations of heme boiled in oxalic acid similarly to the description above.
For high-resolution heme and porphyrin analysis, yeast cultures (125 mL) were
inoculated from a fresh culture at OD600nm of 0.003-0.009 and grown overnight at 37°C
and 225 rpm shaking until OD600nm = 1. One hundred mL of culture was harvested by
centrifugation at 4000 rpm for 5 min. Cells were then washed in 5 ml ice cold water and
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re-centrifuged. Pellets were then resuspended on ice in 4 mL lysis buffer (50 mM TrisMOPS, pH 8.0, 100 mM KCl, 1% sodium cholate) with 40 μL fungal protease inhibitor
cocktail (Sigma P-8215) and transferred to 50-mL conical tubes. Glass beads (4 mL, 0.5
mm) were then added, and cells were vortexed for one minute at maximum speed
followed by one minute on ice, repeated for a total of 5 vortex cycles. Tubes containing
lysate and beads were then centrifuged at ~9000 x g for 5 min. Supernatant was removed
using a 1-mL pipette, taking care not to disturb the pellet. The supernatant was then
transferred to 2-ml microcentrifuge tubes and further centrifuged at 15000 x g for 10 min.
Supernatant was transferred to fresh microcentrifuge tubes and stored on ice for up to 2
hours during measurements. Total protein concentration of yeast lysate was measured via
a NanoDrop spectrophotometer with 1 A = 1 mg/mL setting. Heme and porphyrin
analysis were carried out at the University of Utah Center for Iron and Heme Disorders
core facility as previously described (11, 17).
2.3.3 Hem15 activity assays
Lysate volumes ranging from 0-200 μL were brought to a total volume of 850 μL
with lysis buffer in 3-mL glass tubes. Master mix (150 μL) consisting of 20 mM ferrous
sulfate, ~1 mM protoporphyrin IX, and 33.3 mM β-mercaptoethanol was added to start
the assay. Samples were incubated in the dark at 37°C for 15 min. Heme produced in
lysate activity assays was quantified by pyridine hemochromogen assay. To stop the
assay reactions and produce the pyridine hemochrome derivative, 1 mL 50% (v/v)
pyridine:0.2 N NaOH solution was added to 1-mL assay samples. Heme content was
measured via differential spectra of oxidized and reduced samples as described
previously (69-71).
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2.3.4. Variant construction, protein expression, purification, and X-ray
crystallography
The Hem15 variant H235C was constructed using QuikChange site-directed
mutagenesis (Agilent) and verified by sequencing. His-tag mature wild-type and variant
Hem15 were produced as previously described (52, (72). In vivo ferrochelatase activity
of the variant was assessed by complementation and rescue of a strain of Escherichia coli
lacking functional ferrochelatase, ppfCΔ (73, 74). The H235C variant protein was
concentrated to ~400 μM and crystals were grown by hanging drop with mother liquor
composed of 0.1M Bis-Tris pH 6.5, 25% PEG 3350 within 48 hours.
All data sets were collected at the Advanced Photon Source and SER-CAT on
beamline 22-ID. Phases were obtained by using a monomer of wild-type Hem15 (PDB
ID 1LBQ) as a molecular replacement search model. Molecular replacement was
performed using the program CNS (75). Iterative rounds of model building and
refinement were performed with the programs COOT (76) and CNS, respectively. Data
collection, refinement statistic, and PDB ID for the H235C structure are listed in Table
4.1. Structural representations were created using PyMol (77).
2.3.5. Mass spectrometry and data analysis
Affinity purification and mass spectrometry were carried out as described for
human ferrochelatase (17), except 1% digitonin was used to solubilize purified
mitochondria. Subsequent analysis of candidate hits against the CRAPome database
(www.crapome.org) eliminated known contaminants and non-specific interactors.
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2.3.6. Mitochondrial isolation and assays
Mitochondria-enriched fractions were isolated using established protocols (78).
For ICP-MS measurements, mitochondrial fractions were further purified using
discontinuous 14% / 22% Nicodenz gradients as described (79). Total mitochondrial
protein concentrations were determined using the Coomassie Plus kit (Thermo
Scientific). Proteins or protein complexes were separated by SDS-PAGE, blue native
(BN)-PAGE, or continuous 12-50% sucrose density gradient ultracentrifugation as
previously described (35, (67, 80). Aconitase specific activity was determined as before
(81).
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Table 4.1. Data collection and refinement statistics for yeast Hem15 H235C variant

Data Collection
Beamline
Space Group
Wavelength
Resolution Range (Å)
Outer Shell
Unique Observations
Completeness (%)
Rsym (%)b
CC ½
Redundancy
I/s

APS 22-ID
P212121
0.98
50.0-2.4
2.51-2.4
32,665
99.2(96.8)a
6.6(31)
0.99(0.72)
3.5(2.9)
17.7(2.9)

Refinement
Unit Cell (a, b, c) in Å
Protein Atoms
Solvent Atoms
Resolution Limits (Å)
Rcryst (%)
Rfree (%)
rmsd bonds (Å)
rmsd angles ( ° )
average B factor (Å2)
PDB ID code

49.9, 51.6, 287.3 ; a=g=b=90º
5675
66
50.0-2.4
23.2
29.6
0.009
1.1
45
7L78

a

Numbers in parentheses denote values for the outermost resolution shell. bRsym =
∑hkl[∑I(|Ihkl,I - <Ihkl>|)]/∑hkl,I<Ihkl>, where Ihkl is the intensity of an individual
measurement of the reflection with indices hkl and <Ihkl> is the mean intensity of that
reflection.
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2.3.7. Heme trafficking dynamics assay
Heme trafficking rates were monitored as previously described (39). Briefly, in
this three-step assay: 1) heme synthesis is first inhibited with succinylacetone (SA) in
sensor-expressing cells, 2) the block in heme synthesis is then removed by resuspending
cells into media lacking SA, and 3) the time-dependent change in the heme occupancy of
HS1 is monitored. The fractional heme occupancy of the sensor can be determined using
previously established sensor calibration protocols (37). The percent of sensor bound to
heme (% Bound) is calculated by determining the sensor eGFP/mKATE2 fluorescence
ratio (R) under a given test condition relative to the eGFP/mKATE2 fluorescence ratio
when the sensor is 100% (Rmax) or 0% (Rmin) bound to heme, as described previously (3739, 40). Rmin is determined by measuring the HS1 eGFP/mKATE2 ratio in parallel
cultures that are conditioned with succinylacetone (SA), which inhibits the second
enzyme in the heme biosynthetic pathway, Pbgs (41), and Rmax can be determined by
permeabilizing cells and adding an excess of heme to saturate the sensor (37). Given HS1
is quantitatively saturated with heme in the cytosol, nucleus, and mitochondria of WT
yeast, Rmax is typically determined by measuring the HS1 eGFP/mKATE2 ratio in
parallel WT cultures grown without SA (37).
Growth for the heme trafficking dynamics assay was accomplished by culturing
HS1-expressing cells with or without 500 μM SA (Sigma-Aldrich) in SC media lacking
leucine. Triplicate 5-mL cultures were seeded at an initial optical density of OD600nm =
.01-.02 (~2-4 x 105 cells/mL) and grown for 14-16 hours at 30°C and shaking at 220 rpm
until cells reached a final density of OD600nm ~ 1.0 (~2 x 107 cells/mL). After culturing, 1
OD (or ~2 x 107 cells) were harvested, washed twice with 1 mL of ultrapure water, and
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resuspended in 1 mL of fresh media. The cells that were pre-cultured without SA
provided HS1 Rmax values. The SA-conditioned cells were split into two 500-μL
fractions. One fraction was treated with 500 μM SA to give HS1 Rmin values. The other
fraction was not treated with SA so that heme synthesis could be re-initiated to give
compartment-specific heme trafficking rates. HS1 fluorescence was monitored on 200 uL
of a 1 OD/mL (~2 x 107 cells/mL) cell suspension using black Greiner Bio-one flat
bottom fluorescence plates and a Synergy Mx multi-modal plate reader. Fluorescence of
eGFP (λexc.=488 nm, λem.=510 nm) and mKATE2 (λexc.=588 nm, λem.=620 nm) was
recorded every 5 minutes for 4 hours, with the plate being shaken at “medium-strength”
for 30 seconds prior to each read. Background fluorescence of cells not expressing the
heme sensors was recorded and subtracted from the eGFP and mKATE2 fluorescence
values.
2.3.8. Immunoblotting
Separated proteins were transferred to either nitrocellulose or PVDF membranes,
blocked in 5% non-fat milk in PBS with 0.1% Tween-20 and incubated with relevant
primary antibodies and goat anti-mouse or goat anti-rabbit horseradish peroxidasecoupled secondary antibodies (Santa Cruz Biotechnology). Proteins of interest were
visualized by incubation of membranes with chemiluminescence reagents (Thermo
Scientific) and exposure to X-ray film. For assessment of Hem15 endogenous levels,
proteins were detected using the Odyssey Fc imaging system (LI-COR Biosciences) and
quantified using built-in Image Studio software. The following primary antibodies were
used: mouse anti-porin (459500, Thermo Scientific), mouse anti-Cox1 (ab110270,
Abcam), mouse anti-Cox2 (ab110271, Abcam), mouse anti-Cox3 (ab110259 Abcam),
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and mouse anti-FLAG (sc-166355, Santa Cruz Biotechnology). We also used rabbit sera
against S. cerevisiae Hem15 (produced in the Dailey lab), Rip1 (provided by Dr. D.
Winge), Mic60 (provided by Dr. N. Pfanner), Aco1 (provided by Dr. R. Lill), and βsubunit of F1 ATP synthase (provided by Dr. A. Tzagoloff). All antibodies were tested
for reliability to ensure specificity of detection.
2.4 RESULTS
2.4.1 Functional Hem15 Forms a High-Mass Complex
Hem15 is known to exist as a homodimer (28, 29), but its protein-protein
interaction has not been systematically studied. To that end, an antibody was developed
against Hem15, which specifically recognizes S. cerevisiae Hem15 (Fig. 2.1A). Using
this antibody and purified Hem15 as a reference, mitochondria from galactose-cultured
wild type (WT) cells in the mid-log growth phase were found to contain approximately
1.0 ng of endogenous Hem15 per milligram of mitochondrial protein (Fig. 2.2A). This
concentration is comparable to other mitochondrial heme synthesis enzymes as well as
other IM proteins (30). To assess the oligomerization state of Hem15, mitochondria from
WT cells were lysed with digitonin and the lysate proteins subjected to sucrose gradient
ultracentrifugation followed by SDS-PAGE immunoblotting of the gradient fractions.
Hem15 was detected in the ~250-440 kDa molecular weight range (Fig. 2.1B),
suggesting that endogenous yeast Hem15 exists as a high-mass complex, which likely
includes additional associated components, as seen for the mammalian enzyme (17).
To determine whether the formation of this complex depends on the functional
state of Hem15, the same analysis was performed using a catalytically impaired Hem15
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Figure 2.1. Functional Hem15 forms a high-mass complex. (A) Isolated mitochondria
(15 µg total protein) from wild type (WT) and hem15Δ cells overexpressing Hem15 (from
the HEM15 promoter) or expressing a vector control were subjected to SDS-PAGE and
analyzed by immunoblotting with antibodies against Hem15 and the outer mitochondrial
membrane protein porin (loading control). (B) High-velocity density-gradient fractionation
of digitonin-solubilized lysates from mitochondria of hem1 Δ cells or hem15Δ cells
expressing Hem15 or its H235C catalytically impaired variant, analyzed by SDS-PAGE
with immunoblotting for Hem15 and porin (440-kDa molecular size reference).
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D

Figure 2.2. Biochemical and structural analysis of Hem15 and its H235C
variant. (A) Indicated amounts of E. coli-expressed purified Hem15 along with 100
µg of purified mitochondria from WT cells were analyzed by denaturing gel and
immunoblotting with anti-Hem15 antibody. The linear signal intensities were
assessed by automated densitometry and used to estimate the relative amount of
endogenous Hem15. (B) Steady-state levels of Hem15 and loading control (porin)
in mitochondria from hem15Δ cells overexpressing Hem15, or the Hem15 variant
H235C, analyzed by SDS-PAGE and immunoblotting with respective antibodies,
and heme-dependence growth test of these cells spotted onto SC medium with or
without 20 µM hemin. (C) Ability to rescue E. coli ppfCΔ ferrochelatase mutant by
yeast Hem15 WT and H235C variant and their ferrochelatase catalytic rate constant.
(D) Absorbance spectra of E. coli-purified yeast Hem15 WT and H235C variant,
indicating that the WT Hem15 predominantly co-purifies with bound heme (Soret
lmax = 427 nm; dashed line), while the H235C variant co-purifies with bound PPIX
(Soret lmax = ~410 nm). (E) Crystal structures (2.4 Å) of Hem15 WT and H235C
variant showing views of the active site with the hydrogen-bonding network
(dashes) and key residues involved in catalysis (sticks representation).
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variant, H235C. The yeast Hem15 residue H235 is equivalent to the human FECH
residue H263, which is an essential catalytic histidine involved in proton abstraction prior
to chelation (43). Conversion of this residue to a cysteine yielded a variant that is stably
expressed yet unable to support heme-independent growth or exhibit in vitro Fech
activity (Fig. 2.2B, S1C). While WT Hem15 predominantly copurifies with bound heme,
the H235C variant protein copurifies with PPIX (Fig. 2.2D), further demonstrating this
variant of Hem15 is impaired in catalyzing formation of heme from PPIX substrate. This
H235C variant was found in fractions of lower molecular weight when mitochondrial
lysates were subjected to sucrose gradient ultracentrifugation (Fig. 2.1B), suggesting the
formation of the full complex is impaired when Hem15 is catalytically inactive. The
Hem15 complex was also found to shift to lower molecular weight fractions in gradient
ultracentrifugation of mitochondrial lysates derived from heme synthesis-deficient cells
lacking Alas (yeast Hem1; Fig. 2.1B). These findings suggest that Hem15
oligomerization is at least partially dependent on the functional state of both Hem15 and
an earlier step of the heme biosynthetic pathway.
2.4.2. Human Ferrochelatase Complements the Yeast Deletion Strain
Human FECH was discovered to be fully functional in yeast, complementing the
yeast hem15Δ deletion mutant (Fig. 2.3A), which cannot survive in the absence of
exogenous heme supplementation. This finding reveals that essential interactions between
Fech and other proteins are conserved in S. cerevisiae. This result is also interesting
because there are known differences between the yeast and human ferrochelatase
enzymes. The human enzyme, but not the yeast enzyme, possesses a [2Fe-2S] cluster,
which is required for enzyme activity (44-46). Complementation of the hem15Δ strain
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B

Figure 2.3. Human ferrochelatase is fully functional in yeast, and loss of
Hem15 results in a petite-inducing phenotype that can be reversed by
overexpression of ribonucleotide reductase. (A) Heme-dependence growth test
of WT cells and hem15Δ cells expressing vector control (vector), yeast
ferrochelatase (HEM15), human ferrochelatase (FECH), or the C406S variant of
human ferrochelatase (FECH C406S). Cells were spotted onto SC medium with (+
Heme) or without (- Heme) 20 µM hemin and cultured for 2 days at 28oC. (B)
Heme-dependence fermentative and respiratory growth test of WT cells or
hem15Δ cells expressing vector control (vector), Rnr1 (RNR1 ↑), Hem15 under
control of its native promoter (HEM15 ↑), or co-expressing Rnr1 and Hem15.
Cells were spotted onto SC media with or without 20 µM hemin and cultured for 2
days (glucose) or 5 days (glycerol/lactate) at 28oC. (C) SDS-PAGE immunoblot
showing steady-state levels of three proteins encoded by the mitochondrial
genome (Cox1, Cox2, and Cox3) with aconitase loading control (Aco1), in
mitochondria from cells described in panel B.
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with wild-type human FECH, but not the human FECH variant C406S lacking an
essential (44, 47) cluster ligand residue (Fig. 2.3A), suggests that the FECH iron-sulfur
cluster is assembled properly in yeast.
2.4.3. A Genetic Model Was Developed to Assess Hem15 Functional Roles
While expression of either yeast or human ferrochelatase in the yeast hem15Δ
strain allows cell growth in the presence of glucose, overexpression of Hem15 does not
always permit growth of this strain on respiratory media (Fig. 2.3B). This phenomenon
has been observed previously (48) and has thus far posed an obstacle to further in-depth
functional studies of Hem15.
After hypothesizing this effect to be a petite-inducing phenotype due to loss of
mitochondrial DNA upon deletion of the HEM15 gene, this obstacle was overcome by
employing a known strategy to stabilize the mitochondrial genome. Overexpression of
the dNTP checkpoint enzyme Rnr1, which encodes the large subunit of ribonucleotide
reductase, has previously been very effective to stabilize mitochondrial DNA in various
petite mutants via an unknown mechanism (30, 42, 49-51). Employing this strategy in
hem15Δ cells restored respiratory growth (Fig. 2.3B), returned both respiratory
complexes and their subunit proteins to WT levels, and permitted complementation with
human FECH (Fig. 2.3C; Fig. 2.4).
2.4.4. Hem15 Is Physically Associated with MICOS Machinery
Protein interaction partners of Hem15 were determined by immunoprecipitation
(IP) of a FLAG-tagged Hem15 construct. Since attachment of a C-terminal tag to FECH
results in an inactive enzyme (52), Hem15 was tagged immediately after its N-terminal
mitochondrial targeting sequence, so that the natural proteolytic removal of the targeting
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Figure 2.4. Combined expression of RNR1 and HEM15 permits respiratory
growth of the hem15Δ mutant and results in stabilization of the mitochondrial
respiratory complexes III and IV. (A) Steady-state levels of Hem15 and
representative respiratory complex IV (Cox1-Cox3) and complex III (Rip1) subunits
with loading control (porin) in mitochondria of WT cells and hem15Δ cells with or
without HEM15 overexpression from its native promoter (HEM15 ↑) or the highefficiency heterologous MET25 promoter (HEM15 ↑↑). Samples were analyzed by
SDS-PAGE and immunoblotting with indicated antibodies. (B) BN-PAGE analysis
of dodecyl-β-D-maltoside (DDM)-solubilized mitochondrial proteins from WT cells
or hem15Δ cells co-expressing the indicated combinations of the following plasmids:
vector control (-), Rnr1 (RNR1 ↑), Hem15 under the control of its native promoter
(HEM15 ↑), and Hem15 under the control of the high-efficiency heterologous
MET25 promoter (HEM15 ↑↑). Complexes were visualized by immunoblotting with
the indicated antibodies (mon. Atp2 refers to the monomeric protein). The hemecontaining electron transport chain complexes III and IV, as well as the non-heme
complex V, are severely attenuated in hem15Δ cells regardless of Hem15 reexpression (compare lanes 2, 4, and 6), and these levels are restored to normal upon
co-expression of RNR1 and HEM15 (lanes 5 and 7). (C) Heme-dependence growth
test of Rnr1-expressing hem15Δ cells harboring no other plasmids (-), vector control
(vector), yeast ferrochelatase (HEM15), or human ferrochelatase (FECH), assessed
as described in Fig. 2.3B.
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sequence upon mitochondrial import results in a protein bearing the FLAG tag on the
structurally disordered amino terminus (Fig. 2.5A). This Hem15-iFLAG construct is
stably expressed and functional (Fig. 2.5B, C) and was therefore used for IP experiments.
Clarified mitochondrial lysates from hem15Δ cells stabilized with Rnr1 and
expressing Hem15-iFLAG were incubated with anti-FLAG affinity resin, and affinitypurified proteins were analyzed by LC-MS/MS to identify co-purifying proteins. In
addition to Hem15 and some of its previously known binding partners such as Ppox
(Hem14) (17), the IM GTPase Mgm1 and five of the eight known subunits of the MICOS
complex (Mic60, Mic19, Mic26, Mic27, and Mic12) were all identified as physically
interacting with Hem15 (Fig. 2.6A). Consistent with these findings, targeted co-IP
experiments showed the core MICOS subunit Mic60 co-purifies with Hem15-iFLAG
(Fig. 2.6B), further suggesting physical association between Hem15 and MICOS. These
findings are consistent with interactions observed in IP experiments with yeast MICOS
(53) and human FECH (17, 19).
To examine the functional significance of this Hem15-MICOS association, the
impact of MIC60 deletion on Hem15 was experimentally determined. Steady-state levels
of Hem15 were not affected in the mic60Δ deletion mutant (Fig. 2.5D). However, the
sucrose gradient migration profile of the Hem15 high-mass complex derived from
mic60Δ mutant mitochondria was altered, indicating a shift toward smaller complex size
(Fig. 2.6C). This shift in Hem15 oligomer fractionation pattern is similar to that observed
for both the nonfunctional H235C Hem15 variant and WT Hem15 in the
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Figure 2.5. Generation of a functional Hem15-iFLAG construct and steadystate levels of Hem15 in mic60Δ cells. (A) Schematic depiction of the Hem15iFLAG construct bearing an internal FLAG epitope tag. MTS, mitochondrial
targeting sequence. (B) Heme-dependence glucose growth test of WT and hem15Δ
cells co-overexpressing RNR1 and either vector control, untagged Hem15, or
Hem15-iFLAG under control of the MET25 promoter, assessed as in Fig. 2A. (C)
Expression of Hem15-iFLAG in hem15Δ cells overexpressing RNR1 analyzed by
SDS-PAGE and immunoblotting with anti-FLAG antibody (and anti-porin antibody
as a loading control). (D) Steady-state levels of indicated proteins in mitochondria
from WT, mic60Δ and hem15Δ cells, visualized by SDS-PAGE and
immunoblotting with indicated antibodies.
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Figure 2.6. Hem15 physically interacts with MICOS. (A) Table and schematic
summarizing LC-MS/MS identification of immunoprecipitated proteins from
mitochondrial lysates of hem15Δ cells expressing Hem15-iFLAG. Identified components
of the MICOS machinery are color-coded to reflect the abundance of peptides
corresponding to each identified subunit. Table shows representative data of two
independent biological replicates. (B) Co-immunoprecipitation of Hem15-iFLAG and the
endogenous Mic60 core subunit of MICOS. Digitonin-solubilized mitochondrial lysates
from hem15Δ cells expressing Rnr1 and co-expressing either Hem15-iFLAG or empty
vector control were incubated with anti-FLAG affinity resin; following the incubation,
samples were subjected to SDS-PAGE and analyzed by immunoblotting with indicated
antibodies. The blots show 10% of mitochondrial lysate fractions before (Load, Pre) and
after (Load, Post) pre-clearance with IgG agarose beads, the unbound fraction after
incubation with anti-FLAG affinity resin (Unbound), the whole precipitated fraction
from the final wash (Wash), and half of the eluted fraction (Bound). (C) Sucrose density
gradient ultracentrifugation of digitonin-solubilized Hem15 complexes from
mitochondria of WT and mic60Δ cells. Asterisk marks nonspecific bands.
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hem1Δ mutant (Fig. 2.1B). Collectively, these results suggest that Hem15 associates with
the MICOS complex and Hem15 oligomerization is impaired in the absence of MICOS.
2.4.5. MICOS Facilitates Proper Heme Biosynthetic Activity of Hem15
Respiratory growth in the absence of Mic60 was observed to be slightly impaired,
and this growth defect enhanced markedly when Hem15 levels were elevated by
overexpression from a plasmid (Fig. 2.7A). This result was observed for mic60Δ strains
in both the W303 and BY4741 genetic backgrounds and with plasmids expressing
Hem15 from either its native promoter or a strong heterologous promoter. Hem15 protein
levels remained similar in the presence versus the absence of Mic60 (Fig. 2.7B), ruling
out reduced levels of Hem15 as a possible cause for the growth defect. Therefore, the
activity of that Hem15 protein was examined.
WT and mic60Δ cell lysates do not have significantly different levels of Fech
activity, and overexpression of Hem15 in each cell type results in significantly increased
PPIX metalation by Hem15 (Fig. 2.7C). Strikingly, when Hem15 is overexpressed,
mic60Δ cells have dramatically lower Fech activity than WT cells, suggesting an inability
to maximize heme production in the absence of Mic60 despite abundant Hem15 protein
(Fig. 2.7B, C). This apparent defect in Hem15 activity in the absence of Mic60 raises
questions about the role of MICOS in the function of Hem15, which were pursued next.
2.4.6. MICOS Is Required for Optimal Porphyrin Substrate Delivery to Hem15
MICOS could potentially impact Hem15 activity either directly or indirectly.
MICOS could be directly responsible for substrate import into or heme export out of
mitochondria due to its key role in maintenance of IM-OM contact sites (24, 25), which
are postulated to facilitate bidirectional transport of hydrophobic molecules (e.g.,
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Figure 2.7. Hem15 activity is impaired in the absence of MICOS. (A) Fermentative
and respiratory growth of WT and mic60Δ cells expressing vector control or Hem15
under control of its native promoter (HEM15 ↑) or the heterologous MET25 promoter
(HEM15 ↑↑). Cells were spotted onto SC media and cultured for 2 days (glucose), 3
days (galactose), or 5 days (glycerol/lactate) at 28oC. (B) SDS-PAGE immunoblot of
indicated proteins in mitochondria from cells described in panel A. (C) Ferrochelatase
specific activity in mitochondrial lysates from indicated cells. Bars indicate the
average and S.D. (error bars) of 3 biological replicates. Asterisks indicate a
statistically significant difference by t-test (***p<0.001).
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phosphatidic acid and coenzyme Q biosynthetic intermediates) (26, 27). Alternatively, the
disorganization of the IM stemming from loss of MICOS could negatively impact
mitochondrial carrier proteins required for import of substrates or export of heme, thus
indirectly impacting Hem15.
In either the direct or indirect involvement scenario, 1) impaired heme export due
to the absence of MICOS might lead to mitochondrial heme build-up and inhibition of
Hem15 by heme (54), since heme dissociation from Fech is the rate-limiting step in
catalysis (55), or 2) impaired import of substrates and intermediates required for heme
synthesis into mitochondria might limit substrate availability to Fech. To investigate
these two potential mechanisms for how the MICOS machinery contributes to Fech
activity, experiments were carried out to assess rates of heme transport across the IM,
cellular heme levels, mitochondrial iron levels, and cellular levels of porphyrin
biosynthetic precursors to heme, including PPIX.
To investigate the possibility that loss of MICOS impairs heme export, both rates
of heme transport across the IM and cellular heme levels were determined. A highaffinity, genetically encoded heme sensor (HS1) (37, 38) was employed in an assay to
compare rates of heme transport across the IM in WT and mic60Δ cells. In this assay,
heme synthesis is blocked with succinylacetone, an inhibitor of the heme synthetic
enzyme Pbgs, and then reinitiated by removing the inhibitor from the medium. The heme
occupancy of mitochondrial matrix- and cytosol-targeted HS1 is then monitored as a
function of time (39). In principle, the rates of heme binding to the sensor reflect the
relative rates of heme trafficking from the matrix side of the mitochondrial IM (where the
active site of Fech is located) to the locale of HS1. This assay revealed that hemylation
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rates of cytosol- and mitochondrial matrix-targeted HS1 in the mic60Δ mutant were
comparable to those seen in WT cells, indicating that there is no significant dependence
of heme export on MICOS, either directly or indirectly (Fig. 2.8A). Consistent with this
finding, total heme levels measured by UPLC were not significantly different in the
presence versus the absence of Mic60 (Fig. 2.8B).
To investigate the possibility that loss of MICOS impairs the import of substrates
of either Hem15 or other enzymes in the heme biosynthetic pathway, levels of
mitochondrial iron and cellular porphyrins were measured. The iron content measured by
ICP-MS was comparable in highly purified mitochondrial fractions from WT and mic60Δ
cells with or without Hem15 overexpression (Fig. 2.9A), ruling out iron deficiency as the
reason for reduced Fech activity in the Hem15-overexpressing mic60Δ mutant. In
agreement with this result, the steady-state levels of the mitochondrial iron transporter
Mrs3 were also unchanged by the absence of Mic60 (Fig. 2.9B). Likewise, loss of Mic60
had no appreciable effect on the activity of the iron-sulfur cluster-containing enzyme
succinate dehydrogenase, indicating that iron-sulfur cluster biogenesis is not affected
(Fig. 2.9C).
To test the availability of the other substrate for Fech, PPIX, and intermediates
necessary for its synthesis, cellular porphyrin content was analyzed in cells lacking
Mic60. Spectroscopy revealed that total porphyrinogen fluorescence is increased in
mic60Δ cells compared to WT (Fig. 2.9D). UPLC was then employed to separate
porphyrins to determine which types were causing this elevated fluorescence. This
detailed porphyrin profiling revealed a ~3-fold increase in total intermediate porphyrins
in mic60Δ cells compared to WT cells (Fig. 2.8C) and showed that the
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Figure 2.8. MICOS-deficient cells accumulate reactive porphyrin biosynthetic
precursors. (A) Relative rates of heme binding to the HS1 heme sensor in the
mitochondrial matrix (left) and cytosol (right), the latter of which requires heme export
across the IM, upon re-initiation of heme synthesis in WT and mic60∆ cells. Heme
trafficking kinetics data shown represent mean ± S.D. of independent triplicate cultures.
(B-D) Heme, intermediate (8-, 7-, 6-, 5-, and 4-COOH) porphyrins, and protoporphyrin
IX (PPIX) levels in WT and mic60∆ cells with and without Hem15 overexpression,
analyzed by UPLC. Bars indicate average ± S.D. (error bars) of 4-5 biological replicates
measured in technical triplicates. Asterisks indicate a statistically significant difference by
t-test (*p<0.05, **p<0.01, ***p<0.001).
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Figure 2.9. Analysis of mitochondrial iron, iron-related proteins, mitochondrial
protein lipoylation, and porphyrin fluorescence in MICOS-deficient cells. (A)
Left: Elemental ICP-MS analysis of iron levels in gradient-purified mitochondria from
WT and mic60∆ cells expressing vector control or Hem15 under the heterologous
MET25 promoter (HEM15 ↑↑). Bars indicate the average and S.E.M (error bars) of 3
biological replicates. Right: Steady-state levels of indicated proteins in gradientpurified mitochondria (pure mito.) analyzed by SDS-PAGE immunoblot with
appropriate antibodies. (B) Steady-state levels of indicated proteins in mitochondria
from the cells described in panel A analyzed by SDS-PAGE immunoblot with
appropriate antibodies. (C) Succinate dehydrogenase specific activity in
mitochondrial lysates from cells described in panel A. Bars indicate the average and
S.D. (error bars) of 3 biological replicates. (D) Left: Total porphyrin content of WT
and mic60∆ cells cultured with or without 500 µM succinylacetone (SA) in 2%
glucose or 2% galactose measured by porphyrin fluorescence assay. Data are
mean ± S.D. of triplicate cultures. *p<0.01 (one-way ANOVA with Bonferroni
posthoc test). Right: Fluorescence spectra of steady-state total porphyrinogens from
oxalic acid-digested cell extracts (1×108 cells/mL) of the indicated cell cultures. The
data represent mean ± S.D. of independent triplicate cultures. (E) Steady-state
levels of two lipoylated mitochondrial proteins, pyruvate dehydrogenase subunit
dihydrolipoamide acetyltransferase (DLAT) and dihydrolipoyl succinyltransferase
(DLST), measured in WT and mic60D cells and analyzed by SDS-PAGE
immunoblot with appropriate antibodies.
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proportions of the 8-, 7-, 6-, 5-, and 4-COOH porphyrins were altered in these cells (Fig.
2.10). To rule out the possibility that metabolite transport is universally defective in
mic60Δ cells, mitochondrial lipoylation was measured in WT and mic60Δ cells. Levels of
the lipoylated mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide
acetyltransferase and dihydrolipoyl succinyltransferase were found to be normal in the
absence of Mic60, suggesting IM carrier proteins remain generally functional and the
elevated porphyrins observed in the absence of Mic60 are the result of a specific effect
(Fig. 2.9E).
Interestingly, PPIX was decreased in mic60Δ cells overexpressing Hem15
compared to WT cells overexpressing Hem15 (Fig. 2.8D), suggesting substrate
availability may be a factor that limits Fech activity in these cells. Much like the subtle
growth defect and statistically insignificant decrease in Fech activity seen in mic60Δ cells
compared to WT cells with endogenous Hem15 levels (Fig. 2.7), levels of PPIX are not
significantly different in the presence versus the absence of Mic60 when Hem15 is
present at endogenous levels (Fig. 2.8D). However, when Hem15 is overexpressed, the
growth defect becomes marked, the decrease in Fech activity becomes dramatic, and the
decrease in levels of PPIX becomes significant. These three experiments suggest a role
for MICOS in Hem15 activity that is more apparent under conditions of high Hem15
levels, when PPIX may become limiting for Hem15 activity.
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Figure 2.10. Detailed analysis of identifiable porphyrin biosynthetic precursors in
MICOS-deficient cells. Indicated intermediate (4-, 5-, 6-, 7- and 8-COOH)
porphyrins, as derived from pathway intermediate porphyrinogens, were analyzed by
UPLC. Bars indicate average ± S.D. (error bars) of 4-5 biological replicates measured
in technical triplicates. Asterisks indicate a statistically significant difference by t-test
(*p<0.05, **p<0.01).
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2.4.7. MICOS-Deficient Cells Expressing Hem15 Have Oxidative Stress, Which
Can Be Partially Mitigated by Synthetic Restoration of IM/OM Contact Sites
Since heme synthesis pathway intermediates like those elevated in the absence of
Mic60 are known to be toxic, in part due to their inherent redox reactivity (5, 56-58),
signs of oxidative damage and stress were evaluated in the absence of Mic60. The
metabolic enzyme aconitase was assessed first because of its sensitivity to damage by
superoxide. While steady-state levels of aconitase were the same in WT and mic60Δ cells
overexpressing Hem15 (Fig. 2.11), the cells lacking Mic60 exhibited a significant
decrease in aconitase specific activity, consistent with oxidative damage (Fig. 2.12A).
Furthermore, mic60Δ cells overexpressing Hem15 were significantly less tolerant to
acute oxidative insults than WT cells overexpressing Hem15 (Fig. 2.12B). Consistent
with these observations of oxidative stress, supplementation with the antioxidant Nacetylcysteine partially rescued a growth defect of Hem15-overexpressing mic60Δ cells
on galactose medium (Fig. 2.12C).
To test whether restoring intermembrane connectivity in MICOS-deficient cells
could mitigate some of these cytotoxic effects, an artificial IM-OM tether, mitoT, was
generated (59) (Fig. 2.12D, E). This chimeric protein comprises the N-terminal portion of
the IM protein Sco2 (residues 1-112) encompassing the mitochondrial targeting sequence
and transmembrane domain, followed by a short (12 amino acid residues) unstructured
linker derived from the E. coli LacI protein, a transmembrane helix of the OM import
receptor protein Tom20 (residues 1-20), and the GFP moiety. The optimal length of the
linker region was deduced from the previously reported analogous construct (26).
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Figure 2.11. Steady-state aconitase levels are unaffected in Hem15overexpressing mic60Δ cells. Steady-state levels of indicated proteins in
mitochondria from WT and mic60Δ cells expressing vector control or Hem15
under control of its native promoter (HEM15 ↑) or the heterologous MET25
promoter (HEM15 ↑↑), analyzed by SDS-PAGE immunoblot with appropriate
antibodies. Asterisk indicates non-specific cross-reacting bands.
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Figure 2.12. MICOS-deficient cells expressing Hem15 exhibit oxidative stress that
can be mitigated by a synthetic intermembrane tether. (A) Aconitase enzymatic
activity in mitochondria isolated from WT and mic60Δ cells with and without Hem15
overexpression, harvested after 5 days in culture. Bars indicate the average ± S.D. of 3
biological replicates. Asterisks indicate a statistically significant difference by one-way
ANOVA with Tukey’s post-hoc test (*p<0.05). (B) Hydrogen peroxide sensitivity of
cells described in panel A. Cells were cultured to mid-log phase, normalized, and
acutely treated with 1 mM hydrogen peroxide for 1 h at 28oC. Following treatment,
cultures were diluted to 300 cells per sample and plated to assess viable colony forming
units after 48 h of growth at 28oC. Bars indicate the average ± S.D. (error bars) of 4
biological replicates. Asterisks indicate a statistically significant difference by one-way
ANOVA with Tukey’s posthoc test (*p<0.05). (C) Growth test of cells described in
panel A with or without the addition of 10 mM N-acetylcysteine (NAC), assessed as in
Fig. 4A. (D) Schematic depicting mitoT synthetic intermembrane tether. (E) SDSPAGE immunoblot analysis of mitochondria isolated from WT and mic60Δ cells
expressing vector controls, overexpressing Hem15 or mitoT, or overexpressing both
constructs simultaneously. Steady-state levels of indicated proteins were visualized with
appropriate antibodies (anti-GFP antibody was used to detect mitoT). The outer
mitochondrial membrane protein porin served as a loading control. (F) Growth test of
cells described in panel E. (G) Hydrogen peroxide sensitivity of cells described in panel
E, handled and analyzed as in panel B.

99
Co-expression of mitoT in Hem15-overexpressing mic60Δ cells improved growth
on galactose and glycerol-lactate media, reflecting a partial rescue effect (Fig. 2.12F).
Interestingly, mitoT expression had the opposite effect in Hem15-overexpressing WT
cells, suggesting that excess intermembrane tethering has a negative effect on the normal
function of mitochondria. MitoT expression also resulted in increased steady-state levels
of Hem15 protein in both WT and mic60Δ cells (Fig. 2.12E) although the reason for this
effect is unclear at present. The rescue appears to be due to a remarkable increase in
oxidative stress tolerance in the Hem15-overexpressing mic60Δ cells co-expressing
mitoT (Fig. 2.12G).
2.5 DISCUSSION
Towards the goal of better understanding the molecular and functional
organization of yeast ferrochelatase (Hem15) and, more broadly, the regulation of the
heme biosynthetic pathway, this study has revealed several new findings.
The functional state of Hem15 was assessed and the yeast enzyme compared to
human ferrochelatase. Hem15 assembles into a high-mass oligomer, which likely
represents the functional enzyme, as it is compromised both in hem1Δ cells blocked at a
very early stage of heme biosynthesis and in cells expressing the catalytically inactive
H235C Hem15 mutant. This study demonstrated that the yeast H235 residue is critical for
Fech activity in yeast, much like the homologous H263 residue in humans (43), and
similarly hypothesized to be critical for proton abstraction from PPIX for metallation and
heme formation.
To determine how the active-site structure of Hem15 is impacted by the H235C
mutation, the H235C variant was crystallized and its structure solved at 2.4 Å resolution.
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This structure reveals that the location and orientation of active-site residues in the WT
protein and H235C Hem15 variant are similar, as are the active-site hydrogen-bonding
networks (Fig. 2.2E). This intact network differs from the human H263C variant structure
where the network is disrupted (43). It is unclear why this difference between the yeast
and human catalytic mutants exists, though both variants are inactive due to the absence
of the base (H235 in yeast and H263 in humans) necessary for proton abstraction.
Human FECH is able to efficiently replace the yeast enzyme, despite the human
enzyme requiring a [2Fe-2S] cluster for enzyme activity (44-46) that is absent in the yeast
enzyme. This iron-sulfur cluster is believed to serve as a sensor for the redox state and/or
pH of the mitochondrial matrix (44, 60). The finding that WT human FECH, but not a
mutant bearing the C406S substitution for one of the cluster-binding ligands,
complements the yeast deletion mutant suggests that the cluster is successfully formed in
the context of yeast mitochondria.
Hem15-deficient cells exhibit a petite-inducing phenotype that can be rescued
genetically through overexpression of ribonucleotide reductase subunit Rnr1, a genetic
manipulation known to stabilize mitochondrial DNA in petite mutants(30, 61). This
finding explains previously described difficulties in establishing a robust genetic
complementation of the hem15Δ mutant with plasmid-borne Hem15 (48). While the
exact molecular underpinnings of the petite-inducing phenotype of hem15Δ are currently
unclear, they might arise from impaired hemylation of mitochondrial matrix
hemoproteins with connections to the mitochondrial genome, such as the yeast
flavohemoglobin Yhb1 or translational activator Mss51 (62-65), but further studies are
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warranted to explore the connection between loss of Hem15 and instability of
mitochondrial DNA.
The high-mass Hem15 complex was found by proteomic analysis to contain
components of the MICOS machinery. A portion of the core MICOS subunit Mic60 is
exposed to the matrix side of the IM (24, 25) and is thus likely to mediate this Hem15MICOS association. Loss of Mic60 affects the high-mass oligomeric species of Hem15
akin to the destabilizing effect of the catalytic H235C Hem15 variant and the Alas
(Hem1) deletion mutant, consistent with the idea that MICOS contributes to the
molecular organization of Fech. These results agree with earlier reports suggesting that
mammalian FECH is a component of a large complex termed the mitochondrial heme
metabolon (17-19). Studies in mammalian cells have shown the heme metabolon contains
components of MICOS, underscoring the conservation and importance of this connection.
The yeast MICOS presents as a series of large oligomers (53) and, since Mic60 is
about 1.5-fold more abundant than Hem15 (66, 67), it is unlikely that its subunits form
stable stoichiometric complexes with Hem15. Instead, there may be a dynamic
association between Hem15 and MICOS that is not essential for Hem15 activity but is
nevertheless important for its ideal performance. In agreement with this idea is the
observation that basal Hem15 activity is not significantly affected in the mic60

mutant,

whereas the added strain caused by overexpression of Hem15 results in a profound
respiratory growth defect, reduces levels of PPIX, attenuates Hem15 activity, elevates
levels of intermediate porphyrins, and results in oxidative damage and stress, compared
to similarly treated WT cells. Porphyrin profiling under these conditions revealed that the
levels of some porphyrins like coproporphyrins and PPIX are decreased in the absence of
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Mic60, while others like hexacarboxylporphyrins and heptacarboxylporphyrins are
increased. Low PPIX levels could be attributed to reduced Ppox activity, a downstream
effect of low Cpox activity since Cpox is inhibited by heme (68), or a more complex
result of this apparent disruption of porphyrin homeostasis. The low PPIX levels may be
in turn causing the decreased Hem15 activity, and the elevated intermediate porphyrins
are likely causing the oxidative damage and stress observed when Hem15 is
overexpressed.
These results suggest the FECH-MICOS association has functional significance.
We propose a model wherein IM-OM contact sites formed by MICOS facilitate the
transfer of intermediate porphyrinogen precursors across the mitochondrial membranes,
thereby ensuring optimal substrate delivery to Fech (Fig. 2.13). Data in the current study
do not exclude the possibility that MICOS is directly involved in this transport of heme
biosynthetic intermediates, analogous to its proposed role in transporting phospholipids
such as phosphatidic acid (26) and coenzyme Q biosynthetic intermediates (27).
However, it may be more likely that MICOS plays an indirect role through one or more
plausible mechanisms. For instance, the complex may aid the heme intermediate
transport process through bridging the OM and IM to create a proximity conduit between
these membranes, as suggested by the rescue of oxidative stress tolerance seen in Hem15overexpressing mic60Δ cells co-expressing a synthetic mitoT (59) tether. In mammalian
cells, MICOS might be required for spatial organization of the currently elusive
coproporphyrinogen III and protoporphyrinogen IX transporters in the OM and IM,
respectively, thus accounting for the accumulation of tetrapyrrole intermediates arising
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Wild type

mic60Δ

Figure 2.13. Model for involvement of MICOS in heme biosynthesis. IM-OM
contacts formed by MICOS may facilitate the transfer of intermediate porphyrin
precursors (purple crosses) across the mitochondrial membranes into the matrix,
thus ensuring optimal delivery of substrate to Fech for synthesis of heme (red
crosses). Loss of Mic60/MICOS results in accumulation of porphyrin
intermediates and subsequent oxidative damage.
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from cellular accumulation of the heme synthesis intermediates during uroporphyrinogen
III decarboxylation in MICOS-deficient cells (Fig. 2.8C and Fig. 2.10).
Intriguingly, Mic60 is highly conserved with homologs found in ⍺-proteobacteria,
wherein the gene clusters with heme biosynthetic genes (69, 70), further supporting a
potential functional link between MICOS and the heme biosynthetic pathway. The
additional identification of the conserved dynamin-like GTPase Mgm1 (OPA1 in
humans) as a potential interacting partner of Fech supports earlier proteomic studies in
mammalian mitochondria (17, 19). Our recent study established that the mgm1Δ mutant
exhibits a marked defect in nuclear heme levels (39), further supporting a model in which
IM ultrastructure-related factors like Mgm1 and MICOS may cooperate with Fech to
facilitate delivery of its substrate and/or distribution of its product.
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CHAPTER 3: THE ROLE OF MITOCHONDRIAL DYNAMICS AND ER CONTACT
SITES IN CELLULAR HEME DISTRIBUTION

Note: The results described in this chapter have been published and all text is modified
from the original version.

The citation is: Martinez-Guzman, O., Willoughby, M.M., Saini, A., Dietz, J.V.,
Bohovych, I., Medlock, A.E., Khalimonchuk, O., Reddi, A.R. (2020) Mitochondrialnuclear heme trafficking in budding yeast is regulated by GTPases that control
mitochondrial dynamics and ER contact sites. J. Cell Science. doi: 10.1242/jcs.237917.

3.1 ABSTRACT
Heme is a cofactor and signaling molecule that is essential for much of aerobic life. All
heme-dependent processes in eukaryotes require that heme is trafficked from its site of
synthesis in the mitochondria to hemoproteins located throughout the cell. However, the
mechanisms governing the mobilization of heme out of the mitochondria, and the spatiotemporal dynamics of these processes, are poorly understood. Here, using genetically
encoded fluorescent heme sensors, we developed a live- cell assay to monitor heme
distribution dynamics between the mitochondrial inner membrane, where heme is
synthesized, and the mitochondrial matrix, cytosol and nucleus. Surprisingly, heme
trafficking to the nucleus is ∼25% faster than to the cytosol or mitochondrial matrix,
which have nearly identical heme trafficking dynamics, potentially supporting a role for
heme as a mitochondrial–nuclear retrograde signal. Moreover, we discovered that the
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heme synthetic enzyme 5-aminolevulinic acid synthase (ALAS, also known as Hem1 in
yeast), and GTPases in control of the mitochondrial dynamics machinery (Mgm1 and
Dnm1) and ER contact sites (Gem1), regulate the flow of heme between the mitochondria
and nucleus. Overall, our results indicate that there are parallel pathways for the
distribution of bioavailable heme.
3.2 INTRODUCTION
Heme b is an essential but cytotoxic metallocofactor and signaling molecule. As a
cofactor, heme facilitates diverse processes that span electron transfer, chemical catalysis
and gas synthesis, storage and transport (1, 2). As a signaling molecule, heme-mediated
regulation of transcription factors, kinases, ion channels and microRNA processing
proteins collectively controls iron and redox homeostasis, oxygen sensing, mitochondrial
metabolism, apoptosis, circadian rhythms, cell cycle progression, proliferation and
proteostasis (1, 2).
Although essential for life, heme and its biosynthetic precursors can also act as
toxins, necessitating careful handling of the synthesis and trafficking of this compound
by cells. The hydrophobicity and redox activity of heme causes it to disrupt membrane
and protein structure and deleteriously oxidize various biomolecules (3, 4). Porphyrins
and porphyrinogens, heme biosynthetic intermediates, are photosensitizers that can
catalyze the formation of reactive oxygen species (5). Many diseases are associated with
defects in heme management, including certain cancers (6), cardiovascular disease (7),
neurodegenerative diseases (8, 9,10), porphyrias (11), and anemias (12). Despite the
tremendous importance of heme in physiology, the cellular and molecular mechanisms
that govern the assimilation of heme into metabolism remain poorly understood.
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In eukaryotes, heme is synthesized via a highly conserved eight-step process. The
first and the last three reactions in metazoans (the first and last two in the yeast
Saccharomyces cerevisiae) take place in the mitochondria and the remaining reactions
occur in the cytosol (13). The first committed step of heme synthesis is the condensation
of glycine with succinyl coenzyme A to form 5-aminolevulinic acid (ALA), which is
catalyzed by ALA synthase (ALAS, also known as Hem1 in yeast). ALA is then exported
from the mitochondria into the cytosol where it is converted to coproporphyrinogen III in
four steps. Coproporphyrinogen III is then transported back into the mitochondria where
it is converted to protoporphyrin IX (PPIX) in two steps by the enzymes
coproporphyrinogen oxidase (CPOX) and protoporphyrinogen oxidase (PPOX). In the
final step of heme synthesis, ferrochelatase (FECH) catalyzes the insertion of ferrous iron
into PPIX to make heme. Interestingly, it was recently proposed that the mitochondrial
heme biosynthetic enzymes, ALAS, PPOX and FECH, form a super complex, or
metabolon, that includes additional factors like iron and porphyrinogen transporters, and
putative heme chaperones (14, 15). The rationale for a heme metabolon is that it would
facilitate the channeling of potentially toxic reactive substrates, including porphyrinogen,
porphyrin and iron, for efficient production and trafficking of heme, thereby mitigating
their ability to diffuse freely throughout the cell in an unproductive and deleterious
manner. However, given this rationale, it is unclear why ALAS would interact with
FECH in the heme metabolon if ALA were not the immediate substrate for FECH.
Rather, it is possible that ALAS may regulate FECH to affect heme synthesis or
trafficking.
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Once heme is synthesized by FECH on the matrix side of the mitochondrial inner
membrane (IM), it must be mobilized to hemoproteins present in virtually every
subcellular compartment. However, the specific factors that govern the trafficking of
heme to target hemoproteins are poorly understood (1, 2). The current paradigm for
subcellular heme trafficking is a sequential one in which mitochondrial heme transporters
export heme into the cytosol, where it can then be distributed to other locales. This
sequential paradigm for heme distribution was established with the discovery of feline
leukemia virus subgroup C cellular receptor 1b (FLVCR1b), the only putative
mitochondrial heme transporter identified to date (16).
An alternative, but far less studied potential mechanism for heme distribution is
through mitochondrial membrane contact sites (1). Endoplasmic reticulum (ER)–
mitochondrial encounter structures (ERMES), one type of mitochondrial–ER contact site
(17), are highly dynamic tethers that physically link the mitochondrial and ER networks
and have been proposed to play a role in the transfer of lipids and regulate iron
homeostasis (18, 19, 20). The frequency of ERMES is in part dependent on mitochondrial
division (17). ER tubules facilitate mitochondrial fission by wrapping around and
constricting mitochondria in an ERMES-dependent fashion, thereby ensuring that the
GTPase Dnm1 can oligomerize around a compressed mitochondrial outer membrane
(OM) to catalyze the scission of mitochondria (21). Following fission, the GTPase Gem1
disengages ERMES to dissolve the ER–mitochondrial contact site (22). As a
consequence, ERMES is dependent on mitochondrial fission and fusion dynamics (17).
Indeed, mutants with defects in mitochondrial fission or fusion have increased or
decreased numbers of ERMES, respectively (17).
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Here, using genetically encoded ratiometric fluorescent heme sensors (HS1)
targeted to the mitochondrial matrix, cytosol or nucleus (23, 24, 25), we developed a livecell assay in yeast to monitor heme distribution kinetics and probe the role of ALAS,
ERMES and mitochondrial dynamics in subcellular heme trafficking. Surprisingly, we
found that heme trafficking rates from the matrix side of the IM to the mitochondrial
matrix and cytosol are similar, whereas trafficking to the nucleus is ∼25% faster. We
propose that the increased rate of nuclear heme trafficking is required for heme-based
mitochondrial–nuclear retrograde signaling. These data also indicate that heme is
distributed from the mitochondrial IM to other locales simultaneously via parallel
pathways rather than sequentially. Moreover, we discovered that ALAS negatively
regulates mitochondrial–nuclear heme trafficking, highlighting the close coordination of
heme synthesis and trafficking. In addition, we identified GTPases that directly (Gem1)
and indirectly (Dnm1 and Mgm1) regulate ERMES as being modulators of nuclear heme
transport. Based on our results, we propose a model in which heme is trafficked via ER–
mitochondrial contact sites to other organelles such as the nucleus.
3.3 MATERIALS AND METHODS
3.3.1 Yeast strains, transformations, and growth conditions
S. cerevisiae strains used in this study were derived from BY4741 (MATa,
his3Δ1, leu2Δ0, met15Δ0, ura3Δ0). fis1Δ::KanMX4, dnm1Δ:: KanMX4,
mgm1Δ::KanMX4, pcp1Δ::KanMX4, ugo1Δ::KanMX4, caf4Δ:: KanMX4,
mdv1Δ::KanMX4 strains were obtained from the yeast gene deletion collection (Thermo
Fisher Scientific). We also used the previously reported strains LJ109 (rho0) (26) and
DH001b-3 (hem1Δ::HIS3) (23). AR1029-3 (mdv1Δ::KanMX4 caf4Δ:: HIS3) was
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generated by deleting CAF4 with pAR1047 in mdv1Δ::KanMX4 cells. OM232
(mgm1Δ::HIS3) and OM233 (dnm1Δ::KanMX4 mgm1Δ:: HIS3) were generated by
deleting MGM1 with pAR1051 in WT and dnm1Δ::KanMX4 cells, respectively. All
strains were confirmed by PCR, mitochondrial morphology (Fig. 3.1), and, if derived
from the yeast deletion collection, sequencing the unique barcodes flanking the KanMX4
deletion cassette.
Yeast transformations were performed by the lithium acetate procedure (27).
Strains were maintained at 30°C on either enriched yeast extract (1%) and peptone (2%)
based medium supplemented with 2% glucose (YPD), or synthetic complete medium
(SC; Sunrise Science Products) supplemented with 2% glucose and the appropriate amino
acids to maintain selection (23). Cells cultured on solid medium plates were done so with
YPD or SC media supplemented with 2% agar (23). Selection for yeast strains containing
the KanMX4 marker was done on YPD agar plates supplemented with G418 (200 μg/ml)
(23). WT cells treated with the heme synthesis inhibitor, SA, and hem1Δ cells were
cultured in YPD or SC media supplemented with 50 μg/ml of 5-aminolevulinic acid
(ALA) or 15 mg/ml of ergosterol and 0.5% TWEEN 80 (YPDE or SCE, respectively)
(23,28). All liquid cultures were maintained at 30°C and shaken at 220 rpm.
3.3.2 Plasmids
The caf4::HIS3 disruption plasmid pAR1047 was generated by first PCR
amplifying the upstream (−650 to −129) and downstream (+2110 to +2479) sequences
relative to the CAF4 translational start site, introducing 5′ BamHI and 3′ XhoI, and 5′
XbaI and 3′ BamHI restriction sites, respectively. The CAF4 PCR products were digested
with the enzymes indicated and ligated in a trimolecular reaction into the HIS3
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integrating plasmid pRS403 (29) digested with XhoI and XbaI, resulting in pAR1047.
Transformation of yeast strains with pAR1047 linearized with BamHI resulted in deletion
of CAF4 sequences from −128 to +2109. The mgm1::HIS3 disruption plasmid, pAR1051,
was generated by first PCR amplifying the upstream (−532 to −5) and downstream
(+2736 to +3023) sequences relative to the MGM1 translational start site, introducing 5′
BamHI and 3′ XhoI, and 5′ XbaI and 3′ BamHI restriction sites, respectively. The MGM1
PCR products were digested with the enzymes indicated and ligated in a trimolecular
reaction into the HIS3 integrating plasmid pRS403 (29) digested with XhoI and XbaI,
resulting in pAR1051. Transformation of yeast strains with pAR1051 linearized with
BamHI resulted in deletion of MGM1 sequences from −4 to +2735. Cytosolic,
mitochondrial- and nuclear-targeted heme sensors, HS1, were sub-cloned into pRS415
[American Type Culture Collection (ATCC)] and driven by ADH, TEF, or GPD
promoters as previously described 23The Hap1 reporter plasmid in which eGFP is driven
by the CYC1 promoter was also as previously described (23).
3.3.3 Heme trafficking dynamics assay
Inter-compartmental heme trafficking rates were monitored by inhibiting heme
synthesis with SA in sensor-expressing cells, then removing the block in heme synthesis
by resuspending cells into medium lacking SA and monitoring the time-dependent
change in the percentage of heme bound to heme sensor 1 (HS1) localized to the cytosol,
nucleus, and mitochondrial matrix upon the re-initiation of heme synthesis. The fractional
heme saturation of the sensor was determined using previously established sensor
calibration protocols (23). The percentage of the sensor bound to heme, % Bound, was
calculated by determining the sensor eGFP/mKATE2 fluorescence ratio (R) under a
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given test condition relative to the eGFP/mKATE2 fluorescence ratio when the sensor
was 100% (Rmax) or 0% (Rmin) bound to heme as described in Eqn 1 (23).
Rmin was determined by measuring the HS1 eGFP/mKATE2 ratio in parallel
cultures that were conditioned with SA, which inhibits the second enzyme in the heme
biosynthetic pathway, ALA dehydratase (ALAD) (30), and Rmax was determined by
permeabilizing cells and adding an excess of heme to saturate the sensor (23). Given HS1
is quantitatively saturated with heme in the cytosol, nucleus, and mitochondria of WT
yeast, we typically determined Rmax by measuring the HS1 eGFP/mKATE2 ratio in
parallel WT cultures grown without SA (23).
3.3.4 Growth for SA pulse-chase assay
HS1-expressing cells were cultured with or without 500 μM SA (Sigma- Aldrich)
in SCE-LEU medium. Triplicate 5 ml cultures were seeded at an initial optical density of
OD600=0.01–0.02 (2–4×105 cells/ml) and grown for 14–16 h at 30°C and shaking at 220
rpm until cells reached a final density of OD600nm∼1.0 (2×107 cells/ml). After culturing, 1
OD or 2×107 cells were harvested, washed twice with 1 ml of ultrapure water, and
resuspended in 1 ml of fresh SC-LEU medium. The cells that were pre- cultured without
SA provided HS1 Rmax values. The SA-conditioned cells were split into two 500 μl
fractions. One fraction was treated with 500 μM SA to give HS1 Rmin values. The other
fraction was not treated with SA so that heme synthesis could be re-initiated to give
compartment-specific heme trafficking rates. HS1 fluorescence was monitored using 200
μl of 1 OD/ml (2×107 cells/ml) cell suspension in black Greiner Bio-one flat bottom
fluorescence plates with a Synergy Mx multi-modal plate reader. eGFP (excitation 488
nm, emission 510 nm) and mKATE2 (excitation 588 nm, emission 620 nm) fluorescence
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was recorded every 5 min for 4 h, with the plate being shaken at medium strength for 30 s
prior to each read. Background fluorescence of cells not expressing the heme sensors was
recorded and subtracted from the eGFP and mKATE2 fluorescence values.
3.3.5 Growth for ALA pulse-chase assay
HS1-expressing hem1Δ cells were cultured with or without 400 μM 5aminolevulinic acid (ALA) (Sigma-Aldrich) in SCE-LEU medium. Triplicate 5 ml
cultures were seeded at an initial optical density of OD600nm=0.01–0.02 (2–4×105
cells/ml) and grown for 14–16 h at 30°C and shaking at 220 rpm until cells reached a
final density of OD600∼1.0 (2×107 cells/ml). After culturing, 1 OD or 2×107 cells were
harvested, washed twice with 1 ml of ultrapure water, and resuspended in 1 ml of fresh
SC-LEU medium. The cells that were pre-cultured with ALA provided HS1 Rmax values.
The cells that were cultured without ALA were split into two 500 μl fractions. One
fraction was used to give HS1 Rmin values. The other fraction was treated with 400 μM
ALA so that heme synthesis could be initiated to give compartment-specific heme
trafficking rates. HS1 fluorescence was monitored on 200 μl of a 1 OD/ml (2×107
cells/ml) cell suspension using black Greiner Bio-one flat bottom fluorescence plates and
a Synergy Mx multi-modal plate reader. eGFP (excitation 488 nm, emission 510 nm) and
mKATE2 (excitation 588 nm, emission 620 nm) fluorescence was recorded every 5 min
for 4 h, with the plate being shaken at medium- strength for 30 s prior to each read.
Background fluorescence of cells not expressing the heme sensors was recorded and
subtracted from the eGFP and mKATE2 fluorescence values. It should be noted that due
to evaporation and drying of cell cultures in the plate reader, reliable measurements could
not be achieved after 4 h of continuous monitoring.
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3.3.6 Total heme quantification
Measurements of total heme were accomplished using a fluorometric assay
designed to measure the fluorescence of protoporphyrin IX upon the release of iron from
heme as previously described (31). For all total heme measurements, ∼1×108 cells were
harvested, washed in sterile ultrapure water, resuspended in 500 μl of 20 mM oxalic acid
and stored in a closed box at 4°C overnight (16–18 h). Next, an equal volume (500 μl) of
2 M oxalic acid was added to the cell suspensions. The samples were split, with half the
cell suspension transferred to a heat block set at 95°C and heated for 30 min and the other
half of the cell suspension kept at room temperature (∼25°C) for 30 min. All suspensions
were centrifuged for 2 min on a table-top microfuge at 21,000 g and the porphyrin
fluorescence (excitation 400 nm, emission 620 nm) of 200 μl of each sample was
recorded on a Synergy Mx multi-modal plate reader using black Greiner Bio-one flat
bottom fluorescence plates. Heme concentrations were calculated from a standard curve
prepared by diluting 500–1500 μM hemin chloride stock solutions in 0.1 M NaOH into
ultrapure water, which was then added back to extra cell samples as prepared above. In
order to calculate heme concentrations, the fluorescence of the unboiled sample (taken to
be the background level of protoporphyrin IX) was subtracted from the fluorescence of
the boiled sample (taken to be the free base porphyrin generated upon the release of heme
iron). The cellular concentration of heme was determined by dividing the moles of heme
determined in this fluorescence assay by the number of cells analyzed, giving moles of
heme per cell, and then converting to a cellular concentration by dividing by the volume
of a yeast cell, taken to be 50 fl (23).
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In order to measure heme synthesis rates, exponential phase cells were preconditioned with 500 μM SA for 14–16 h in SCE-LEU medium as described above for
the heme trafficking dynamics assay. Following this, cells were washed and resuspended
in medium lacking SA and aliquots of cells were harvested and washed for total heme
quantification as described above.

3.3.7 Hap1 activity
Cells expressing p415-CYC1-eGFP, where eGFP expression is driven by the
Hap1 regulated CYC1 promoter, were cultured in 50 ml of SCE-LEU in 250 ml
Erlenmeyer flasks, with or without 500 μM SA, for 14–16 h to an optical density of
OD600∼1.0 (2×107 cells/ml). Cells were washed with sterile ultrapure water and diluted
into fresh SC-LEU medium at an optical density of OD600=0.25 and allowed to grow for
an additional 4 h. The culture that was initially not conditioned with SA remained
untreated during the 4 h growth phase and these cultures represented basal Hap1 activity.
The culture that was pre-conditioned with SA was split into two fractions. One fraction
was treated with 500 μM SA for the 4 h growth phase and these cultures served as a
negative control, representing minimal Hap1 mediated activation of CYC1. The other
fraction was not treated with SA for the 4 h growth phase and these cultures represented
Hap1 activity under conditions in which Hap1 was not saturated with heme. After growth
for 4 h, cells were washed in sterile ultrapure water and resuspended in PBS to a
concentration of 1×108 cells/ml and 100 μl was used to measure eGFP fluorescence
(excitation 488 nm, emission 510 nm). Background auto-fluorescence of cells not
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expressing eGFP was recorded and subtracted from the p415-CYC1-eGFP expressing
strains.
3.3.8 Isolation of mitochondria and nuclei to confirm heme sensor localization
Mitochondria and nuclei were isolated using yeast mitochondrial (Cat # K259-50)
and nuclear (Cat # K289-50) isolation kits from BioVision according to the
manufacturer’s instructions. All reagents and buffers were supplied by the isolation kits.
For isolation of mitochondria, 50 ml of sensor expressing cells were cultured in SC-LEU
in 250 ml Erlenmeyer flasks to a final density of OD600=1.0 (2×107 cells/ml). A total of
4×108 cells were harvested, washed in ultrapure water, and resuspended in ‘Buffer A’
containing 10 mM DTT for 30 min at 30°C with occasional gentle agitation.
Cells were then harvested by centrifugation at 1500 g for 5 min at room
temperature. Cells were then resuspended in 1 ml of ‘Buffer B’ containing manufacturerprovided zymolyase and incubated at 30°C with occasional gentle inversion. Spheroplast
formation was monitored by diluting 10 μl of the cell suspension into ultrapure water and
monitoring the decrease in OD600 such that it was >80% less than the initial value, which
typically took 30–60 min. Spheroplasts were harvested by centrifugation at 1500 g for 5
min, resuspended in ‘Homogenization Buffer’ containing a protease inhibitor cocktail,
and lysed with 15 strokes of a Dounce homogenizer on ice. The lysate was centrifuged at
600 g for 5 min at 4°C to remove cell debris. The supernatant, which contained the
mitochondria, was again centrifuged for 5 min at 600 g to remove additional debris.
Finally, mitochondria were harvested by centrifugation at 12,000 g for 10 min at 4°C.
The mitochondrial pellet was resuspended in 50 μl of ‘Storage Buffer’. In order to
validate sensor mitochondrial localization, 5% of the total spheroplast fraction,
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mitochondrial fraction, and the post-mitochondrial fraction (supernatant from the 12,000
g centrifugation step) were electrophoresed on a 14% Tris-glycine SDS–PAGE gel and
immunoblotted using anti-PGK1 (Life Technologies; Cat # PA528612; 1:5000 dilution)
to detect the cytosolic marker protein PGK1, anti-porin (Life Technologies; Cat #459500;
1:5000 dilution) to detect the mitochondrial marker protein porin, and anti-GFP
(Genetex; Cat # GTX30738; 1:5000 dilution) to probe HS1 expression. A goat anti-rabbit
secondary antibody conjugated to a 680 nm emitting fluorophore (VWR/ Biotium, Cat #
89138-520; 1:10,000 dilution) was used to probe for PGK1 and GFP. A goat anti-mouse
secondary antibody conjugated to a 680 nm emitting fluorophore (VWR/Biotium, Cat #
89138-516; 1:10,000 dilution) was used to probe for Porin. All gels were imaged on a
LiCOR Odyssey Infrared imager (23, 26).
For isolation of nuclei, 50 ml of sensor-expressing cells were cultured in SC-LEU
in 250 ml Erlenmeyer flasks to a final density of OD600=1.0 (2×107 cells/ml). A total of
4×108 cells were harvested, washed in ultrapure water, and resuspended in ‘Buffer A’
containing 10 mM DTT for 30 min at 30°C with occasional gentle agitation. Cells were
then harvested by centrifugation at 1500 g for 5 min at room temperature. Cells were then
resuspended in 1 ml of ‘Buffer B’ containing manufacturer provided zymolyase and
incubated at 30°C with occasional gentle inversion. Spheroplast formation was monitored
by diluting 10 μl of the cell suspension into ultrapure water and monitoring the decrease
in OD600 such that it was >80% less than the initial value, which typically took 30– 60
min. Spheroplasts were harvested by centrifugation at 1500 g for 5 min, resuspended in 1
ml of ‘Buffer N’ containing a protease inhibitor cocktail, and lysed with 5 strokes of a
Dounce homogenizer on ice. The suspension was incubated for 30 min at room
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temperature with gentle agitation every 3–5 min. The lysate was centrifuged at 1500 g for
5 min at 4°C to remove cell debris. Finally, nuclei were harvested by centrifugation at
20,000 g for 10 min at 4°C. The nuclear pellet was resuspended in 100 μl of ‘Buffer N’.
In order to validate sensor nuclear localization, 5% of the total spheroplast fraction,
nuclear fraction, and the post-nuclear fraction (supernatant from the 20,000 g
centrifugation step) were electrophoresed on a 14% Tris-glycine SDS–PAGE gel and
immunoblotted using anti-PGK1 (Life Technologies; Cat # PA528612; 1:5000 dilution)
to detect the cytosolic marker protein PGK1, anti-NOP1 (Life Technologies; Cat
#MA110025; 1:10,000 dilution) to detect the nuclear marker protein NOP1, and anti-GFP
(Genetex; Cat # GTX30738; 1:5000 dilution) to probe HS1 expression. A goat anti-rabbit
secondary antibody conjugated to a 680 nm emitting fluorophore (VWR/Biotium; Cat
#89138-520; 1:10,000 dilution) was used to probe for PGK1 and GFP. A goat anti-mouse
secondary antibody conjugated to a 680 nm emitting fluorophore (VWR/Biotium; Cat
#89138- 516; 1:10,000 dilution) was used to probe for NOP1. All gels were imaged on a
LiCOR Odyssey Infrared imager (23, 26).
3.3.9 Confirmation of heme sensor localization by microscopy
To confirm mitochondrial or nuclear localization of the sensors, prior to
microscopy, 1×107 exponential phase cells were incubated with 5.5 μg/ml 4′,6diamidino-2-phenylindole (DAPI) (Invitrogen) in SC-LEU medium for 40–60 min to
stain nuclear or mitochondrial DNA (23). The concentration or duration of DAPI
exposure can be used to selectively stain nuclei versus mitochondria (32, 33). In our
hands, a 40 min exposure preferentially stained the mitochondrial network, while >60
min exposures stained the nucleus. Laser scanning confocal microscopy was
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accomplished on a Zeiss ELYRA LSM 780 super-resolution microscope equipped with a
63×, 1.4 numerical aperture oil objective. DAPI was excited at 405 nm and emission was
collected using 410–483 nm bandpass filters. eGFP was excited with the 488 nm line of
an argon ion laser, while mKATE2 was excited using the 594 nm of a HeNe laser line.
The 491–588 nm and 599–690 nm bandpass filters were used to filter emission for eGFP
and mKATE, respectively. Images were collected using Zeiss software and analyzed with
ImageJ 1.48v (Rasband, W.S., ImageJ, NIH, Bethesda, MD, http://rsb.info.nih.gov/ij/,
1997-2007). Auto-fluorescence of unlabeled cells was subtracted from the DAPI, eGFP,
and mKATE2 channels to produce the images in Fig. 3.2B.
3.3.10 Confirmation of mitochondrial morphology in fission and fusion
To visualize the mitochondrial network, 1×107 exponential phase cells were
incubated with 500 μM MitoTracker Red CM-H2Xros (Thermo Fisher Scientific) in SCLEU medium for 45–60 min. Confocal microscopy was done on a Zeiss ELYRA LSM
780 super-resolution microscope equipped with a 63×, 1.4 numerical aperture oil
objective. Mito Tracker Red was excited using the 594 nm of a HeNe laser line and
emission was collected using a 415–735 nm bandpass filter. Images were collected using
Zeiss software and analyzed with ImageJ 1.48v. The various mitochondrial network
morphology types observed are outlined in Fig. 3.1A and ∼50 cells from each strain were
analyzed to confirm the expected mitochondrial morphology (Fig. 3.1B). A
representative image of the mitochondrial network from each strain is depicted in Fig.
3.1C. Fission and fusion mutants had characteristic elongated or punctate mitochondrial
networks, respectively.
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Fig. 3.1. Validation of the
mitochondrial network
morphology defects in yeast
fission and fusion mutants. (a)
Sampling and classification of
mitochondrial network
morphologies observed using
Mitotracker staining of cells. (b)
Histograms of mitochondrial
network morphology in the fission
and fusion mutants used
throughout this study. Mutants
defective in mitochondrial fission
exhibit an elongated mitochondrial
network. Mutants defective in
mitochondrial fusion exhibit a
punctate mitochondrial network.
WT and mgm1∆ dnm1∆ cells tend
to have a more equal distribution
of elongated and punctate
mitochondrial networks. The
histograms were generated by
analyzing ~50 cells per mutant. (c)
Representative images of the
mitochondrial network in the
fission and fusion mutants utilized
in this study. Scale bar: 5.0 um.

132

3.3.11 Mitochondrial fragmentation assay
Mitochondrial morphology was assessed in wild-type yeast (W303, MATα ade2-1
can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1) transformed with the pYX142-Su9-RFP
plasmid (34). The pYX142-Su9- RFP plasmid expresses a mitochondria-targeted red
fluorescent protein (RFP), allowing for visualization of mitochondria using a
fluorescence microscope. Cells were grown overnight in SC medium with 2% glucose as
the sole carbon source. The cells were then subcultured into fresh pre- warmed medium
at an OD600 of 0.2 for 3 h, and then treated with SA at a final concentration of 500 μM
and cultured for 4, 5, or 6 h post-SA treatment. Imaging was performed on an Olympus
IX81-FV5000 confocal laser-scanning microscope with a 543 nm laser line, using a 100×
oil objective. Images were acquired and processed with Fluoview 500 software (Olympus
America). Mitochondrial fragmentation was quantified based on the ratio of the cells
displaying punctated or dotted-like morphology versus normal ribbon-like mitochondrial
networks. At least 300 cells were analyzed for each sample per replicate.
3.3.12 Mitochondrial membrane potential assay
The mitochondrial membrane potential was assayed on cells cultured in a similar
manner to that described above for the assessment of heme- dependent changes in
mitochondrial fragmentation, using a BD FACSCanto™ II system (Becton Dickinson) as
previously described (35). After culturing for the indicated times, cells were first washed
with phosphate-buffered saline (PBS), and then stained with 200 nM 3,3′Dihexyloxacarbocyanine iodide (DiOC6) (Molecular Probes) for 30 min at 30°C. Finally,
the cells were washed twice with PBS and analyzed by flow cytometry using the FL3
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channel without compensation. The data were collected, analyzed and plotted using BD
FACSDiva software v6.1.1 (Becton Dickinson).
3.4 RESULTS
3.4.1 Inter-compartmental heme transport kinetics
In order to probe inter-compartmental heme trafficking in yeast, we developed an
in vivo pulse-chase assay in which, upon the initiation of heme synthesis, heme
mobilization into the mitochondrial matrix, cytosol and nucleus is monitored using a
previously reported genetically encoded ratiometric fluorescent heme sensor (HS1) (23).
Heme binding to HS1 Fig. 3.2A) results in a decrease in the eGFP to mKATE2
fluorescence ratio of the sensor. We targeted HS1 to the mitochondria and nucleus by
appending N-terminal Cox4 mitochondrial matrix or C-terminal SV40 nuclear
localization sequences, respectively, as previously demonstrated (23) and confirmed the
localization by microscopy Fig. 3.2B) and organelle isolation and immunoblotting (Fig.
3.2C, D). HS1 lacking nuclear or mitochondrial targeting sequences had a diffuse pattern
of expression throughout the cytosol Fig. 3.2B) and was found primarily in the cytosolic
fractions of mitochondrial and nuclear preparations (Fig. 3.2C, D). Nuclear- and
mitochondrial-targeted HS1 colocalized with 4′,6-diamidino- 2-phenylindole (DAPI)
(Fig. 3.2B), which can be used to selectively mark nuclear or mitochondrial DNA
depending on concentration or duration of exposure (31,33), and was found primarily in
nuclear and mitochondrial fractions, respectively Fig. 3.2C, D). It is possible that a small
fraction of mitochondrial- or nuclear-targeted sensor might be present in the cytosol and
confound analysis of sub-compartmental heme. In order to assess whether this were the
case, we permeabilized heme-deficient cells lacking HEM1, which encodes ALAS, with
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digitonin, which selectively permeabilizes the plasma membrane and treated cells with
heme. As indicated in Fig. 3.2E, only cells expressing cytosolic HS1 exhibited a
significant heme-dependent reduction in eGFP to mKATE2 fluorescence ratio, with little
perturbation to the fluorescence of mitochondrial- and nuclear-targeted HS1. These data
indicate that mitochondrial- and nuclear-targeted HS1 is unresponsive to cytosolic heme.
Inter-compartmental heme trafficking rates were monitored by inhibiting heme synthesis
with 500 μM succinylacetone (SA), an inhibitor of the second enzyme in the heme
biosynthetic pathway, porphobilinogen synthase (PBGS; also known as ALAD), then
removing the block in heme synthesis by resuspending cells into medium lacking SA and
monitoring the subsequent time-dependent change in the eGFP to mKATE2 ratio (R) of
HS1 localized to different locations upon the re-initiation of heme synthesis (Fig. 3.3A–
D). As described by Eqn 1, the fractional saturation of HS1 (% Bound) is calculated by
considering the R-value of the sensor relative to that when it is 0% (Rmin) or 100% (Rmax)
bound (Fig. 3.3E), which are parameters derived from parallel cultures of cells
continuously maintained in medium with and without SA (23, 24) (Fig. 3.3A–C).
To confirm the SA-mediated block in heme synthesis, we determined that SA-

conditioned wild-type (WT) cells exhibited intracellular heme concentrations (31) (Fig.
3.4A) and HS1 R-values (23) (Fig. 3.4B) similar to hem1Δ cells, which cannot make
heme due to the deletion of ALAS (23). SA pre- conditioned cells shifted to medium
lacking SA exhibited a time-dependent decrease in HS1 R-values (Fig. 3.3A–C) in the
cytosol, nucleus, and mitochondria, which is characteristic of increased heme loading of
the sensor due to binding of newly synthesized heme (Fig. 3.3E). By contrast, the HS1 R-
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values in cells continuously maintained with or without SA remained characteristically
high or low, respectively Fig. 3.3A–C), albeit with some modest time-dependent changes.
The change in sensor heme saturation following the re-initiation of heme
synthesis revealed three distinct phases: a lag phase, an exponential phase and a
stationary phase Fig. 3.3E). The lag phase is interpreted to be the time required to
alleviate the SA-mediated block in heme synthesis and re-initiate heme production. The
exponential phase represents the rate of heme binding to HS1, which is governed by the
D
D

relative rates of heme synthesis and trafficking to the different subcellular locations.
However, when comparing HS1 heme saturation kinetics between different
compartments within a given strain, the data strictly represent the inter-compartmental
heme trafficking rates since the contribution from heme synthesis is a constant. Indeed,
expression of cytosolic, nuclear or mitochondrial HS1 did not perturb heme synthesis Fig.
3.5A). Since the final step of heme synthesis occurs with the insertion of ferrous iron into
PPIX, a reaction catalyzed by FECH at the matrix side of the mitochondrial IM, the heme
trafficking rates reflect heme mobilization from the mitochondrial IM to the matrix,
cytosol, or nucleus, as well as equilibration of heme between the sensor and endogenous
hemoproteins within a given compartment. Given the high affinity of HS1 for both ferric
and ferrous heme, KIII 10 nM and KII , 1 nM (calculated to be 1 pM based on a
thermodynamic cycle) at pH 7.0 (24), which is amongst the tightest measured for an
intracellular soluble hemoprotein 23we assume the HS1 reporter acts as a heme sink that
does not exchange with other endogenous hemoproteins due to their presumably weaker
heme affinities. If this assumption is valid, the exponential phase of sensor heme
saturation would only reflect the inter-compartmental transport rates. Additionally, due to
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the high affinities of ferric and ferrous heme and their ability to similarly affect HS1
fluorescence (23), we cannot resolve the two oxidation states of heme. The stationary
phase represents the maximum limiting heme saturation of the sensor 4 h after alleviating
the SA-mediated block in heme synthesis and typically spans ∼70–100% saturation.
The kinetics of heme binding to HS1 Fig. 3.3E) can be fitted to the logistic
function described in Eqn 2, where [A] is the maximal value of HS1 fractional saturation
(amplitude), k is the first order rate constant (min−1), t is the time (min), and t0.5 is the
midpoint of the transition. The lag time can be defined as t0.5–2/k (36).

Quite surprisingly, the kinetics of HS1 heme saturation indicated that heme trafficking to
locations as disparate as the mitochondrial matrix, cytosol, and nucleus is similar, but
with heme transport to the nucleus exhibiting an ∼25% increase in rate constant relative
to heme transport to the cytosol and mitochondrial matrix (Fig. 3.3E, F). This observation
was highly reproducible and the rate constants for heme trafficking to the cytosol (kCYTO),
nucleus (kNUC), and mitochondrial matrix (kMITO) were found to be 0.030±0.005 min−1,
0.039±0.003 min−1 and 0.031±0.004 min−1, respectively (mean±s.d.; Fig. 3.3F).
Importantly, in every trial conducted, even if the absolute rates were different, the relative
differences always followed the same trend, with kNUC>kCYTO∼kMITO. Fitting of the ‘raw’
unprocessed sensor ratios, R, revealed a similar trend in the relative rates of heme binding
to HS1, with kNUC (0.039±0.003 min−1)>kCYTO (0.026±0.001 min−1)=kMITO (0.027±
0.002 min−1) (Fig. 3.3D), albeit with different absolute rate constants to those determined
through fitting processed ‘% Bound’ traces. This is due to the fact that, for reasons not
completely understood, there are fluctuations in Rmin and Rmax over the course of a heme
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trafficking experiment Fig. 3.3A–C). The ‘% Bound’ is our preferred metric because it
accounts for non-heme dependent changes in fluorescence ratios.
The similarity in the observed rates of heme trafficking to different locales might
suggest that heme binding to the sensor is rate limiting. However, measurements of the
rate of heme binding to HS1 in cell lysates of WT cells depleted of heme indicated that
heme binding to the cytosolic, mitochondrial, and nuclear sensors occurs
in less than 2 min (Fig. 3.6), which is much faster than the ∼90– 120 min it takes 50% of
total cellular heme to be synthesized (Fig. 3.5A) or 50% of HS1 to become heme
saturated in the SA pulse-chase assays (Fig. 3.3).
In order to rule out any potential artefacts associated with heme sensor expression
itself perturbing the observed heme trafficking rates, we expressed cytosolic HS1 under
the control of weak (pADH1), medium (pTEF1), or strong (pGPD) promoters and found
that the observed heme trafficking rates were not affected (Fig. 3.5B) despite a nearly 10fold range in sensor expression (Fig. 3.5C). These results are consistent with our previous
findings that sensor expression does not perturb heme homeostasis or otherwise affect
cell viability (23). Analogous experiments titrating expression with mitochondrial and
nuclear sensors could not be completed due to low sensor expression and correspondingly
low sensor signal-to-noise ratios associated with pTEF1- or pADH1-driven expression.
Taken together, our data indicate that the SA pulse-chase assays can be used to measure
the rates of heme trafficking to multiple compartments and that the rates of
mitochondrial–nuclear heme trafficking are ∼25% faster relative to heme trafficking to
the cytosol and mitochondria.
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In order to rule out that the observed rates of heme trafficking are due to artefacts
associated with SA treatment, we recapitulated the in vivo heme transport assay in hem1Δ
cells pulsed with a bolus of ALA to initiate heme synthesis. As shown in Fig. 3.7A, heme
trafficking kinetics to the matrix, cytosol, and nucleus in hem1Δ cells were qualitatively
similar to the results obtained from the SA pulse-chase assay using WT cells (Fig. 3.3E,
F), with transport to the nucleus (kNUC=0.059±0.005 min−1) being faster than to the
cytosol (kCYTO=0.030±0.003 min−1) and mitochondrial matrix (kMITO=0.028±0.004 min−1)
(Table 3.1). Notably, the rate enhancement for heme trafficking to the nucleus was
greater in magnitude in hem1Δ cells pulsed with ALA (kNUC/kCYTO=2.0±0.1; Fig. 3.7A)
than in WT cells that have the SA- mediated block in heme synthesis alleviated
(kNUC/kCYTO=1.3±0.2; P<0.01, one-way ANOVA; n=3) (Fig. 3.3E, F). This observation
suggests that either the use of SA suppresses nuclear heme trafficking or that the first
enzyme in the heme biosynthetic pathway, ALAS, is a negative regulator of
mitochondrial–nuclear heme trafficking.
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Fig. 3.2. Molecular model and
subcellular targeting of the heme
sensor HS1. (A) Model of HS1. (B)
The subcellular localization of HS1
was assessed by laser-scanning
confocal microscopy. Cells expressing
nuclear- or mitochondrial-targeted
HS1 were stained with DAPI to label
nuclei or mitochondria and live cells
were imaged at a magnification of
63×. Scale bar: 5 μm. (C, D)
Confirmation of mitochondrial
(mito), nuclear (nuc), and cytosolic
(cyto) HS1 localization as assessed
by cell fractionation and
immunoblotting. Nuclei (C) and
mitochondria (D) were isolated and
expression of HS1 was probed using
anti- GFP antibodies. The indicated
fractions were confirmed by probing
the expression of PGK1, NOP1, and
POR1, which are cytosolic, nuclear,
and mitochondrial marker proteins,
respectively. Whole cell extract
(WCE), derived from the spheroplast
fraction (5% of input loaded), nuclear
fraction (NF), mitochondrial fraction
(MF), post-mitochondrial fraction
(PMF), or post-nuclear fraction (PNF)
were electrophoresed on a 14% Trisglycine SDS–PAGE gel. Blots shown
are representative of n=2
experiments. (E) Validation that
mitochondrial- and nuclear-targeted
HS1 do not respond to cytosolic
heme. hem1Δ cells expressing
cytosolic, nuclear, or mitochondrial
HS1 were permeabilized with
digitonin, a plasma-membranespecific permeabilizing agent, and
incubated with the indicated
concentration of heme. Fluorimetry
data represent mean±s.d. of three
biological replicates. *P<0.00001
(one-way ANOVA with Dunnett’s
post-hoc test).
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Fig. 3.3. Inter-compartmental heme trafficking dynamics as measured by the heme
sensor HS1. WT cells expressing HS1 in the cytosol (A), nucleus (B), or mitochondria
(C) were either depleted of heme by addition of 500 μM succinylacetone (SA; heme
biosynthetic inhibitor) before removal of SA to allow re-initiation of heme synthesis
(+SA/−SA), or continually treated (+SA/+SA) or untreated (−SA/−SA) with SA. Upon reinitiation of heme synthesis in +SA/−SA samples, the rates of heme trafficking to the
indicated subcellular locations were monitored by measuring the time-dependent change
in sensor eGFP/mKATE2 fluorescence ratio (D) or the fractional saturation of HS1 (E),
which is determined using Eqn 1 and the ‘raw’ fluorescence ratio values shown in A–C.
The data in D and E are fitted to Eqn 2. (F) Rate constants for cytosolic, nuclear, and
mitochondrial heme trafficking, which were extracted from fits to the data represented in
E, for triplicate cultures in nine independent experimental trials, are shown. *P<0.0001;
ns, not significant (one-way ANOVA with Dunnett’s post-hoc test). Heme trafficking
kinetics data shown in A–E represent mean±s.d. of independent triplicate cultures.
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Fig. 3.4. A 500 µM dose of succinylacetone (SA) depletes (a) total heme
and (b) heme-loading of the heme sensor, HS1, to values similar to heme
deficient hem1∆ cells, which lack the 1st enzyme in the heme biosynthetic
pathway. Moreover, the expression of cytosolic, nuclear, and mitochondrial
HS1 do not affect steady- state cellular heme content. All data represent the
mean ± SD of triplicate cultures.
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Fig. 3.5. Heme sensor expression in the indicated compartments do not perturb
(a) the rates of heme synthesis or (b) heme trafficking dynamics to the
cytosol. (a) WT cells expressing GPD driven cytosolic (Cyto, black),
mitochondrial (Mito, blue), or nuclear (Nuc, green) HS1, or empty vector (EV,
grey) were heme depleted with 500 µM succinylacetone (SA) for 15 hours and
then the cells were resuspended in fresh SC-LEU media lacking SA, where
the re-synthesis of heme was monitored by harvesting 2 x 108 cells every
hour and analyzed for heme content as described in the Method Details. (b) The
heme trafficking dynamics assay was conducted on cells expressing ADH
(black), TEF (green) and GPD (blue) driven cytosolic HS1. Despite the ~10- fold
increase in HS1 expression between ADH and GPD promoters, as measured by
mKATE2 fluorescence in the right panel (c), cytosolic heme trafficking rates are
virtually identical. All data represent the mean ± SD of triplicate cultures.
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Fig. 3.6. Heme binding kinetics of cytosolic, nuclear, and mitochondrialtargeted HS1. 2 x 108 exponential-phase WT cells expressing GPD driven
cytosolic (Cyto, black), mitochondrial (Mito, blue), or nuclear (Nuc, green)
HS1 were lysed in 500 µL of PBS buffer containing 10 mM ascorbate and 0.1%
Triton X-100. 100 uL of the cell lysate was analyzed by fluorescence (ex.
488 nm, em. 510 nm; ex. 588 nm, em. 620 nm) over the indicated time
period, and at time 0, an automatic dispenser pipetted 5 µL of a 1 mM hemin
chloride stock solution in DMSO, giving a final concentration of 50 µM heme
in the cell lysate. All data represent the mean ± SD of triplicate cultures.
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mgm1∆

WT

rho 0

WT

fzo1∆

WT

ugo1∆

WT

pcp1∆

WT

mic60∆

WT

dnm1∆

WT

fis1∆

Location
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito

t1/2
(min)
86(4)
75(3)*
89(4)
171(7)
150(2)***
173(9)
92(2)
84(3)*
93(2)
90(4)
42(9)***/***
85(5)
97(3)
82(4)*
99(3)
85(2)
77(2)*
96(3)
87(2)
78(3)*
93(3)
89(2)
79(2)*
89(2)
85(3)
75(2)*
87(2)
100(4)
77(3)*
96(3)
89(2)
75(2)*
92(2)
85(2)
69(3)*
90(3)
119(3)
110(4)
111(3)
114(3)
104(3)
114(2)
102(3)
88(4)*
99(4)
80(2)
64(2)*/*
82(2)
86(2)
75(3)*
89(2)
92(2)
83(3)*
95(3)

k
(min -1)
.032(.003)
.041(.002)*
.034(.003)
.030(.003)
.059(.005)***
.028(.004)
.033(.001)
.039(.002)*
.033(.002)
.034(.002)
.02(.01)
.037(.003)
.033(.002)
.041(.001)*
.034(.003)
.035(.002)
.044(.003)*
.034(.002)
.033(.002)
.042(.002)*
.030(.002)
.033(.002)
.039(.002)*
.032(.002)
.031(.001)
.041(.002)*
.031(.002)
.028(.003)
.039(.002)*
.028(.001)
.030(.002)
.041(.002)*
.032(.002)
.033(.002)
.045(.003)*
.034(.001)
.033(.003)
.041(.003)*
.033(.002)
.033(.003)
.039(.003)*
.031(.002)
.030(.002)
.038(.002)*
.031(.001)
.038(.002)*
.055(.003)****
.036(.002)*
.032(.002)
.042(.003)*
.033(.002)
.032(.002)
.040(.001)*
.032(.002)

Amplitude
(% Bound)
93(5)
87(4)
88(5)
86(7)
108(5)*
75(8)
75(5)
91(6)*
75(4)
74(6)
27(5)***/***
77(6)
85(6)
105(5)*
82(4)
98(5)
99(4)
93(5)
80(4)
100(6)*
78(4)
87(5)
95(4)
90(4)
87(4)
94(5)
75(3)
95(4)
102(6)
96(4)
88(4)
105(5)*
83(4)
90(4)
105(6)
86(5)
78(5)
96(5)*
80(4)
78(6)
96(5)*
81(4)
80(4)
85(6)
75(5)
93(4)
105(5)*
93(3)
87(3)
93(4)
84(3)
84(3)
95(5)
80(4)

Lag Time
(min)
24(4)
26(3)
29(4)
104(7)
113(2)
102(9)
31(2)
33(3)
32(2)
31(4)
20(5)*/*
31(5)
36(3)
33(4)
40(3)
27(2)
31(2)
37(3)
26(2)
30(3)
26(3)
28(2)
28(2)
27(2)
20(3)
26(2)
22(2)
28(4)
25(3)
25(3)
22(2)
26(3)
28(2)
24(2)
24(3)
31(3)
58(3)
61(4)
50(3)
54(3)
53(3)
50(2)
35(3)
35(4)
34(4)
27(2)
27(2)
26(2)
24(2)
27(3)
28(2)
30(2)
33(3)
32(3)

Goodness of Fit
(R 2)
.9908
.9851
.9942
.9596
.9739
.9445
.9926
.9724
.9914
.9901
.5293
.9908
.9805
.9779
.9668
.9797
.9768
.9795
.9854
.9692
.9783
.9888
.9805
.9897
.9908
.9840
.9867
.9924
.9854
.9906
.9889
.9873
.9824
.9872
.9898
.9859
.9886
.9488
.9767
.9874
.9686
.9876
.9833
.9449
.9778
.9874
.9669
.9885
.9876
.9827
.9931
.9898
.9714
.9820
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WT
caf4∆
mdv1∆
WT
dnm1∆
mgm1∆
dnm1∆
mgm1∆
WT

gem1∆

WT

mdm12∆

WT

mdm34∆

WT

psd1∆

WT

ypt7∆

WT

vps39∆

Cyt
Nuc
Mito
Cyt
Nuc
Mito
Nuc
Nuc
Nuc

132(7)
78(2)*
115(10)
144(9)
81(4)*
137(4)
114(5)
100(7)*
82(4)*

.018(.002)
.035(.002)***
.021(.001)
.017(.002)
.031(.002)***
.020(.001)
.034(.005)
.050(.003)**
.010(.004)**

80(4)
107(5)*
90(3)
79(5)
104(6)*
95(6)*
60(5)
103(7)**
26(3)***

21(7)
21(2)
20(10)
26(9)
17(4)
37(4)
55(5)
57(7)
48(4)

.9756
.9800
.9880
.9836
.9754
.9887
.9599
.9439
.6445

Nuc

99(5)

.032(.003)

69(4)

36(5)

.9402

Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito
Cyt
Nuc
Mito

95(3)
88(4)*/*
93(3)
87(4)
61(4)**/**
93(3)
99(3)
89(4)*
96(4)
113(4)
101(5)
109(4)
33(3)
19(3)**
35(4)
50(5)
22(3)
43(4)
154(5)
115(3)***
145(6)
156(3)
106(5)***
145(4)
83(4)
67(3)
86(3)
100(4)
94(3)
101(3)
67(2)
59(2)*
65(3)
75(3)
64(4)*
81(4)

.031(.002)
.041(.003)*
.032(.002)
.031(.001)
.051(.002)**/*
.033(.002)
.031(.002)
.039(.003)*
.033(.002)
.028(.002)
.035(.002)*
.029(.003)
.029(.001)
.045(.002)**
.031(.002)
.024(.003)
.040(.004)**
.024(.002)
.018(.001)
.030(.003)***
.020(.002)
.019(.001)
.033(.003)***
.023(.003)
.031(.002)
.039(.002)*
.032(.003)
.032(.002)
.038(.002)*
.029(.003)
.031(.002)
.038(.002)*
.029(.003)
.029(.003)
.039(.002)**
.027(.002)

80(4)
90(3)
87(3)
86(3)
104(5)*
77(6)
81(3)
93(3)*
79(3)
84(3)
100(5)*
70(3)
91(3)
106(5)*
91(3)
93(4)
106(4)*
105(5)
80(5)
85(4)
82(4)
80(3)
82(4)
84(3)
90(3)
98(4)
90(2)
99(3)
100(4)
92(5)
88(4)
105(6)*
85(3)
95(3)
104(5)
103(5)

34(3)
37(4)
31(3)
21(4)
17(4)
30(3)
35(3)
37(4)
35(4)
41(4)
43(5)
40(4)
0
0
0
0
0
0
43(5)
48(3)
45(6)
50(3)
45(5)
55(4)
19(4)
16(3)
24(3)
38(4)
42(3)
32(3)
3(2)
6(2)
1(3)
6(3)
13(4)
7(4)

.9814
.9403
.9833
.9890
.9753
.9837
.9724
.9580
.9696
.9830
.9481
.9669
.9947
.9775
.9873
.9943
.9678
.9841
.9871
.9921
.9808
.9826
.9863
.9891
.9860
.9738
.9781
.9791
.9172
.9206
.9867
.9748
.9791
.9836
.9490
.9699

Table 3.1. Kinetic parameters derived from fits to the heme trafficking data using
Equation 2. The values indicated represent the mean ± SD of independent
triplicate cultures. *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with
Dunnett’s post-hoc test. Red asterisks indicate statistical significance relative to
the cytosol within a given strain. Black asterisks indicate statistical significance
relative to the WT strain of a givencompartment.

146
3.4.2 ALAS regulates mitochondrial-nuclear heme trafficking
In order to determine if ALAS plays a role in regulating heme distribution
kinetics, we directly compared inter-compartmental heme trafficking kinetics in WT and
hem1Δ cells. To this end, we monitored heme distribution dynamics in WT and hem1Δ
cells with SA-inactivated PBGS that were pulsed with 500 μM porphobilinogen (PBG),
the product of the reaction catalyzed by PBGS, to re-initiate heme biosynthesis. As with
the SA pulse-chase experiment in WT cells (Fig. 3.3E, F), the rates of heme trafficking to
the nucleus were greater than rates of trafficking to the cytosol and mitochondrial matrix
in SA-treated WT cells pulsed with PBG (Fig. 3.6B, C): kNUC/kCYTO=1.5±0.2 versus
kMITO/kCYTO=1.1±0.2 (P=0.05, one-way ANOVA; n=3). Strikingly, in SA-treated hem1Δ
cells pulsed with PBG, heme trafficking to the nucleus was significantly augmented
relative to that in WT cells Fig. 3.7B,C): kNUC/kCYTO=2.0±0.1 in hem1Δ cells versus
kNUC/kCYTO=1.5±0.2 in WT cells (P=0.05, one-way ANOVA; n=3). The relatively low
final fractional saturation of the sensor using PBG can be attributed to the fact that hemedeprived cells were less efficient at using PBG to make heme (Fig. 3.7D). WT and
hem1Δ cells treated with SA and PBG made ∼33% of the heme that WT or hem1Δ cells
treated with ALA made. Thus, it is all the more impressive that in hem1Δ cells pulsed
with PBG, the nuclear sensor was completely saturated with heme, unlike in WT cells.
Importantly, WT and hem1Δ cells synthesized similar levels of heme when supplied with
PBG Fig. 3.7D). In total, our results demonstrate that ALAS negatively regulates
mitochondrial–nuclear heme trafficking.
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Fig. 3.7. ALA synthase (Hem1) negatively regulates mitochondrial–nuclear
heme trafficking. (A) hem1Δ cells expressing HS1 in the cytosol (black), nucleus
(green), or mitochondria (blue) were pulsed with a bolus of ALA to initiate heme
synthesis and the rates of heme trafficking to the indicated subcellular locations
were monitored by measuring the fractional saturation of HS1 over time, as in Fig. 2.
(B) WT and hem1Δ cells expressing the HS1 sensor were pre-cultured with SA to
deplete heme and pulsed with a bolus of PBG to re-initiate heme synthesis. The rates
of heme trafficking to the indicated subcellular locations were monitored by
measuring the fractional saturation of HS1 over time, as in Fig. 2. Data shown in A
and B are mean±s.d. of n=3 cultures (C) Heme trafficking rate constants for the
indicated compartments of WT and hem1Δ strains, based on data represented in B.
Data are mean±s.d. of triplicate cultures. *P<0.05, **P<0.001 (one-way ANOVA with
Dunnett’s post- hoc test). (D) Analysis of total heme in WT and hem1Δ strains treated
with SA, ALA or PBG. Data represent the mean±s.d. of triplicate cultures.
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3.4.3 Gem1, a GTPase that regulates ERMES, negatively modulates
mitochondrial-nuclear heme trafficking
Since mitochondria form dynamic physical contacts with other organelles such as
the ER (17, 19), we surmised that one potential route for the distribution of mitochondrial
heme to other compartments, such as the nucleus, could be through membrane contact
sites. In this scenario, heme may be trafficked to the nucleus via the ER network,
bypassing the cytosol, thereby accounting for the increased rate of nuclear heme
trafficking. To test this idea, we probed heme distribution rates in deletion mutants with
increased or decreased ER–mitochondrial contact sites.
The ER–mitochondrial encounter structure (ERMES), which constitutes one type
of physical interface between these organelles, is a complex that consists of four proteins,
Mmm1, Mdm10, Mdm12 and Mdm34 (37, 38, 39, 40). Mmm1 and Mdm10 are anchored
in the ER and outer mitochondrial membranes, respectively, while the cytosolic protein
Mdm12 and the mitochondrial protein Mdm34 help to bridge the interaction between
Mmm1 and Mdm10 in the ERMES complex (37, 38, 39, 40). The absence of any single
ERMES protein results in dissociation of the entire complex, compromising the
formation of ER–mitochondrial contact sites, mitochondrial division and morphology
(37, 38, 39, 40, 41). ERMES is negatively regulated by Gem1, which is a mitochondrial
outer-membrane localized GTPase that disengages ERMES after mitochondrial division
(42, 22).
As shown in Fig. 3.8A, B, gem1Δ cells, which have increased ERMES, exhibited
a significantly increased rate of mitochondrial– nuclear heme trafficking, with minimal
impact on heme trafficking to the cytosol and mitochondrial matrix: kNUC/kCYTO=1.6±0.1
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in gem1Δ cells versus kNUC/kCYTO=1.2±0.1 in WT cells (P<0.01, one- way ANOVA:
n=3). These data suggest that more stable ER– mitochondrial contacts increase the flow
of heme to the nucleus. However, in ERMES-compromised mdm12Δ and mdm34Δ
strains, heme trafficking rates were unaffected (Fig. 3.8C–F).
ERMES has been implicated in the transfer of lipids, for example
phosphatidylserine (PS), between the ER and mitochondria (38, 43, 44). PS is required
for the synthesis of phosphatidylethanolamine (PE) and phosphatidylcholine (PC) (45). In
order to rule out confounding contributions that may arise due to general defects in PE or
PC synthesis in ERMES mutants, we tested heme trafficking dynamics in psd1Δ cells,
which lack PS decarboxylase, the enzyme that catalyzes the formation of PE. As shown
in Fig. 3.8G, H, there were no defects in heme trafficking dynamics in psd1Δ cells.
ERMES are highly dynamic and sensitive to the presence of mitochondrial–
vacuolar contact sites, termed vCLAMPs for vacuolar and mitochondrial patches. Like
ERMES, vCLAMPs are important for metabolite trafficking between mitochondria and
the endomembrane system (17). The absence of one causes expansion of the other, and
ablation of both ERMES and vCLAMPs is lethal (17). We therefore sought to determine
if a defect in vCLAMPs also increased mitochondrial– nuclear heme trafficking rates as
in gem1Δ cells, which have an increased number of ERMES foci as found in vCLAMP
mutants. However, neither vps39Δ nor ypt7Δ cells (Fig. 3.8I–L), which lack a component
of the HOPS (homotypic fusion and vacuole protein sorting) tethering complex (Vps39)
and a Rab GTPase (Ypt7), both core components of vCLAMPs (17, 19, 46), exhibited
defects in heme distribution kinetics. We conclude that Gem1, but not the core
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components of ERMES and vCLAMP machineries, regulates mitochondrial–nuclear
heme trafficking.
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Fig. 3.8. Gem1 is a negative
regulator of mitochondrial–nuclear
heme trafficking. Heme trafficking
rates were monitored using the SA
pulse-chase assay and rate
constants calculated, as described
in Fig 3.2, for (A, B) gem1Δ, (C,
D) mdm12Δ, (E, F) mdm34Δ, (G,
H) psd1Δ, (I, J) ypt7Δ, and (K, L)
vps39Δ cells. Data represent the
mean±s.d. of independent
triplicate cultures.
*P<0.05, **P<0.01, ***P<0.001
(one-way ANOVA with Dunnett’s
post-hoc test).
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3.4.4 Mgm1 and Dnm1 are positive and negative regulators of mitochondrialnuclear heme trafficking, respectively
The mitochondrial network is highly dynamic and is constantly remodeled by
fusion and fission events. The dynamic behavior of the mitochondrial network is thought
to be responsible for the proper cellular distribution and trafficking of a number of
mitochondrial-derived metabolites, including various lipids (47, 48). Given that we
identified that Gem1, an ERMES-regulating GTPase, modulates mitochondrial– nuclear
heme trafficking, and because ERMES are associated with sites of mitochondrial division
and the frequency of their formation can be impacted by mitochondrial fission and fusion
(17, 21), we reasoned that other GTPases that regulate mitochondrial dynamics might
regulate mitochondrial–nuclear heme trafficking.
3.4.4.1 Mitochondrial fusion
In yeast, a pair of dynamin-like GTPases, Fzo1 and Mgm1, drive OM and IM
fusion, respectively (49). In order to coordinate double membrane fusion, a protein
spanning the mitochondrial intermembrane space, Ugo1, physically tethers Fzo1 and
Mgm1. Mgm1 is proteolytically processed by the rhomboid protease Pcp1 (50, 51) into
long (l-Mgm1) and short (s-Mgm1) isoforms. It is thought that l-Mgm1, which has an
inactive GTPase domain, acts as an anchor in the IM and interacts with and activates the
GTPase activity of s-Mgm1 in the intermembrane space to promote IM fusion (50, 51).
The mgm1Δ strain exhibited a marked defect in nuclear heme trafficking relative
to that in WT cells, with a greater than 50% reduction in HS1 heme loading Fig. 3.9A).
The modest changes in sensor loading and variability between biological replicates
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resulted in a poor goodness-of-fit (R2=0.5293) and large error in the rate constant when
fitting the mitochondrial–nuclear heme trafficking data to Eqn 2 (Fig. 3.9B, Table 3.1).
Conversely, heme trafficking to the mitochondrial matrix and cytosol was not
significantly impacted in mgm1Δ cells Fig. 3.9A, B). Interestingly, heme availability to
HS1 in the nucleus was similar between WT and mgm1Δ cells after a prolonged growth
period of ∼16 h, suggesting that there are compensatory mechanisms that overcome the
defects in nuclear heme trafficking in mgm1Δ cells (Fig. 3.10A). The rate of heme
synthesis was unperturbed by loss of Mgm1, indicating that the nuclear trafficking defect
is not related to general defects in heme synthesis Fig. 3.10B). The effects of the mgm1Δ
mutant on nuclear heme trafficking is not due to the loss of mitochondrial DNA, which
occurs with high frequency in mgm1Δ cells; rho0 cells, which lack mitochondrial DNA,
did not exhibit an appreciable defect in nuclear heme trafficking Fig. 3.9C, D).
Surprisingly, ablation of other components of the mitochondrial fusion machinery,
including Fzo1 and Ugo1, did not affect heme trafficking rates (Fig. 3.9E–H). Because
the regulation of nuclear heme transport is specific to Mgm1, we tested whether
proteolytic processing of Mgm1 was important for heme mobilization. As seen in Fig.
3.9I, J, pcp1Δ cells, which cannot convert l-Mgm1 to s-Mgm1, did not exhibit a defect in
mitochondrial–nuclear heme trafficking.
In order to determine whether the defect in mitochondrial– nuclear heme
trafficking in mgm1Δ cells is related to the role of Mgm1 in maintaining the proper
folding and structure of cristae in the IM (52), we determined whether heme trafficking
was altered in a mutant that lacks the mitochondrial contact site and cristae organizing
system (MICOS). As seen in Fig. 3.9K, L, mic60Δ cells, which are missing a core
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component of MICOS that is required for proper IM folding (53), did not exhibit a defect
in mitochondrial–nuclear heme trafficking. Taken together, our data strongly suggest that
full length Mgm1, but not mitochondrial fusion or IM architecture per se, positively
regulates mitochondrial–nuclear heme trafficking (Fig. 3.9).
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Fig. 3.9. Mgm1 is a positive
regulator of mitochondrial–
nuclear heme trafficking. Heme
trafficking rates were monitored
using the SA pulse-chase assay and
rate constants calculated, as
described in Fig. 2, for (A, B)
mgm1Δ, (C, D) rho0, (E, F) fzo1Δ,
(G, H) ugo1Δ, (I, J) pcp1Δ cells and
(K, L) mic60Δ cells. Data represent
the mean±s.d. of independent
triplicate cultures. *P<0.05 (one-way
ANOVA with Dunnett’s post-hoc
test).
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Fig. 3.10. The effects of mgm1∆ and dnm1∆
on steady-state HS1 heme loading and heme
synthesis. (a) Cytosolic (Cyto), nuclear (Nuc),
or mitochondrial (Mito) HS1 expressed in WT
(black, gray), dnm1∆ (dark and light green),
and mgm1∆ (dark and light blue) cells were
cultured for 16 hours in SCE-LEU media with
(+SA, dark colors) or without (-SA, light
colors) 500 µM succinylacetone (SA).
Following growth and washing cells with
ultrapure water, HS1 sensor fluorescence was
measured in a 100 µL suspension of 5
OD’s/mL in PBS. (b and c) The rates of heme
synthesis were measured in (b) mgm1∆ and (c)
dnm1∆ cells by first heme depleting cells with
500 µM SA for 15 hours and then re-initiating
heme synthesis by re-suspending cells in media
lacking SA. 2 x 108 cells were harvested every
hour and analyzed for heme content as
described in the Materials and Methods. All
data represent the mean ± SD of triplicate
cultures.
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3.4.4.2 Mitochondrial fission
In yeast, mitochondrial fission involves recruitment of the GTPase Dnm1 to its
receptor Fis1 on the mitochondrial OM, which is dependent on the paralogous adapter
proteins Mdv1 and Caf4 (49). Once assembled and oligomerized around the OM, Dnm1
drives the GTP-dependent constriction and scission of mitochondrial tubules.
Relative to WT cells, the dnm1Δ strain exhibited statistically significant increases
in heme trafficking rates to all three compartments tested, including the matrix, cytosol
and nucleus, but with the most pronounced effect on nuclear heme trafficking:
kNUC/kCYTO=1.5±0.1 in dnm1Δ cells versus kNUC/kCYTO=1.2±0.1 in WT cells (P<0.01, oneway ANOVA; n=3) (Fig. 3.11A, B). After prolonged growth for 16 h, heme availability
to HS1 in all three compartments was similar in WT and dnm1Δ cells (Fig. 3.10A).
Additionally, the rate of heme synthesis was unperturbed by loss of Dnm1, indicating that
the increase in the rate of heme trafficking is not due to an increase in the rate of heme
synthesis (Fig. 3.10C). However, loss of other essential components of the mitochondrial
fission machinery, including Fis1 (Fig. 3.11C, D) and Caf4/Mdv1 (Fig. 3.11E, F), did not
affect heme trafficking. Taken together, our data indicate that Dnm1, but not
mitochondrial fission per se, negatively regulates mitochondrial–nuclear heme trafficking
Fig. 3.11).
We next sought to determine the consequence of ablating both Mgm1 and Dnm1
on mitochondrial–nuclear heme trafficking. Interestingly, mgm1Δ dnm1Δ double mutants
exhibited WT rates of mitochondrial–nuclear heme trafficking (Fig. 3.11G, H).
Therefore, Mgm1 and Dnm1 regulate heme trafficking in opposing directions with
similar magnitude.
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Fig. 3.11. Dnm1 is a negative regulator of mitochondrial–nuclear heme
trafficking. Heme trafficking rates were monitored using the SA pulse-chase assay
and rate constants calculated, as described in Fig. 2, for (A, B) dnm1Δ, (C, D)
fis1Δ, (E, F) caf4Δ mdv1Δ cells and (G, H) mgm1Δ dnm1Δ cells. Fluorimetry
data represent the mean±s.d. of three independent cultures. *P<0.05, **P<0.01,
***P<0.001 (one-way ANOVA with Dunnett’s post-hoc test).
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3.4.5 Mgm1 and Dnm1 regulate the activation of the nuclear heme-regulated
transcription factor Hap1
Given that Mgm1 and Dnm1 are positive and negative regulators of
mitochondrial–nuclear heme trafficking, we sought to determine their impact on the
activation of the heme-regulated transcription factor Hap1. Heme binding to Hap1 alters
the ability of the protein to promote or repress transcription of a number of target genes,
including CYC1, which Hap1 positively regulates (23, 54, 55, 56, 57). In order to probe
Hap1 activity, we used a transcriptional reporter that employs the promoter of a Hap1
target gene, pCYC1, to drive the expression of enhanced green fluorescent protein (eGFP)
(23). As demonstrated in Fig. 3.12A, not only was steady-state Hap1 activity greatly
diminished in the heme-deficient hem1Δ mutant and in response to SA treatment, as
expected, it was also reduced nearly 3-fold as a result of loss of Mgm1. Conversely, loss
of Dnm1 did not affect basal Hap1 activity (Fig. 3.12A, –).
Because basal Hap1 activity in WT cells might already reflect heme saturation of
Hap1, it is possible that the effects of the loss of Dnm1 are masked. To address this, we
also measured Hap1 activity under non-heme saturating conditions in which Hap1
activity was probed just 4 h after alleviation of the SA-mediated block in heme synthesis.
Under these conditions, dnm1Δ cells had increased Hap1 activity, and mgm1Δ cells
exhibited diminished Hap1 activity relative to that in WT cells Fig. 3.12A, Δ).
The Dnm1 and Mgm1 dependent regulation of Hap1 is not due to general defects
in fusion or fission since fis1Δ and fzo1Δ cells exhibited WT levels of Hap1 activity
when probed 4 h after alleviation of the SA-mediated block in heme synthesis Fig. 3.12B,
Δ). However, for reasons unclear at this time, steady-state Hap1 activity was diminished
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in both fis1Δ and fzo1Δ strains Fig. 3.12B, –). Taken together, the respective positive and
negative effects of Mgm1 and Dnm1 on nuclear heme trafficking correlate with their
effects on heme activation of Hap1 and appear to be distinct from their roles in fusion and
fission dynamics Fig. 3.12A, B, Δ).
We next addressed whether Mgm1- and Dnm1-regulated nuclear heme trafficking
affected heme-dependent growth of cells. To this end, we determined the degree to which
heme-depleted cells pre- cultured with SA were able to recover in medium lacking SA
(GΔSA) relative to cells continually maintained with (G+SA) or without SA
(G−SA). As such, the ‘% Recovery’ can be calculated using Eqn 3:

Interestingly, as seen in Fig. 3.12C, after 12 h of growth, mgm1Δ cells were better
able to tolerate the re-synthesis of heme compared to WT cells. The superior ability of
mgm1Δ cells grown with SA to recover in medium lacking SA was not phenocopied by
another fusion mutant, fzo1Δ, suggesting that Mgm1-mediated nuclear heme trafficking
may be inhibitory to growth. Conversely, the fission mutants dnm1Δ and fis1Δ had WT
levels of recovery from the alleviation of the SA-mediated block in heme synthesis,
presumably because sufficient heme was accessing the nucleus to control growth in a WT
manner. After 24 h, all cells achieved maximal growth recovery after re-initiation of
heme synthesis Fig. 3.12C). In total, our data suggest that Mgm1 is not only a positive
regulator of mitochondrial–nuclear heme trafficking, but that this trafficking is negatively
correlated with tolerance to the re-initiation of heme synthesis.
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Fig. 3.12. Mitochondrial–nuclear heme trafficking regulates Hap1 activity
and sensitivity to new heme synthesis. (A, B) Hap1 activity in the indicated
strains as measured by a transcriptional reporter that uses eGFP driven by the
CYC1 promoter, a Hap1 target gene. Hap1 activity in cells that were untreated with
SA (−), treated with 500 μM SA (+), or treated with 500 μM SA followed by
shifting to medium lacking SA for 4 h (Δ) is shown. Fluorimetry data represent
the mean±s.d. of three biological replicates. *P<0.001, asterisks not associated
with an indicated pair-wise comparison (blue) were compared to WT untreated
samples; ns, not significant (one-way ANOVA with Bonferroni’s post-hoc test).
(C) Cellular tolerance to new heme synthesis. Cells were pre- cultured
overnight with or without 500 μM SA then allowed to recover on medium
without SA. Sensitivity to new heme synthesis was scored as ‘% Recovery’, as
described by Eqn 3, by comparing growth at the indicated times to growth of cells
continually maintained in medium without SA and with SA. Growth data
represent the mean±s.d. of three biological replicates. *P<0.001 (one-way
ANOVA with Dunnett’s post-hoc test relative to WT cells).
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3.4.6 Heme regulates mitochondrial dynamics
Heme and targets of heme signaling, such as the heme activator proteins Hap1
and the HAP complex (Hap2/3/4/5), collectively transcriptionally regulate genes involved
in mitochondrial metabolism, including respiration and fission-fusion dynamics (58, 59,
60, 61). We therefore sought to determine whether heme itself could regulate
mitochondrial fragmentation, a proxy for fission and fusion dynamics. To this end, by
inhibiting heme synthesis using a 500 μM dose of SA for 4–6 h, we found that there was
a nearly 2-fold increase in mitochondrial fragmentation in SA-treated cells relative to
control cells as early as 4 h post-treatment (Fig. 3.13A, B). The number of cells with
fragmented mitochondria further increased upon prolonged incubation with SA. The 500
μM dose of SA resulted in an ∼60–80% decrease in intracellular heme (Fig. 3.13C) and
alterations in mitochondrial network preceded any appreciable changes in mitochondrial
membrane potential (Fig. 3.13D). Hence, the SA- dependent increase in mitochondrial
fragmentation is consistent with a role for heme in positively influencing mitochondrial
fusion and/or negatively regulating mitochondrial fission.
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Fig. 3.13. Heme regulates mitochondrial morphology. (A) Representative image
of the mitochondrial network in cells conditioned with 500 μM SA, showing a
mix of tubular (*) and punctate (^) morphology. Scale bar: 5 μm. (B) Quantitative
analysis of the mitochondrial network in Su9–RFP-expressing WT cells incubated
with or without 500 μM SA for varying lengths of time. Mitochondrial
fragmentation was quantified as the ratio of the number of cells displaying
punctate morphology versus the number of cells displaying tubular morphology.
Data show mean±s.d. of three biological replicates, with 300–400 cells per
biological replicate. *P<0.05, **P<0.01, ***P<0.001 (Student’s t-test). (C) Heme
levels in WT or hem1Δ cells treated or untreated with 500 μM SA for the indicated
periods of time. Data represent the mean±s.d. of three biological replicates. (D)
Changes in mitochondrial membrane potential in WT cells treated with or
without 500 μM SA or 45 μM of the mitochondrial uncoupler CCCP for varying
time periods. Cells were stained with 200 nM membrane- potential-sensitive dye
DiOC6 and analyzed by flow cytometry using the FITC channel. Data show the
mean±s.d. of three independent experiments. ns, not significant (t-test).
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3.5 DISCUSSION
We developed a live-cell assay in yeast to monitor heme transport dynamics
between the mitochondrial IM and the mitochondrial matrix, cytosol, and nucleus in
order to identify new aspects of heme trafficking and distribution. Saccharomyces
cerevisiae is an unparalleled model system to probe heme distribution dynamics because,
unlike many eukaryotes including mammalian cells, yeast lacking heme can be made
viable if supplemented with ergosterol and oleic acid. Thus, heme trafficking and
transport dynamics can be monitored without a background associated with pre-existing
heme pools. By integrating the heme trafficking dynamics assay with yeast molecular
genetics approaches, we have, for the first time, probed the biodistribution of heme while
it is being synthesized in live cells, and identified new factors that regulate heme
trafficking, including the heme biosynthetic enzyme ALAS (also known as Hem1) (Fig.
3.7), and GTPases that regulate ERMES (Gem1; Fig. 3.8A) and mitochondrial fusion
(Mgm1; Fig. 3.9A) and fission (Dnm1; Fig. 3.11). As discussed below, our results
provide fundamental new insights into heme trafficking and signaling.
The heme trafficking kinetics data challenge the current conceptual paradigm for
the cellular distribution of mitochondrial heme. The discovery of the first putative
mitochondrial heme exporter, FLVCR1b, the only mitochondrial heme transporter
identified to date (16), has often been taken to imply that heme distribution is sequential,
with heme first transported into the cytosol followed by its mobilization to other
organelles (1, 2, 25). However, we found that heme distribution to the mitochondrial
matrix, cytosol, and nucleus occurs virtually simultaneously, suggesting the existence of
parallel pathways for heme mobilization to different cellular locales (Figs. 3.2 and 3.6).
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Thus, there must be additional factors and mechanisms that distribute heme, in addition
to mitochondrial heme transporters that export heme into the cytosol. Our data suggest
that GTPases that regulate mitochondrial dynamics and ER contact sites constitute novel
components of a newly defined heme distribution network.
We propose that the ∼25% faster rate of heme trafficking to the nucleus relative
to the cytosol or mitochondrial matrix (Fig. 3.3F) is suggestive of heme acting as a
mitochondrial–nuclear retrograde signal that enables cells to adapt their metabolism and
physiology for life with heme and properly functioning mitochondria. Indeed, the activity
of the heme-regulated nuclear transcription factor, Hap1, correlated with perturbations to
mitochondrial–nuclear heme
trafficking caused by deletion of Mgm1 or Dnm1, which are positive and negative
regulators of heme trafficking, respectively (Fig. 3.12A). Rather surprisingly, as part of
this heme-based retrograde signal, diminished mitochondrial–nuclear heme trafficking in
mgm1Δ cells correlated with enhanced cellular growth in response to the re-initiation of
heme synthesis (Fig. 3.12C). This may be due to the detrimental effects of potentially
cytotoxic levels of heme accumulation in the nucleus. Indeed, as a redox active molecule,
heme may promote oxidative damage in the nucleus (1,2). Alternatively, heme may act as
an anti-proliferation signal through its ability to act as a transcriptional regulator by
binding G-quadruplexes in DNA (62) or by controlling transcription via Hap1 and the
HAP complex (55, 56, 57, 58, 59). Taken together, our results indicate that the relatively
fast rate of nuclear heme acquisition may play an important role in mitochondrial–nuclear
retrograde signaling.
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Interestingly, we found that ALAS negatively regulated mitochondrial–
nuclear heme trafficking (Fig. 3.7). This result may explain the functional role of ALAS
and FECH interactions in a proposed IM heme biosynthetic supercomplex (14,15). The
rationale for protein-protein interactions in a biosynthetic pathway usually invokes the
requirement for substrate channeling in order to mitigate the dissociation of potentially
toxic substrates and ensure rapid flux. However, the biochemical necessity for an
interaction between ALAS and FECH, the first and last enzymes in the heme synthesis
pathway, is not clear in the context of substrate channeling. Our results suggest that
interactions between ALAS and FECH may be regulatory because we find that ALAS
decreases heme trafficking from FECH in the mitochondrial IM to the nucleus. Because a
number of factors are known to regulate ALAS expression and mitochondrial import,
including glucose, iron and heme (63, 64), we propose that the regulation of
mitochondrial–nuclear heme trafficking by ALAS might be part of a complex circuit that
links nutrient status to heme-based retrograde signaling. However, the precise
physiological context and mechanism of ALAS-mediated regulation of mitochondrial–
nuclear heme trafficking needs to be further explored.
What is the mechanism of mitochondrial–nuclear heme trafficking? We identified
three conserved GTPases in control of mitochondrial fusion (Mgm1) and fission (Dnm1),
and ER– mitochondrial contact sites (Gem1) as regulators of mitochondrial– nuclear
heme trafficking. One unifying model consistent with our data is that mitochondrial–ER
contact sites facilitate the distribution of heme to the nucleus and other extramitochondrial locales. Indeed, both dnm1Δ and gem1Δ cells, which exhibit more stable
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mitochondrial–ER contact sites (17, 22), also exhibit increased rates of nuclear heme
trafficking (Figs. 3.7A, 3.10A).
In accordance with this model, we suggest that Mgm1-mediated regulation of
mitochondrial–nuclear heme trafficking occurs in a Dnm1 and ERMES-dependent
manner. In such a model, Mgm1 promotes mitochondrial–nuclear heme trafficking
because of its ability to drive mitochondrial fusion and provide a balancing force to
oppose Dnm1-dependent mitochondrial fission. As a consequence, mgm1Δ cells would
be expected to – and do – exhibit diminished mitochondrial–nuclear heme trafficking
because there is no Mgm1 present to counteract Dnm1-mediated fission Fig. 3.9A).
Consistent with this model, we observed a restoration of WT levels of mitochondrial–
nuclear heme trafficking in mgm1Δ dnm1Δ cells Fig. 3.11D).
However, a number of issues must be resolved regarding the ERMES-dependent
model for heme trafficking. First, we do not currently have a means to monitor heme at
ER membranes to more directly assess the impact of ERMES and ER–mitochondrial
contact sites on heme trafficking. Second, it is unclear at this time why other fission and
fusion mutants did not exhibit defects in heme trafficking (Figs. 3.8, 3.10), which
suggests additional functions of Mgm1 and Dnm1 beyond mitochondrial dynamics.
Third, we did not observe that mutants with defects in essential components of the
ERMES complex, including mdm12Δ and mdm34Δ, exhibit altered mitochondrial–
nuclear heme trafficking rates. One explanation is that there are multiple types of ER–
mitochondrial contact sites in addition to ERMES that exist, including the conserved ER
membrane protein complex (EMC) (65). It is also possible that mitochondrial-derived
vesicles, which are responsible for the trafficking of cargo to vacuoles and lysosomes,
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offer alternative routes of mitochondrial heme efflux (2Thus, a heme distribution
phenotype may only be observed in multigenic knockouts defective in many parallel
routes for heme trafficking.
An alternative to the ERMES-dependent model for heme trafficking is that each
GTPase identified may play distinct and unrelated roles in heme trafficking. For instance,
the human homolog of Mgm1, OPA1, was previously found to physically associate with
FECH in the heme metabolon (15As such, it is possible that Mgm1/OPA1 regulates the
heme metabolon, and its interactions with putative heme trafficking factors, to effect
mitochondrial–nuclear heme trafficking. Given the lipid-like properties of heme (2 and
the fact that Dnm1 and Gem1 are lipid-interacting OM-associated GTPases (66), we
speculate that heme may be sequestered by Dnm1 or Gem1 in the OM to suppress heme
trafficking. Gem1 also has roles in mitochondrial positioning and cytoskeleton anchoring
that may contribute to heme distribution dynamics (67). We are currently exploring the
molecular mechanisms underlying Mgm1-, Dnm1- and Gem1- mediated heme trafficking
and whether they cooperate through a common mechanism or act independently of each
other. Since ablation of both Mgm1 and Dnm1 restored heme trafficking to WT levels,
these factors may positively and negatively regulate a common downstream target,
respectively, and are likely to play indirect roles in regulating heme trafficking. It is also
possible that the mutants identified to have altered heme trafficking rates also have
changes in expression of endogenous hemoproteins that have the capacity to compete
with HS1 for heme.
Interestingly, our data suggest that heme may impact mitochondrial dynamics
(Fig. 3.13). We speculate that there may be feedback mechanisms by which heme itself,
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possibly acting through Mgm1 or Dnm1, can regulate heme distribution dynamics
between the mitochondrial network and the nucleus. Notably, mitochondrial
fragmentation alone does not impact heme trafficking dynamics since certain fission and
fusion mutants with hyper-fused or hyper- fragmented mitochondria (i.e., fis1Δ and fzo1Δ
cells, respectively) exhibited WT rates of heme trafficking. We are currently probing the
underlying mechanisms that govern heme regulation of mitochondrial fragmentation.
The in vivo assay to monitor real-time dynamics of inter- compartmental heme
trafficking has revealed new insights into mobilization. We expect that the tools and
approaches presented here could be used to probe a number of human diseases, including
certain cancers, neurodegenerative disorders and blood diseases, that are associated with
defects in heme homeostasis, mitochondrial dynamics and contact sites (8, 9, 68). Indeed,
given that mitochondrial dynamics and contact sites with the endomembrane system are
conserved between yeast and humans, and the factors that regulate them have homologs
or functional analogs between lower and higher eukaryotes (49, 69, 70, 71, 72), our
studies in yeast may be of broad applicability to better understand how membrane and
organelle dynamics impact heme transport and trafficking.
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CHAPTER 4: COORDINATION OF METAL CENTER BIOGENESIS IN HUMAN
CYTOCHROME C OXIDASE PREVENTS THE BUILDUP OF CYTOTOXIC
REACTIVE INTERMEDIATES

Note: The results presented in this chapter are to be published with the following authors:
Eva Nyvltová, Jonathan V. Dietz, Javier Seravalli, Oleh Khalimonchuk, Antoni
Barrientos.
4.1 ABSTRACT
Mitochondrial cytochrome c oxidase (CcO) or respiratory chain complex IV is a heme
aa3-copper oxygen reductase, whose metal centers are essential for holo-complex
biogenesis and enzymatic function and are assembled by subunit-specific
metallochaperones. The enzyme has two copper sites located in the catalytic core
subunits. The COX1 subunit harbors the CuB site that tightly associates with heme a3
while the COX2 subunit contains the binuclear CuA site. Here, we report that in human
cells the CcO copper chaperones form macromolecular assemblies and cooperate with
several twin-CX9C proteins to control heme a biosynthesis and coordinate copper transfer
sequentially to the CuA and CuB sites. These data on CcO illustrate a mechanism that
regulates the biogenesis of macromolecular enzymatic assemblies with several catalytic
metal redox centers and prevents accumulation of cytotoxic reactive assembly
intermediates.
4.2 INTRODUCTION
Aerobic life relies on electron transport reactions that facilitate fundamental
processes such as cellular respiration (1). These biological electron transfer reactions are
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performed predominantly by proteins and rely on the presence of critical redox cofactors
such as heme a and copper (Cu), the prosthetic groups of cytochrome c oxidase (CcO)
(2). However, for enzymatic complexes with multiple redox cofactors, uncoordinated or
dysregulated biogenesis of the redox centers may result in the accumulation of reactive
intermediates that can lead to a progressive loss of cellular function and eventual death
(3). Therefore, cells must develop safety mechanisms to coordinate the biogenesis of
multimeric enzymes that contain multiple redox centers. In most systems, such as for
mammalian CcO, these mechanisms remain incompletely characterized.
CcO is the terminal complex of the electron transport chain (ETC), required
for aerobic adenosine 5’-triphosphate (ATP) production from aerobic bacteria to
mammals (2). Mammalian CcO or mitochondrial ETC complex IV (CIV) is formed by
three conserved catalytic core transmembrane subunits (COX1, COX2, and COX3)
encoded by the mitochondrial genome (mtDNA) and eleven nucleus-encoded accessory
subunits (2). CcO has two copper (Cu)-centers: CuA in COX2, and CuB in COX1. The
CuA site includes two Cu atoms of mixed valence and localizes to a hydrophilic COX2
domain in the intermembrane space (IMS). The CuB site contains a single Cu ion and,
with a high-spin heme a3 and a cross-linked His-Tyr cofactor, forms the O2 reduction, or
‘active’, site (4). Near the active site, COX1 also harbors a low-spin heme a. During
catalysis, the CuA center in COX2 receives electrons from reduced cytochrome c and
transfers them sequentially to COX1 heme a, and then to the CuB-heme a3 center, where
O2 binds and is reduced to H2O (2). The process is coupled to proton flow across the
inner membrane to contribute to the proton gradient required for ATP synthesis by
oxidative phosphorylation (5). CcO deficiency is among the most recurrent causes of
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human mitochondrial disorders, frequently owing to mutations that impair CcO
biogenesis and cause devastating cardio- and encephalomyopathies (6, 7).
Mitochondrial CcO biogenesis is a modular process believed to involve the
independent maturation of COX1 and COX2 followed by sequential interactions with
accessory subunits and assembly factors. The overall process requires over 30 nucleusencoded assembly factors (Table 4.1) (2), five of which are required to assemble the
four-subunit aa3-type CcO of α-proteobacteria, such as Rhodobacter sphaeroides. They
function to synthesize (COX10 and COX15) or deliver (SURF) heme a and assemble
CuA (SCO) or CuB (COX11) sites (2, 8). In mitochondria, heme a and Cu insertion into
COX1 and COX2 is essential for modular assembly (2). In the current model, the soluble
IMS Cu-chaperone COX17, which has a twin CX9C structural motif and a CHCH Cu(I)
binding motif, transfers Cu(I) to the IMS-exposed Cu-binding domains of IM-anchored
COX11 and SCO1/2. COX11 and SCO1/2 specifically and directly transfer Cu to the CuB
and CuA sites, respectively. The human CuA assembly mechanism is relatively well
understood. It occurs in a module that contains the COX2 folding chaperone COX20,
SCO1 for Cu transfer, SCO2 in Cu binding and disulfide reduction, and the IMS twin
CX9C protein COA6 cooperating as a copper chaperone or a thiol oxidoreductase (2, 914). Formation of CuB site in COX1 is less understood. The requirement of COX11 is
only supported by studies in bacteria and yeast (8, 15-16), and assumed to occur similarly
in human mitochondria. In yeast, COX11 activity is essential for CuB assembly
Protein
Function
Expression, and membrane insertion of core subunits
TACO1
Translational activator of COX1 mRNA
LRPPRC
Stability of mitochondrial mRNAs, particularly COX1/2/3
COX1 stabilization factor proposed to regulate COX1
COA3
MITRAC12 synthesis

Refs.
(17)
(18-20)
(21-22)
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COX25
COX14
C12orf62
OXA1L
COX18
COX20

COX1 stabilization factor proposed to regulate COX1
synthesis
COX1/2/3 inner membrane insertase
Translocates the COX2 C-terminal tail into the IMS
COX2 chaperone. Presents COX2 to SCO1/2 for copper
insertion
Heme A biosynthesis and assembly of heme a and hem a3 sites
COX10
Farnesylation of heme B to generate heme O
COX15
Hydroxylation of heme O to form heme A
PET117
Proposed to couple heme A synthesis and assembly
FDX2
Cooperates with COX15 in heme O oxidation
ADR
Cooperates with COX15 in heme O oxidation
SURF1
Proposed to participate in heme a3 center assembly or
stabilization
Copper trafficking and assembly of CuA and CuB sites
Carrier that imports copper and inorganic phosphate into mitochondria
SLC25A3
Twin CX9C protein that binds Cu1+ in the IMS for its delivery
COX17
to SCO1/2 and COX11
SCO1
Receives Cu1+ from COX17 and delivers it to COX2
Receives Cu1+ from COX17 and uses it to reduce the CuA
SCO2
coordinating cysteines in COX2
COA6
Cooperates with SCO2 in copper delivery to COX2
COX11
Receives Cu1+ from COX17 and delivers it to COX1
PET191
Twin CX9C protein that stabilizes complexes containing apo
forms of COX1 and COX2 copper chaperones, acting as a
COA5
place holder for COX17. Promotes CuB assembly in the
absence of COX11
CMC1
Twin CX9C protein that forms a complex with newly
synthesized COX1, COX14 and COA3 prior to CuB assembly
CMC2
Twin CX9C protein of unknown specific function
COX23
Twin CX9C protein of unknown specific function
Assembly chaperones
COA1
Interacts with SURF1-containing CcO subassemblies
MITRAC15
MITRAC7 Stabilizes newly synthesized COX1 in the COX1-COX5ACOX4 -containing module
MR-1S
Interacts PET100 and PET117 chaperones
TMEM177 Associates with newly synthesized COX2, COX20, and SCO2.
COX16
Coordinates the merging of COX1 and COX2 modules
Complexes with the COX4-COX5A module to promote its
HIGD1A
assembly with COX1
Promotes the assembly of the COX3 module
HIGD2A
COA4
Twin CX9C protein of unknown specific function

(23-24)
(25-26)
(27)
(28)

(29-30)
(31-33)
(34-35)
(36)
(36)
(37-38)

(39)
(40-41)
(42-43)
(43-44)
(45-47)
(3,8)
(48-49)
This
study
(50)
(51)
(52)
(22, 37)
(54)
(34)
(55)
(56-57)
(34,58)
(58-59)
(60)
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PET100

Fuels the late stages of CcO assembly

Table 4.1 CcO assembly factors identified in humans

(34)

185
and depends on the twin CX9C protein COX19, which prevents COX11 overoxidation
(61). Newly-synthesized human COX1 associates with its folding chaperones COA3 and
COX14 and another IMS twin CX9C protein, CMC1 (62). Cu insertion into COX1 was
proposed to occur in this module, but interaction with human COX11 or COX19 has not
been demonstrated.
Despite the wealth of biochemical and structural information available on
human CcO biogenesis, the process of CuB site assembly has been experimentally
disregarded. Whether mechanisms are in place to couple heme a biosynthesis and CuB
assembly, to synchronize Cu delivery to CuB and CuA, and to coordinate the merging of
the COX1 and COX2 assembly modules remains unknown. Herein, we set out to unravel
these mechanisms using human cell lines lacking COX11 and COX19 that were
physiologically and biochemically characterized to determine the essentiality of these
factors, screen for suppressor genes, establish the transient and stable protein interactome
of CcO Cu-chaperones and CX9C proteins during COX1 and COX2 maturation, and
assess their Cu binding and redox state during the process. We conclude that dynamic
metallochaperone modules -involving heme a biosynthetic enzymes, COX1- and COX2specific copper chaperones, and several twin CX9C proteins, coordinate the assembly of
catalytic metal redox centers in human CcO. The regulatory mechanism is fundamental
for CcO assembly by preventing the accumulation of heme-containing CcO assembly
intermediates lacking copper, which induce oxidative-stress mediated cytotoxicity.
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4.3 MATERIALS AND METHODS
4.3.1 Human cell lines and cell culture conditions
Human HEK293T embryonic kidney cells (CRL-3216, RRID: CVCL-0063),
HEK293 (CRL-1573, RRID: CVCL-0045), and 143B osteosarcoma cells (CRL-8303,
RRID: CVCL-2270), were obtained from ATCC. Cybrid cell lines were constructed
using enucleated control fibroblasts and the osteosarcoma 143B TK 206 rho zero cell
lines (63). COX1 and COX2 mutant cybrid cells carry a homoplasmic G6930A or
G7896A, respectively, mitochondrial mutation that generates a stop codon and a
truncated version of the protein (64, 65). The HEK293T COX16 knock-out (KO) cell line
was provided by Dr. Peter Rehling (University Medical Center Göttingen, Göttingen,
Germany), and the COA6-KO cell line by Dr. Mike Ryan (Monash University,
Melbourne, Australia). The HEK293T COX18-KO and COX20-KO cell lines were
previously reported by our group (11, 66).
Cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS), 2 mM Lglutamine, 1 mM sodium pyruvate, 50 µg/ml uridine, and 1x GlutaMax (Thermo
Scientific) at 37 °C under 5% CO2. Cell lines were routinely tested for mycoplasma
contamination.
4.3.2 Generation of knockout cell lines and plasmid transfection
To create stable human PET191-KO lines in HEK293T cells, two genespecific pairs of TALEN constructs were obtained from Thermo-Invitrogen. The pair of
left and right TALENs was designed to target the corresponding exon 1 (Fig. 4.1). To
create stable human COX19-KO and COX11-KO lines in HEK293T cells, we
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Figure 4.1 Generation of COX11-KO, COX19-KO and PET191-KO cell lines in the
HEK293T background. (A, C, and E) Schematic showing the location of the target
sites in the COX11, COX19, and PET191 loci for the CRISPR guide RNAs or
TALEN constructs used to knockout each gene. (B, D, and F) Screening of
CRISPR or TAL clones by immunoblotting to identify cell lines knockout (KO) for
COX11, COX19 or PET191. (G) Table detailing the genotype of the generated
HEK293T cell lines carrying edited COX11, COX19 or PET191 alleles.
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used CRISPR-CAS9 guide RNAs obtained from OriGene (KN210770 and KN203238,
respectively) designed to bind the exon 1 region of the corresponding gene (Fig. 4.1).
1.5x106 HEK293T cells were transfected with 4 µg of the right and left
TALEN plasmids as a pair with 1 µl of EndoFectin (GeneCopoeia) pre-incubated in 200
µl of OptiMEM-I (Thermo Scientific). Alternatively, HEK293T cells were transfected
with 2 µg of donor DNA plasmid with puromycin resistance and gRNA with 1 µl of
EndoFectin pre-incubated in 200 µl of OptiMEM-I. After 16 hours of incubation, media
were changed to complete DMEM medium. Four consecutive transfections were
performed every 3 days. In the case of CRISPR-CAS9 transfection, the cells were
selected with 2.5 µg/ml puromycin for 3 weeks. Next, the cells were sorted as single cells
in 96-well plates. Single clones were grown and screened by immunoblotting against
PET191, COX11, or COX19 antibodies (Fig. 4.1), and by genotyping (11). For
genotyping, the PET191 locus was sequenced using the oligonucleotides PET191Forward and PET191-Reverse, COX11-Forward and COX11-Reverse were used to
sequence the COX11 locus and COX19-Forward and COX19-Reverse were used to
sequence the COX19 locus (Table 4.2 and Fig. 4.1).
The KOs cell lines were reconstituted with C-terminal Myc-DDK-tagged wildtype version of the corresponding gene and other genes. The genes PET191, COX19,
COA6, COX17, COX16, and COX10 were obtained in plasmids from OriGene. The genes
COX11, SCO1, and SCO2 were cloned from cDNA using primers listed in the Table 4.2.
All genes were cloned under the control of a truncated Δ5-CMV promoter in the Δ5pCMV6-A-Myc-DDK-Hygro plasmid (created from OriGene, PS100024) using Sfg1 and
Mlu1 sites. To generate mutant variants of COX11 and
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Gene

Oligonucleotides

COX11_F
COX11_R
SCO2_F
SCO2_R
SCO1_F
SCO1_R
talenPET191_F
talenPET191_R
CRISPR/CAS9Cox11_F

AAGCGATCGCATGGGAGGGCTCTGGCGT
AAACGCGTATTATATCCTGGAACTGGCA
AAAGCGATCGCATGCTGCTGCTGACTCGGA
AAAACGCGTAGACAGGACACTGCGGAAA
AAGCGATCGCCATGGCGATGCTGGTCCTA
AAACGCGT GCTCTTTTTTCTGTATGG
GTTGTTGCCGCTGGCTTCCGGT
CCTGGACCACACAGTCCGA

CRISPR/CAS9Cox11_R
CRISPR/CAS9Cox19_F
CRISPR/CAS9Cox19_R
PET191_mut_C30A_F
PET191_mut_C30A_R
PET191_mut_C41A_F
PET191_mut_C41A_R
COX11_mut_C217A_F
COX11_mut_C217A_R
COX11_mut_C219A_F
COX11_mut_C219A_R

TGGCAATAGAGCCGATA
GTGCTCGGCGCTCCCGGGGT
TCACCTAAGTGATCCA
GCAGTCGGACGCGGTGGTCCAGGAAGGAAAATCACCTC
AGCAGACACGCGCCCAGG
ACCTCGGCAGGCGTTGAAGGAAGGATAC
GATTTTCCTTCCTGGACC
TAAAATACAGGACTTCTGTTTTGAAGAAC
TTGAAATACTGTCCAGCTTC
ACAGTGCTTCGACTTTGAAGAACAAAGG
ATTTTATTGAAATACTGTCCAG

TTCAGAGGGTTATGGGAGGGCT

Table 4.2. List of oligonucleotides used in this study.
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PET191, we used the Q5® Site-Directed Mutagenesis Kit from NEB. ~ 10 pg of template
Δ5-pCMV6-A-Myc-DDK-Hygro-COX11 or Δ5-pCMV6-A-Myc-DDK-Hygro-PET191
vector were used, along with the primers COX11_mut_C217A_F,
COX11_mut_C217A_R, COX11_mut_C219A_F, COX11_mut_C219A_R,
PET191_mut_C30A_F, PET191_mut_C30A_R, PET191_mut_C41A_F,
PET191_mut_C41A_R (Table 4.2), designed to include the codon to be mutated. After
exponential amplification and the treatment with kinase and ligase, 2.5 µl of the reaction
were transformed in competent Escherichia coli cells. For transfection of all constructs,
we used 1 µl of EndoFectin mixed with 1-2 µg of vector DNA in OptiMEM-I media
according to the manufacturer’s instructions. Media was supplemented with 200 µg/ml of
hygromycin after 24 h and drug selection was maintained for at least 1 month.
For co-overexpression of PET191 and COX17, COX11-KO cells were
transfected with 1 µl of EndoFectin mixed with 1-2 µg of each vector DNA in
OptiMEM-I media according to the manufacturer’s instructions. The cells were selected
in 200 µg/ml of hygromycin after 24 h. After 3 weeks of selection, the pool of cells was
sorted as single cells in 96-well plates. Single clones were grown and screened by
immunoblotting against PET191 and COX17 with respective antibodies and clones
expressing both proteins were selected. For co-overexpression of PET191 and COX17,
and one of the SCO genes, SCO1 and SCO2 were cloned into the pCMV6-A-BSD
plasmid (OriGene, PS100022) using Sfg1 and Mlu1 sites. The selected clones of cooverexpressing PET191 and COX17 were transfected with 1 µl of EndoFectin mixed with
1-2 µg of SCO1 or SCO2 expression constructs in OptiMEM-I media according to the
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manufacturer’s instructions. The cells were selected in 50 µg/ml of blasticidin after 24 h
and for 3 weeks in total.
4.3.3 siRNA transfection
HEK293T cells or PET191-KO were grown on 6-well plate at 10% confluency
and transfected using 5 μl of Lipofectamine RNAiMAX (Invitrogen) mixed with either
10 nM of COX10 (GGUGCCAUUUGACUCAAACtt) siRNA (Ambion‐Life
Technologies); or scrambled control [BLOCK‐iT Alexa Fluor (Invitrogen)] in 200 μl
OptiMEM-I (GIBCO), according to the manufacturer’s specifications. The cells were
silenced for 10 days, and efficiency of silencing was confirmed by immunoblotting.
4.3.4 Whole-Cell extracts and Mitochondrial isolation
For SDS-PAGE electrophoresis, pelleted cells were solubilized in RIPA buffer
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1%
SDS) with 1 mM PMSF and mammalian protease inhibitor cocktail (Sigma). Whole-cell
extracts were cleared by 5 min centrifugation at 20,000 x g at 4 oC.
Mitochondria-enriched fractions were isolated from at least ten 80% confluent
15-cm plates as described previously (11, 67, 68). Briefly, the cells were resuspended in
ice-cold T-K-Mg buffer (10 mM Tris–HCl, 10 mM KCl, 0.15 mM MgCl2, pH 7.0) and
disrupted with 10 strokes in a homogenizer (Kimble/Kontes, Vineland, NJ, USA). Using
a 1 M sucrose solution, the homogenate was brought to a final concentration of 0.25 M
sucrose and a post-nuclear supernatant was obtained by centrifugation of the samples
twice for 5 min at 1000 x g. Mitochondria were pelleted by centrifugation for 20 min at
10,000 x g and resuspended in 0.25 M sucrose, 20 mM Tris-HCl, 40 mM KCl, 10 mM
MgCl2, pH 7.4.
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4.3.5 Depletion of CcO core subunits
To deplete the cells from mtDNA-encoded polypeptides, including CcO core
subunits, COX1, COX2, and COX3, WT HEK293T and COX11-KO cells stably
expressing COX11-FLAG were treated with 200 µg/ml chloramphenicol for 10 days to
inhibit mitochondrial protein synthesis. As a control, cells were treated with the same
volume of the vehicle 100% ethanol. The medium was changed every 48 h and
supplemented with fresh chloramphenicol solution. Mitochondria were isolated as
described above.
4.3.6 Denaturing and native electrophoresis, followed by immunoblotting
Protein concentration was measured by the Lowry method (69). 40–80 µg of
mitochondrial protein extract was separated by denaturing SDS–PAGE in the Laemmli
buffer system (70). Then, proteins were transferred to nitrocellulose membranes and
probed with specific primary antibodies against the following proteins: COX11
(OriGene, TA323960), PET191 (Sigma, HPA057768), COX19 (Sigma, HPA021226),
ACTIN (Proteintech, 60008-1-Ig), COX1 (Abcam, ab14705), COX2 (Abcam, ab110258),
COA6 (Sigma, HPA028588), COX17 (OriGene, TA315013), COX16 (Proteintech,
19425-1-AP), COX10 (Sigma, HPA032005), COA3 (Sigma, HPA031966), SCO1 and
SCO2 (kind gift of P. Rehling), CMC1 (Sigma, HPA043333), COX5B (Santa Cruz, sc374417), SURF1 (Abcam, Ab155251), CORE2 (Abcam, ab14745), FLAG (Sigma,
F3165), COX20 (Sigma, HPA045490), HIGD2A (Sigma, HPA042715). Horseradish
peroxidase-conjugated anti-mouse or anti-rabbit IgGs were used as secondary antibodies
(Molecular Probes). β-ACTIN was used as a loading control. Signals were detected by
chemiluminescence incubation and exposure to X-ray film. Optical densities of the
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immunoreactive bands were measured using the ImageLab (Biorad) software or the
ImageJ software in digitalized images.
Blue-Native polyacrylamide gel electrophoresis (BN-PAGE) analysis of
mitochondrial respiratory chain complexes, supercomplexes, and CIV assembly
intermediates in native conditions was performed as described previously (71, 72). To
extract mitochondrial proteins in native conditions, mitochondria were pelleted and
solubilized in 100 μl buffer containing 1.5 M aminocaproic acid and 50 mM Bis-Tris (pH
7.0). After optimizing solubilization conditions, we used digitonin at the optimal 1:2
(digitonin: protein) proportion. Solubilized samples were incubated on ice for 15 min and
pelleted at 20,000 x g for 30 min at 4 °C. The supernatant was combined with 10 µl of
sample buffer 10X (750 mM aminocaproic acid, 50 mM Bis-Tris, 0.5 mM EDTA, 5%
Serva Blue G-250). Native PAGE™ Novex® 3-12% Bis-Tris Protein Gels (Life
Technologies) gels were loaded with 60-100 µg of mitochondrial protein or total cell
extracts. After electrophoresis, proteins were transferred to PVDF membranes using an
eBlot L1 protein transfer system (GenScript) and used for immunoblotting.
4.3.7 Characterization of the MRC and oxidative phosphorylation system
The enzymatic activity of mitochondrial respiratory chain Complex IV or
cytochrome c oxidase (CcO) was assessed spectrophotometrically using frozen-thawed
cells by following the oxidation of exogenous reduced cytochrome c as reported (73).
Values were normalized by total protein concentration measured by the Lowry method
(69).
Endogenous cell respiration was measured polarographically at 37 oC using a
Clark-type electrode from Hansatech Instruments (Norfolk, United Kingdom). Cell
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respiration was assayed in cultured cells as reported (73). Briefly, trypsinized cells were
washed with respiration buffer (RB) containing 0.3 M mannitol, 10 mM KCl, 5 mM
MgCl2, 0.5 mM EDTA, 0.5 mM EGTA, 1 mg/ml BSA and 10 mM KH3PO4 (pH 7.4), and
resuspended at ~2 × 106 cells/ml in 0.5 ml of the same buffer, air-equilibrated at 37 °C.
The cell suspension was immediately placed into the polarographic chamber to measure
endogenous cell respiration. The specificity of the assay was determined by inhibition of
complex IV activity and then, respiration, with 0.8 µM KCN. Values were normalized by
total cell number.
To obtain total mitochondrial cytochrome spectra, cytochromes were released
from 8mg of WT or KOs mitochondria by resuspending them in 1190 μl of water with 70
mg of KCl (to 670 mM concentration), then adding a buffer containing 50 mM Tris, pH
7.5, and 1% potassium deoxycholate in a final volume to 1,4 ml, and gently mixing by
pipetting. The extracts were cleared by centrifugation at 21,000 x g for 20 min at 4°C. To
the clear supernatant, sodium cholate was added to a 1% final concentration. Half of the
solution was reduced with sodium dithionite, while the other half was oxidized with
potassium ferricyanide and the difference of spectra of the reduced versus oxidized
extracts between 500 to 650 nm were recorded at room temperature using a UV-2401PC
Shimadzu spectrophotometer. The ⍺ absorption bands corresponding to cytochromes a
and a3 have maxima at 603 nm; the maxima for cytochrome b and for cytochrome c and
c1 are 560 and 550 nm, respectively.
4.3.8 Pulse Labeling of Mitochondrial Translation Products
Mitochondrial protein synthesis was determined by pulse-labeling 70-80%confluent 15 cm plates of HEK293T, 143B, cybrid cell lines or KO cell lines. The cell
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cultures were incubated for 30 min in DMEM without methionine and then,
supplemented with 100 µl/ml emetine to inhibit cytoplasmic protein synthesis as
described (11). Cells were labeled for 30 min (Pulse) at 37 °C with 100 μCi/ml [35S]
methionine (PerkinElmer Life Sciences, Boston, MA). After incubation, the cells were
washed once with 1X PBS, collected by trypsinization, and whole-cell extracts were
prepared by solubilization in RIPA buffer (1% NP-40, 0.1% SDS, 0.5% Nadeoxycholate, 150 mM NaCl, 2 mM EDTA (ethylenediaminetetraacetic acid), and 50
mM Tris-HCl, pH 8.0) supplemented with 1 mM PMSF (phenylmethylsulfonyl fluoride)
and 1X EDTA-free mammalian protease inhibitor cocktail (Roche # 11836170001). After
incubation, the cells were washed, trypsinized, collected, and proteins were extracted.
100 μg of each sample was separated by SDS (sodium dodecyl sulfate)-PAGE on a
17.5% polyacrylamide gel, transferred to a nitrocellulose membrane and exposed to
Kodak X-OMAT X-ray film. The membranes were then probed with a primary antibody
against β-ACTIN as a loading control.
For immunoprecipitation assays, pelleted cells were extracted in 800 µl of
PBS, 0.4% n-dodecyl-β-D-maltoside (DDM), 1 mM PMSF, and 8 µl of protease inhibitor
cocktail (Sigma, P8340) for 10 min on ice. After centrifugation at 20,000 x g for 30 min
at 4°C, the extract (Ex) was incubated overnight with 25 µl of protein A agarose beads
with rabbit IgG (negative control) or specific antibody raised in rabbit. The unbound
material (Un) was removed, and the beads were washed five times in 1 ml PBS with
0.05% DDM. Then, the beads were incubated at 37 °C for 1h in 60 µl of Laemmli buffer
2x to release bound material (IP). Equivalent amounts of all fractions were separated by
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SDS-PAGE using a 17.5% polyacrylamide gel. Gels were transferred to a nitrocellulose
membrane and exposed to X-ray film.
4.3.9 Immunoprecipitation
For immunoprecipitation of Myc-DDK-tagged proteins, 1 mg of mitochondria
of KOs with Myc-DDK-tag or wild-type HEK293T (as negative control) were incubated
in 1 mM DSP (dithiobis[succinimidylpropionate], Thermo Scientific) or in DMSO carrier
control for 1,5 h at 4 °C. DSP is thiol-cleavable, primary amine-reactive with an 8-carbon
spacer arm crosslinker. The reaction was stopped by incubation with 10 mM Tris-HCl
solution, pH ~ 7,4. After spin the mitochondria were extracted in 600 µl of PBS, 0.4%
DDM, 1 mM PMSF, and 8 µl of protease inhibitor cocktail (Sigma, P8340) for 10 min on
ice. After centrifugation at 20,000 x g for 30 min at 4 °C, the extract (Ex) was incubated
for 4 h at 4 °C with 25 µl of beads conjugated with a FLAG antibody (anti-DYDDDDDK
beads, Sigma), previously washed in PBS. The unbound material (Un) was removed, and
the beads were washed five times in 1 ml of PBS 0.05% DDM. Then, beads were
incubated for 30 min in 65 °C with 100 µl of Laemmli buffer 2x to release bound
material (IP). Equivalent amounts of all fractions were analyzed by SDS-PAGE and
immunoblotting.
4.3.10 Thiol trapping analyses of COX11, SCO1, and SCO2
To analyze the in organello redox state of cysteines in COX11, SCO1, and
SCO2 state of cysteines, we used a reverse thiol trap assay as described (63, 66). Briefly,
100 µg of mitochondria purified from WT or KO cell lines were first incubated for 30
min under isotonic conditions with 80 mM of membrane-permeable iodoacetamide
(IAA), a compound that covalently binds free thiols. After incubation, the samples were
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washed twice with 1ml of PBS to remove unbound IAA. Mitochondria were then
resuspended in 60 µl of PBS and solubilized in the presence of 0.2% SDS. Next, to
reduce all the originally oxidized cysteines (not bound by IAA), 5 mM of the reducing
agent TCEP (tris(2-carboxyethyl)phosphine) was added to the samples that were
incubated for 12 min at 95°C and let to cool down. The cysteines that had not been
blocked by IAA were subsequently identified by incubation for 1h at room temperature in
the dark with 4.5 mM AMS (4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid), a
compound that binds free thiols, adding ~ 0.5 kDa for every molecule bound. Full
reduction of COX11, SCO1 or SCO2 was tested by reducing the proteins first with
TCEP, and then adding excess IAA, followed by AMS addition. The maximum shift of
reduced COX11, SCO1, or SCO2 was determined by reducing the sample with TCEP
during extraction, quickly followed by treatment with AMS. Finally, the samples were
supplemented with non-reducing Laemmli sample buffer and analyzed by non-reducing
SDS-PAGE (12% for COX11 or 10% for SCO1 and SCO2) followed by immunoblotting.
4.3.11 Sucrose gradient sedimentation analysis
Sucrose gradient sedimentation analyses were performed as described
previously (74). One mg of WT or KOs mitochondria were extracted in 300 µl of 20 mM
Tris pH 7.5, 50 mM KCl, 1% digitonin, 1mM PMSF, and 1 x protease inhibitor cocktail.
The lysate was spun at 20,000 x g for 30 min at 4 oC and the clarified extract was loaded
onto a 5ml 7 – 20% sucrose gradient containing 20 mM Tris pH 7.5, 50 mM KCl, 0.1%
digitonin, and 1 mM PMSF buffer and centrifuged at 150,000 x g for 15h at 4°C. The
gradients were fractionated into 13 fractions, TCA-precipitated and the pellets
resuspended in Laemmli buffer and analyzed by immunoblotting.
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4.3.12 Determination of copper
Determination of copper in COX11- or PET191-containing metallochaperone
modules was performed by using inductively coupled plasma mass spectrometry (ICPMS). For sample preparation, we used 16 mg of mitochondria purified from the following
cell lines: HEK293T WT or COX11-KO cells stably expressing WT or cysteine mutant
versions of COX11-FLAG, COX11-KO cells stably expressing PET191-FLAG, and
PET191-KO cells stably expressing PET191-FLAG. Mitochondria were solubilized in
0.4% DDM as described earlier to extract COX11 or PET191 in native conditions,
performed a large-scale immunoprecipitation assay using anti-FLAG-conjugated
sepharose beads, and the metals were extracted by protein denaturation with 1% SDS.
The samples were lyophilized, incubated overnight with 100 μl of nitric acid at 65 °C,
diluted 20-fold, and metals in the samples were measured using ICP-MS as described
previously (75). Briefly, the samples were digested in 100 μl of 70% w/v trace metal
grade nitric acid for 14 hours at 65 °C. The digests were cooled down to room
temperature, centrifuged and diluted 20-fold into the autosampler of the ICP-MS, with a
2% nitric acid spiked with 50 μg/L Gallium as internal standard (final concentration). The
instrument consists of an Agilent 7500cx (Santa Clara, CA) operating in Mix reaction
mode (3.5 ml H2 and 1.5 ml He per min) for removal of polyatomic interferences in the
collision cell. The samples were loaded using an autosampler (ESI, Omaha, NE) using a
6-port injection valve with a 125 μl sample loop. The samples were injected at a flow rate
of 55 μl/min with the following operating conditions for the ICP-MS: Ar carrier flow,
1.0 L/min); Ar make-up flow, 0.1-0.2 L/min; forward power, 1500 W; Ar plasma gas, 15
L/min, Ar auxiliary gas, 1 L/min. Concentrations were calculated using an external
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calibration curve, also with 50 ppb Ga as internal standard. All solutions for metal
analysis used metal-grade water and nitric acid.
4.3.13 Oxidative stress measurements
Reactive oxygen species (ROS) measurements were performed by flow
cytometry, using three different dyes, DHE (2.5 mM) and MitoSOX (2 mM) to
preferentially detect superoxide anion, and CM-H2DCFDA (5 mM) to preferentially
detect hydrogen peroxide. Cells were grown in a 6-well plate and incubated with the dye
for 30 min. Then, the cells were washed in PBS, resuspended in Hanks solution, and
analyzed using a BD LSR II flow cytometer. As a positive control, we used cells treated
for 1 h at 37 °C with 100 μM H2O2 or 1 μM antimycin A.
4.3.14 Cytotoxicity assay
The cell sensitivity to oxidative stress was assessed colorimetrically with the
Cytotoxicity Detection LDH Kit (Sigma, 11644793001). WT and KOs cells were grown
to 80% confluency in 6-well plates. Following aspiration of the medium, the cultures
were carefully washed with PBS and incubated in FBS-free medium supplemented with
0, 300 or 500 μM H2O2 for 7 h. One hundred μl of medium was used per assay. LDH
activity was measured according to the manufacturer’s instructions.
4.3.15 Yeast strains and Growth Conditions
Yeast strains used in this work were of the W303 genetic background (Table
4.3). The cox11Δ, pet191Δ, pet117Δ, coa3Δ, cox11Δcoa3Δ, cox11Δpet191Δ, and
cox11Δpet117Δ strains were generated in vivo using homologous recombination of PCRamplified gene-specific knock-out cassettes containing HIS3, URA3MX, KanMX, or
KanMX4 selection markers flanked by DNA sequences with
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Strain
W303-1B
cox11Δ
pet191Δ
pet117Δ
coa3Δ
cox11Δ coa3Δ
cox11Δ
pet191Δ
cox11Δ
pet117Δ

Genotype
MATα ade2-1 can1-100 his3-11,15 leu2-3 trp1-1 ura31
MATa ade2-1 his3-11 leu2-3,112 ura3-1 canr galr
cox11::HIS3
MATα ade2-1 can1-100 his3-11,15 leu2-3 trp1-1 ura31
pet191::URA3MX
MATα ade2-1 can1-100 his3-11,15 leu2-3 trp1-1 ura31 pet117::URA3MX
MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1
coa3::KanMX
MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1
coa3::KanMX cox11::HIS3
MATa ade2-1 his3-11 leu2-3,112 ura3-1 canr galr
cox11::HIS3 pet191::URA3MX
MATa ade2-1 his3-11 leu2-3,112 ura3-1 canr galr
cox11::HIS3 pet117::KanMX4

Table 4.3. Yeast strains used in this study.

Reference/Source
ATCC
(76)
This study
(35)
(77)
(77)
This study
(35)
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homology to the upstream and downstream chromosomal regions of the coding sequence
for the deleted gene. The plasmid for wild-type Pet191-6xHIS (containing the His6
epitope) expression were produced by PCR amplification of PET191 from genomic DNA
followed by restriction enzyme cloning into the pRS426 containing the MET25 promoter
and CYC1 terminator. Depending on experiment, yeast cells were cultured in yeast
extract-peptone (YP) or synthetic complete (SC) media lacking nutrients (amino acids or
nucleotides) necessary to maintain plasmid selective pressure (78) containing either 2%
glucose, 2% galactose, or 2% glycerol/2% lactic acid mix as the carbon source. Growth
tests to assess respiratory capacity and quantify hydrogen peroxide sensitivity were
carried out as before (79, 80). Cultures used for growth tests were grown overnight in SC
media lacking relevant nutrients to maintain plasmid selection then normalized to OD600
of 1 and spotted onto SC plates with or without 1 mM CuSO4.
4.3.16 Assays in Saccharomyces cerevisiae
To assess hydrogen peroxide sensitivity of yeast cells of interest, cells were
cultured to mid-log phase, normalized, and acutely treated with 1 mM H2O2 for 1 h at 28
°C. Following treatment, cultures were diluted to 300 cells per sample and plated to
assess viable colony forming units after 48 h of growth at 28 °C. Cells were examined in
7 biological replicates and obtained experimental values were statistically analyzed by
one-way ANOVA and Student’s T test.
For immunoblot analysis of yeast mitochondria, mitochondria-enriched
fractions were isolated using established protocols (81). Mitochondrial proteins were
separated by SDS-PAGE and transferred to nitrocellulose membrane, blocked in 5% nonfat milk in PBS with 0.1% Tween-20, and incubated with relevant primary antibodies and
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goat anti-mouse or goat anti-rabbit horseradish peroxidase-coupled secondary antibodies
(Santa Cruz Biotechnology). Proteins of interest were visualized by incubation of said
membranes with chemiluminescence reagents (Thermo Scientific) and exposure to X-ray
film. The following primary antibodies were used: mouse anti-porin (459500, Thermo
Scientific) and rabbit anti-Pet191 (kindly provided by Dr. A. Chacinska). All antibodies
were tested for reliability to ensure specificity of detection.
4.3.17 Statistical analysis
Unless indicated, all experiments were performed at least in biological
triplicates and results were presented as mean ± standard deviation (SD) or standard error
of the mean (SEM) of absolute values or percentages of control. Statistical p values for
comparison of two groups were obtained by application of a Student’s two-tailed
unpaired t-test. For comparison of multiple groups, performed one-way analysis of
variance (ANOVA) followed by Tukey’s post-hoc test for all the groups, using the SPSS
v21.0 program. A p < 0.05 was considered significant test (*p < 0.05; **p < 0.01). Data
in X-ray films was digitalized and analyzed with the ImageJ software or the histogram
panel of Adobe Photoshop.
4.4 RESULTS
4.4.1 COX11 is not essential for CcO biogenesis in human mitochondria
We used the CRISPR-Cas9 technology to create stable human HEK293T cell
line KOs for COX11, or COX19 (Fig. 4.1). Compared to wild-type (WT), the COX11-KO
line retained 50% of COX1 and 15% of COX2 steady-state levels and 15% of residual
fully assembled CcO (labelled as CIV in the BN-PAGE assays) and CcO activity, which
supported 60% of respiratory capacity (Fig. 4.2A-F). By contrast, the COX1 levels in the
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Fig. 4.2: COX11 is not essential for CcO biogenesis in human mitochondria. (A)
Steady-state levels of CcO subunits and assembly factors in COX11-KO cells. (B)
Heat map showing the levels of CcO subunits and assembly factors in COX11-KO,
COX19-KO and PET191-KO cells. (C) BN-PAGE analysis of ETC complexes in
COX11-KO cells. (D) Endogenous cell respiration. (E) Overexpression of CcO
assembly factors in COX11-KO cells. (F-H) CcO activity in the indicated cell lines.
The bar graphs represent the average ± SD of at least three independent experiments.
Paired T-test, *p<0.05, **p<0.01, ***p<0.001. (I) Total mitochondrial cytochrome
spectra.
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COX19-KO line were 25% of WT and COX2 was undetectable resulting in the loss of
holo-CIV, CcO activity, and cellular respiration (Fig. 4.2B, D, F and Fig. 4.3). The two
cell lines accrue COX1-containing CIV subassemblies (Fig. 4.2C and Fig. 4.3D),
reflecting an early CcO assembly defect. The COX11-KO total mitochondrial cytochrome
spectra showed an α peak corresponding to hemes a+a3 of ~75% of WT, higher than
expected for the residual CcO activity in this line.
Approximately 15% of hemes a+a3 was detected in the COX19-KO line
despite lacking CcO. In both mutants, the spectra revealed a 5–6 nm blue shift in the α
peak (597 nm versus 603 nm for WT) (Fig. 4.2I) indicating alterations in the
environments surrounding the heme centers in COX1, as observed in cox11D R.
sphaeroides strains (8). It also implies that COX11 and COX19 are not involved in heme
a biosynthesis and delivery to COX1. All the phenotypes in the KO lines were restored to
WT levels by reconstitution with the corresponding FLAG-tagged WT proteins (Fig.
4.3A, C), which excluded CRISPR off-target effects. Whereas COX19 is essential for
human CcO biogenesis, COX11 is not – suggesting a potential alternative pathway for
CuB metalation in metazoans. Culture media supplementation with Cu(I), His-Cu(II), or
elesclomol-Cu(II), known to mitigate the CcO deficiency in SCO2 patient cell lines and a
coa6D yeast mutant (82, 83), did not enhance CcO activity in COX11-KO cells (Fig.
4.2G). Thus, CuB cannot self-assemble, and an alternative Cu-chaperone is not driven by
high Cu concentrations to substitute for COX11.

205

Fig. 4.3: Steady state levels of mitochondrial respiratory chain complexes, subunits
and assembly factors are altered in the COX19-KO, and PET191-KO cell lines. (A-B)
Steady-state levels of mitochondrial respiratory chain complex subunits and assembly
factors in the indicated cell lines, assessed by immunoblotting. ACTIN served as the
loading control. (C-D) Blue-Native (BN)-PAGE analysis of the steady state levels of
respiratory complexes and supercomplexes, as well as complex IV subcomplexes or
assembly intermediates. (E-F) Overexpression of PET191 alone or in combination
with COX17, partially restores CcO activity in COX11-KO cells. (E) Immunoblot
analysis of the steady-state levels of the indicated proteins in HEK293T wild-type
(WT) and COX11-KO cells transfected with constructs expressing FLAG-tagged
PET191, alone or in combination with COX17, SCO1 or SCO2 as indicated. ACTIN
was used as a loading control. (F) CcO specific activity measured
spectrophotometrically in frozen-thawed cells following the oxidation of exogenous
reduced cytochrome c. The bars are the average ± S.D. of three independent replicates.
Paired t- test, for comparison with the WT, *p<0.001.
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4.4.2 Overexpression of PET191 partially mitigates the CcO deficiency of
COX11-KO cells
COX19 contains four structural cysteine residues in two disulfides but lacks
any Cu-binding motif. It does not play any overlapping role with COX11, as
overexpression of COX19 in the COX11-KO cell line did not improve its residual CcO
activity or vice versa. Although SCO proteins have been implicated in the assembly of
CuB in α-proteobacteria with cbb3-type oxidases (16), SCO1 or SCO2 overexpression did
not restore CcO activity in COX11-KO cells even in the presence of exogenous Cu (Fig.
4.2F). Neither COA6 nor COX17 had a suppressive effect in COX11-KO cells (Fig.
4.2F). By contrast, our screen identified another IMS-resident twin CX9C protein,
PET191 (alias COA5), as being able to enhance CcO levels and activity in COX11-KO
cells from 15% to 40% of WT, and up to 50% when co-overexpressed with COX17 (Fig.
4.2F-H and Fig. 4.3E-F). Additional overexpression of SCO1/2 (Fig. 4.3) or exogenous
Cu had no additive effect on CcO activity (Fig. 4.2H).
PET191 is essential for CcO assembly in yeast (84), and weakly suppresses the
respiratory growth defect of a cox11D strain (Fig. 4.4). Human PET191 mutations lead to
CcO deficiency and fatal hypertrophic cardiomyopathy (85). We used transcription
activator-like effector nucleases (TALENs) to generate HEK293T PET191-KO cell lines
(Fig. 4.1E-G), which had a phenotype akin to COX19-KO cells, with undetectable levels
of COX2 and holo-CIV (Fig. 4.5). Thus, PET191 is essential for CcO biogenesis in
human cells. PET191 has four structural cysteines forming two disulfides and two
additional cysteines (C30 and C41), one of which is functionally essential in yeast (84).
Reconstitution of PET191-KO cells with WT PET191 restored all the phenotypes while
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the mutant PET191(C30A, C41A) partially restored CcO activity (Fig. 4.5A-C). The
extra cysteines in PET191 may play a role in Cu or redox transfer since their mutation
abolished PET191 capacity to suppress the COX11-KO CcO deficiency (Fig. 4.2F and
Fig. 4.5E-G).
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Fig. 4.4: Saccharomyces cerevisiae Pet191 is a weak high-copy suppressor of
cox11∆ mutant. (A) Steady-state levels of Pet191 in mitochondria isolated from the
indicated S. cerevisiae strains, assessed by immunoblotting with respective antibodies.
Porin was used as the loading control. (B, C) Serial dilutions growth tests of the
indicated strains in synthetic media containing glucose (SCD) or galactose (SCGal) as
sole carbon sources (panel B) or complete media containing glucose (YPD), galactose
(YPGal), or glycerol (YPGL), as the carbon sources, with or without supplementation
with 1 mM CuCl2 (panel C). (D) Sensitivity of the indicated strains to hydrogen
peroxide. Cells were cultured in YPD medium at 30 oC to mid-log phase and then
normalized and acutely treated with 1 mM or 6 mM H2O2 for 1 h at 30 oC. Cultures
were diluted and 300 cells were plated on YPD agar for assessment of colony forming
units after 48 h incubation at 30°C. The bars represent the average ± S.D. of five
independent replicates. T-test, *p<0.05, **p<0.01, ***p<0.001.
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Fig. 4.5: A double-cysteine mutant (C30A, C41A) of PET191 partially impairs CcO
assembly, but does not suppress the CcO assembly defect of COX11-KO cells despite
having an interactome like that of WT PET191. (A and E) Steady-state levels of
PET191, COX1, COX10, and CcO subunits COX1 and COX2 in the indicated cell
lines, assessed by immunoblotting. ACTIN served as the loading control. (B) CcO
specific activity following the oxidation of exogenous reduced cytochrome c.. Paired
t-test, **p<0.001. (C and F) Steady-state levels of complex IV subassemblies,
holocomplex and respiratory supercomplexes in the indicated cell lines, separated by
BN-PAGE and detected by immunoblotting with an antibody against COX1. (D and
G) Immunoprecipitation analysis of PET191-FLAG or PET191 mutant-FLAG in the
indicated cellular backgrounds. Mitochondria were purified from each strain, treated
with DSP or the vector DMSO, extracted with 0.4% DDM (n-dodecyl β-D-maltoside),
incubated with anti-FLAG-conjugated protein A beads, and processed for immunoblot
analyses to detect the indicated proteins. HEK293T cells without FLAG (WT) were
used as negative control. Ex, extract; Un, unbound; IP, immunoprecipitate.
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4.4.3 COX19, PET191, COA6 and COX2 are essential to maintain the redox
state and copper binding capacity of COX11
We used a reverse thiol-trapping approach to assess the native redox state of
human COX11 (Fig. 4.6A). COX11 has three conserved cysteine residues, two in the
CFCF motif required for Cu binding in yeast and bacteria, while the third, C121, is
required for Cu transfer (15-16, 86). Functional COX11 is a dimer (87), with 2Cu(I) 4Cys centers facing the membrane and bent to be near one of the two C121 residues
while also interacting with two of the three COX1 histidine-ligands of CuB enabling Cu
transfer (16). Cu-bound dimeric COX11 (Cu(I)·COX11) has two cysteines, C217 and
C219, engaged in Cu coordination, and a reduced cysteine, C121, per monomer, which
should result in the addition of 2 AMS molecules, whereas no AMS is expected to bind to
apo-COX11 (Fig. 4.6B). In WT HEK293T cells 50% of COX11 is Cu(I) ·COX11, but in
COX19-KO and PET191-KO cells, COX11 is fully reduced in the apo-state (Fig. 4.6C).
Also, while the fraction of Cu(I)·COX11was slightly increased compared to WT in
COX16-KO (Fig. 4.6D), only apo-COX11 was detected in COA6-KO, which links
COX11 to proteins, such as COA6, involved in COX2 metalation. We then assessed the
COX11 redox state in WT 143B cells, in which more than 80% is Cu(I)·COX11, and
homoplasmic cybrid cell lines lacking COX1, COX2 or COX3. The proportion of
Cu(I)·COX11 in COX3 cybrids was similar to WT, 50% in COX1 cybrids, and ~5% in
COX2 cybrids (Fig. 4.6E). These data functionally link COX11 -as well as COX19 and
PET191- to COX2 metalation.
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Fig. 4.6. COX11 redox state and Cu binding are regulated by PET191 and COX19.
(A) Reverse thiol trapping approach to detect the native cysteine residues
inaccessible to a cell-permeable alkylating compound (2-iodoacetamide) that upon
denaturation and full reduction were bound to AMS (4-acetamido-4'maleimidylstilbene-2,2'- disulfonic acid), which adds ~540 Da per thiol. (B)
Potential redox and Cu binding states of COX11. (C-D) Reverse COX11 thiol
trapping in the indicated cell lines. The graph shows the quantification of at least 3
independent experiments. Paired T-test, *p<0.05, ***p<0.001.
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4.4.4 COX11 physically interacts with newly synthesized COX2
Metabolic labeling of mitochondrial polypeptides in whole cells with 35Smethionine followed by COX11 immunoprecipitation (IP) revealed that COX11 exhibits
a stable interaction with newly synthesized COX2 but not with COX1 in WT HEK293T
and 143B cells (Fig. 4.7A).
The interaction persists in the absence of COX1 but is abolished in the absence
of COX20, a factor that stabilizes COX2 during insertion of its N-proximal
transmembrane domain, or COX18, which transiently interacts with COX2 to promote
translocation across the inner membrane of the COX2 C-tail that contains the apoCuA site. The lack of COX2 did not promote COX11-COX1 association, nor did COX19
or PET191 stably interact with newly synthesized COX2 (Fig. 4.8A). Instead, the three
proteins - COX11, COX19, and PET191- affected the interaction between COX2 and
known COX2 folding and CuA metalation chaperones. The absence of COX11
diminished the interaction of COX2 with SCO2 by 20% and of COX20 by 50% (Fig.
4.8B). Furthermore, SCO1, COA6, and COX16 failed to interact with the newly
synthesized COX2 in the absence of PET191 (Fig. 4.8B). The absence of COX19
produced similar effects, although 20% of the COA6-COX2 interaction was preserved.
By contrast, the interactions of COX11 or SCO2 with COX2 were independent of
PET191 or COX19 (Fig. 4.8B). These data indicate that SCO2 and COX11 interact with
apo-COX2 before the action of PET191 and COX19, and prior to the joining of SCO1,
COA6, and COX16.
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Fig. 4.7. CcO subunits and metallochaperones undergo stable and transient
interactions to drive and coordinate metal center assembly. (A) Co-IP of COX11
with newly synthesized mitochondrial polypeptides. (B) Co-IP of COX11 with CcO
subunits and assembly factors in the presence or absence of the crosslinker DSP.
(C) Stable interactions among CcO assembly factors determined by IP followed by
either immunoblotting (WB) or mass spectrometry (MS). (D) Transient interactions
among CcO assembly factors determined by IP in the presence of DSP followed by
either immunoblotting. The heat maps show the average quantification of at least 3
independent experiments. Paired T-test. *p<0.05
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Fig. 4.8: COX11 interacts with newly synthesized COX2 and accumulates in several partially
overlapping high-mass complexes that partially overlap with those containing COX19 and
PET191. (A-B) Mitochondrial translation products were pulse-labeled in HEK293T (WT) and
the indicated KO cell lines for 30 min. Whole-cell extracts were then used for
immunoprecipitation using protein A-conjugated agarose beads and antibodies against the
indicated proteins or IgG as a control. Equivalent amounts of total protein from extract (E),
unbound (U), and immunoprecipitate (IP) fractions were separated by SDS-PAGE. The heat
map shows the average quantification of immunoprecipitated COX2 across the cell lines of
interest, of three independent experiments. (C) Sedimentation analyses of CcO
metallochaperones in 7%-20% linear sucrose gradients using mitochondrial extracts prepared
in the presence of 1% digitonin. Following fractionation, the samples were analyzed by
immunoblotting. (D) Mitochondrial extracts prepared as in (A) were analyzed by BN-PAGE
and immunoblotting against the indicated proteins.
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4.4.5 COX1 and COX2 metallochaperones form stable and transient modules
The steady-state levels of COX19 and COX11 were interdependent in all contexts tested,
whereas the levels of PET191 were unaltered in the COX19-KO or COX11-KO lines
(Fig. 4.2A-B and Fig. 4.3A-C). COA6 and SCO2 levels were attenuated in COX11-KO
cells to 50% of WT but those levels, and the levels of SCO1 and COX16 were below
25% in the COX19-KO or PET191-KO lines (Fig. 4.2A-B, Fig. 4.3, and Fig. 4.5).
Density gradient fractionation and Blue-Native (BN)-PAGE analyses of digitoninextracted native protein complexes showed that COX11 is part of a ~250 kDa complex
whose integrity depends on COX19 and PET191 (Fig. 4.8C-D). The three proteins also
form several complexes ranging from ~50 to 150 kDa (Fig. 4.8C-D). Next, we performed
IP assays in mitochondria extracts from WT and each respective KO cell line
reconstituted with a functional FLAG-tagged version of the corresponding protein, or
candidate protein interactors relevant to COX1 and COX2 biogenesis - SCO1, SCO2,
COX17, COA6, COX16, and COX10. The results (Fig. 4.7B-C) indicate that COX11
stably interacts with COX2, the SCO1/2 CuA metallochaperones, the COX11 chaperone
COX19, the heme o synthase COX10, and the putative COX1 heme a insertase SURF1.
Taken together, these novel interactions merge the COX1 and COX2 assembly modules.
Moreover, COX17 forms stable interactions with SCO1/2, and COX10, but not PET191
or COX11. Likewise, COA6 stably interacts with COX2, SCO1/2 and COX16 (Fig.
4.7C). To examine protein-protein interactions in an unbiased manner, the IPs of COX11,
COX19, and PET191 were analyzed by LC-MS-MS, which confirmed the interaction of
these three proteins with SCO1, and the interactions of COX11 with COX19, SCO2, and
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COX2 (Fig. 4.7C). The MS studies also indicated potential interactions of COX11 and
PET191 with the heme a synthase COX15, the IMS CcO assembly factor COA7, and the
holo-cytochrome c synthase HCCS, as the most relevant proteins (Fig. 4.7C).
To capture transient protein-protein interactions with CcO metallochaperones
occurring during CcO assembly, we used mitochondria purified from each respective line
treated with the crosslinker DSP (dithiobis(succinimidyl propionate)) or the vehicle
DMSO. Samples were extracted with 0.4% DDM (n-dodecyl β-D-maltoside), incubated
with anti-FLAG agarose beads, and analyzed by immunoblotting to detect 13 candidate
proteins: the 9 bites plus COX2, COX1, COA3, and SURF1. The original DSP data is
summarized in a compilation of heatmaps (Fig. 4.7D) that reflect the existence of several
independent complexes with progressively overlapping compositions. For example, in
WT mitochondria, COX11, SCO1, SCO2, and COX16 co-IP with all of the 13 proteins
analyzed; COX10, PET191, and COX17 do not interact with COX1, COX2, or SURF1,
and COX11 and COX19 always co-assemble (Fig. 4.7D). PET191 does not co-IP with
COX17 or COA6, suggesting that it acts before their incorporation (Fig. 4.7D).
Furthermore, by revealing the effect of the lack of each deleted protein on the stability
and interaction of other factors from the same CcO assembly module (Fig. 4.7D), we can
determine the composition thereof. For example, the capacity of COX11 to interact with
COX2 and its chaperones is hindered in the absence of COX19 or PET191; and PET191
coincides with COX17 in the same complex only in the absence of COA6 (Fig. 4.7D).
Our data indicate that a complex containing unmetallated Cu-chaperones and heme a
biosynthetic enzymes assembles and is stabilized by PET191, the protein that also acts as
a placeholder for COX17. COX17 delivers Cu to COX11 and SCO1/2 before interacting,
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as a multi-metallochaperone module, with their target CcO subunits, first COX2 and then
COX1. The COX1/2-independent formation of the metallochaperone module is further
supported by demonstrating that COX11 interactions - particularly with COX19, COX10,
and the SCO1/2 proteins - are preserved in WT cells treated with chloramphenicol for
72h to inhibit mitochondrial protein synthesis, and thus preventing any accumulation of
COX1/2 (Fig. 4.7D and Fig. 4.9). The entrapment of COX10 in complexes with CuA and
CuB chaperones until their Cu-loading reflects a concerted regulation of metalation of all
the redox centers in CcO. Also, COA3 is detected in the same complexes with COX10,
and both factors are undetectable in complexes containing the COX2-COX20-COX18
module, up until the COX1-COA3-COX14 module is incorporated. These data suggest a
negative feedback regulatory loop to coordinate COX1 synthesis and stabilization with
heme a and copper bioavailability.
4.4.6 The redox and Cu-binding state of SCO1 and SCO2 are modified by CuA
and CuB assembly chaperones
Protein-protein interaction data predicts that the redox state and Cu binding to
the CuA metallochaperones SCO1/2 could depend on CuB assembly chaperones. SCO1
and SCO2 have different roles in CuA assembly (10). Cu(I)·COX17 delivers Cu(I) and
electrons to oxidized SCO1, but only Cu(I) to SCO2, which may be reduced by COA6 (2,
13, 14, 88, 89). SCO1 selectively transfers Cu(I) ions to COX2 based on loop
recognition, and SCO2 is a Cu-dependent thiol reductase of the CuA cysteine ligands in
COX2 (90). SCO1 and SCO2 have two essential cysteines (C169 and C173 in SCO1, and
C133 and C137 in SCO2), arranged in a thioredoxin fold, which together with a
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Fig. 4.9: Details of the interaction network of COX11. (A) Steady-state levels of the
mitochondrial respiratory chain complex subunits and assembly factors in the
indicated cell lines, assessed by immunoblotting with respective antibodies. ACTIN
served as the loading control. (B) Immunoprecipitation (IP) of COX20-FLAG in the
indicated cellular backgrounds analyzed as described in Figure S4. Ex, extract; Un,
unbound; IP, immunoprecipitate. (C) Steady-state levels of mitochondrial respiratory
chain complex subunits COX1 and COX2 and the indicated assembly factors in cells
incubated with or without 200 μg/ml chloramphenicol for 10 days. (D) IP of COX11FLAG in the indicated cellular backgrounds analyzed as described in panel (B). (E)
Steady-state levels of COX11, COX19, and CcO subunit COX2 in the indicated cell
lines, assessed by immunoblotting with respective antibodies. (F) CcO specific
activity measured spectrophotometrically. (G) Steady-state levels of complex IV
subassemblies, holocomplex, and supercomplexes in the indicated cell lines, detected
by BN-PAGE using an antibody against COX1. (H) IP of COX11-FLAG or
COX11C219D-FLAG in the indicated cellular backgrounds analyzed as described in
panel (B).
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conserved histidine constitute the Cu-binding residues. SCO2 has an additional cysteine
residue, C115, which is not near the copper coordination center. Each protein can have
the two key cysteines forming a disulfide, binding Cu, or reduced and Cu-free. In reverse
thiol trapping assays, the first two scenarios would result in the addition of two AMS
molecules, and none in the latter scenario. For SCO1, 75% of the protein binds 2AMS in
WT HEK293T or 143B cells. The proportion was elevated to 90% in COX16-KO cells,
decreased to 50% in COA6-KO or PET191-KO, and to 35% in COX11-KO or COX19KO, while it was restored to 60% in COX11-KO cells overexpressing PET191 (Fig.
4.10). No changes were observed in COX1 or COX2 cybrids, suggesting processes
independent of these core subunits. The data depicted a different pattern for SCO2. In
WT HEK293T and COX11-KO cells, 75% of SCO2 bound 2AMS, but increased to 100%
in COX16-KO cells. The absence of COA6 or PET191 lowered the proportion to 3540%, and the absence of COX19 to 20% (Fig. 4.10), suggesting SCO2-COX19 functional
cooperation. In WT 143B cells, 90% of SCO2 bound 2 AMS, compared to 65% in the
absence of COX1 or COX2 (Fig. 4.10), which may reflect slower redox recycling of
SCO2 in these scenarios.
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Fig. 4.10: SCO1/2 redox state and Cu binding are regulated by COX11, PET191, and
COX19. (A and F) Potential redox and Cu binding states of SCO1/2. (B, D, G, and I)
Reverse SCO1/2 thiol trapping in the indicated cell lines. (C, E, H, and J) The
graphs show the quantification of at least 3 independent experiments (mean ± SD).
Paired T-test, **p<0.01, ***p<0.001.
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4.4.7 Copper binding to SCO1/2 depends on COX19 or copper metalation of
COX11
To probe the interaction of apo-COX11 with the other metallochaperones we
generated cell lines expressing non-functional but stable C217D and C219D variants of
COX11 that mimic the SOH state of these residues (Fig. 4.9E-H). The point mutations
prevented COX19 accumulation and decreased COX2 levels as in COX11-KO cells,
although the residual amounts of COX2 remained associated with COX11 (Fig. 4.7D).
Moreover, the FLAG-tagged C219D variant co-IPed SCO1/2, COX10, and COX1 as did
the WT COX11 protein. However, it did co-IP 2-3-fold more of COA6, COX16, COX17,
PET191, COA3, and particularly SURF1, with which it forms a stable interaction (Fig.
4.7D). These data represent an accumulation of COX1 and COX2 metallochaperone
modules stalled in assembly. Inductively coupled plasma MS (ICP-MS) elemental
analysis revealed that these complexes do not contain appreciable quantities of bound Cu,
whereas we could detect significant amounts of Cu63 in the complexes associated which
WT COX11 (Fig. 4.11A). Thus, either the presence of apo-COX11 or, most likely, the
absence of COX19, impedes Cu binding by SCO1/SCO2, and probably also by COX17,
which is present in the metallochaperone modules. Moreover, IP of functional PET191FLAG, but not PET191(C30A, C41A)-FLAG, overexpressed in COX11-KO cells yielded
Cu levels 50% of the WT COX11-FLAG IP (Fig. 4.11A). On the contrary, IP of
PET191-FLAG expressed in PET191-KO cells did not yield any significant Cu signal
(Fig. 4.11A). Because PET191 does not interact with COX17 or SCO1/2 in any
background, the data demonstrate that PET191 binds Cu in the absence of COX11, but
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Fig. 4.11: COX11- and PET191-containing metallochaperone modules coordinate
copper and heme center assembly to minimize accumulation of pro-oxidant
deleterious CcO assembly intermediates. (A) Cu content in COX11- and PET191containing metallochaperone modules measured by ICP-MS. (B) ROS generation in
the indicated cell lines measured using superoxide-sensitive dyes dihydroethidium
(DHE) and MitoSOX and the H2O2-sensitive dichlorodihydrofluorescein diacetate
(CM-H2DCFDA). (C) H2O2 sensitivity measured as the release of lactate
dehydrogenase (LDH) to the growth medium.

223
in the presence of COX11, PET191 either does not bind Cu or binds it loosely.
4.4.8 Coordination of metal center assembly in COX1 minimizes the transient
accumulation of pro-oxidant heme A-Cox1 stalled intermediates
The trapping of COX10 and COX15 in complexes with CuA and CuB
chaperones, until the latter are Cu-charged, indicates a precise regulation of the
metallation of all the redox centers in CcO to coordinate the process and avoid
accumulation of pro-oxidant intermediates. In yeast and human cells, endogenous
superoxide production, measured with the fluorescent probes DHE and MitoSOX,
positively correlates with CcO activity and cellular respiration, as observed for the
COX11-KO, COX19-KO, and PET191-KO cells (Fig. 4.11B). However, the levels of
H2O2 detected by the probe H2DCFDA signal were enhanced in COX19-KO, and
PET191-KO cells (Fig. 4.11B). Heme a-Cox1 stalled intermediates are potentially
cytotoxic to cells as shown in yeast by the H2O2-sensitivity of sco1D and cox11D mutants
(3) and, to a lesser extent, in pet191D cells (Fig. 4.4D). The cox11D mutation yields an
H2O2-sensitivity phenotype dominant over other CcO mutations, including pet191D,
which can be prevented by blocking heme a synthesis by deleting the PET117 assembly
factor (Fig. 4.4D). Similarly, the human COX19-KO and PET191-KO lines are
hypersensitive to H2O2, a phenotype that can be ablated by COX10 silencing (Fig.
4.11C). These data indicate that the H2O2 sensitivity of COX19-KO and PET191-KO
lines arises from pro-oxidant Cox1 assembly intermediates involving COX1 and heme a,
which underscores the physiological need for coordination of heme a and Cu centers
assembly during CcO biogenesis.
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4.5 DISCUSSION
This study highlights a set of dynamic protein-protein interactions among
CcO-specific metallochaperones and assembly factors as well as regulatory checkpoints,
acting to ensure the coordinated and hierarchical assembly of metal centers in human
mitochondrial CcO. Our research provides a new paradigm to understand how the
synthesis of CcO core subunits and maturation, and assembly thereof are concerted to
prevent the accumulation of cytotoxic pro-oxidant intermediates. Our discovery could
impact the study and understanding of other multimeric enzymes carrying various metal
co-factors, such as the mitochondrial respiratory complex III (bc1 complex) (64) or the
bacterial nitrogenases that play a critical role in biological nitrogen fixation (65).
This work also discloses unanticipated levels of sophistication surrounding
CuB center assembly in human CcO. We find that contrary to the established dogma,
COX11 is important but dispensable in metazoans. Our screen for suppressors of the
partial CuB assembly defect of COX11-KO cells identified PET191 as a key contributor
in human cells. These proteins have relatively extensive stable and transient protein
interactomes that include heme a biosynthetic enzymes and CuA metallochaperones.
Mutations in many of these factors, including PET191, SCO1/2, COA6, COA3, COX14,
COX10, COX15, COX16, COX20, and SURF1, result in devastating human
mitochondrial cardio- and encephalomyopathies. Therefore, this study may also shed
light on the pathogenic mechanisms underlying these disorders.
The data reported herein represent an important step to unveil the mechanism
of action for several elusive twin CX9C proteins in the mitochondrial IMS. The role of
COX17 as a Cu-chaperone that transfers Cu to SCO1/2 and COX11 is well established
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(88, 91). Our work has identified PET191 as an apo-metallochaperone complex stabilizer
and the placeholder for COX17. Moreover, PET191 can also promote CuB assembly in
the absence of COX11. We also report that COX19 plays several roles: it regulates the
redox state of COX11 and cooperates with SCO2 in COX2 metalation.
Our results challenge the postulate that the maturation of COX1 and COX2
proceeds independently and sets the structural framework for CuB biogenesis
coordination with both heme a biosynthesis and CuA assembly. The data are compatible
with recent high-throughput Bio-ID studies in yeast that found Cox15 and Cox11 to
localize to mitoribosomal exit tunnel vicinity (92), and in human cells wherein, using
SCO1 as a prey, researchers captured COX11, COX19, COX17, COX16, SCO2, COA6,
COX5B-COX6B1, and COX15 (93, 94). As depicted in Fig. 6, our analyses demonstrate
that COX11, COX19, and PET191 stably interact with the CuA assembly factors SCO1SCO2-COA6 prior to Cu acquisition. This dual Cu-center assembly module subsequently
undergoes a substitution of PET191 by COX17, thereby enabling Cu transfer from
COX17 to the downstream metallochaperones. In the mature CcO, most CuA ligands lie
within a region of COX2 that interacts strongly with a shallow depression on the surface
of COX1, such that the accessibility of CuA to other proteins is minimal. This implies that
chaperone-mediated CuA assembly must occur before COX2 associates with
COX1. Concurrently, upon COX17 release, the metallochaperone module recruits and
inserts Cu into COX2 before recruiting and delivering Cu to COX1. At this stage, COX1
must be hemylated at least in the a site since it is detected in the COX19-KO and
PET191-KO lines. Our model does not address the mechanism and precise order of heme
loading into the a and a3 sites, which may involve presently unidentified heme delivery
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Fig. 4.12: Model of CcO assembly depicting the coordination of metal center
biogenesis. The role of metallochaperone modules and the several regulatory
checkpoints are indicated. See explanation in the text.
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factors. However, studies in R. sphaeroides (8) and yeast cox11Δ strains (3) have shown
that the heme a3 moiety can be delivered to this site in the absence of Cu. We cannot
discard that the CuB site formation could coincide with incorporation of the
heme a3 moiety into the heterobimetallic center.
Several regulatory mechanisms have been proposed to facilitate the formation
of the CcO metal centers while minimizing the formation of reactive assembly
intermediates. Different translation regulation mechanisms coordinate COX1 synthesis
and assembly in yeast (95) and human cells, wherein COA3 and COX14 interact with
nascent COX1 polypeptides (96). Heme a biosynthesis and incorporation into Cox1 in
yeast is regulated by assembly intermediates (97) harboring Cox15 with or without
association with Shy1, the homolog of human SURF1 (98). Our data show that human
COX11 forms complexes with COX10 and COX15 as well as COA3 in early apometallochaperone modules until they are Cu-loaded and competent to metalate COX2
and COX1. In that way, two novel negative feedback regulatory loops coordinate COX1
synthesis, CcO metal center formation, and holocomplex assembly, thereby minimizing
accumulation of deleterious reactive CcO assembly intermediates.
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Chapter 5: Summary and Conclusions
5.1 Final Discussion
Fe and Cu are essential cofactors for a plethora of cellular and mitochondrial
functions and are instrumental in maintaining cellular and mitochondrial homeostasis.
Within mitochondria, Fe is, in part, used to generate the metallolipid-like cofactor heme,
which is an essential cofactor for both the mitochondrion and cell (1-10). Fe, heme, and
Cu require meticulous, highly regulated transport due to their inherent cytotoxicity (11).
This thesis attempts to summarize and uncover new wrinkles in the mechanisms required
in the movement and utilization of these cofactors. In trying to answer these outstanding
questions, this thesis primarily focuses on the synthesis and trafficking of heme in the
yeast mitochondria, and the utilization of Cu in mammalian cytochrome c oxidase (CcO).
First, we investigated the molecular organization and structural features of the
terminal enzyme in heme biosynthesis, the yeast ferrochelatase Hem15. To this end, we
attempted to analyze the Hem15 interactome. Through this analysis, we found that
Hem15 resides in a high mass complex approximately 250-400 kDa, which requires
catalytically functional Hem15. Going forward, it would be intriguing and of great
interest to determine which protein interactions are lost when Hem15 catalytic activity is
disrupted. Further experimentation in this direction could provide significant insight
towards uncharacterized mitochondrial heme chaperones and proteins involved in
substrate delivery to Hem15. Furthermore, within the Hem15 high mass complex, we
revealed that Hem15 dynamically interacts with several subunits of the mitochondrial
contact site and cristae organizing system (MICOS), including the core component of
MICOS, Mic60, which are necessary for cristae formation and the bridging of the inner
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and outer mitochondrial membranes (12-14). Subsequent analysis of the relationship
between Hem15 and Mic60 showed that Mic60 is necessary for the proper formation of
the Hem15 high mass complex. We discovered that Hem15 overexpression in Mic60deficient yeast impaired respiratory growth and that in Mic60-lacking cells Hem15
catalytic activity was reduced. Upon analyzing mitochondrial Fe levels, heme levels and
trafficking, and cellular heme precursor content, we revealed that cytosolic heme
precursors are accumulating and causing oxidative damage and stress in MICOSdeficient cells. We were able to reverse this effect in cells lacking Mic60 and
overexpressing Hem15 with antioxidant treatment and by expressing an artificial
molecular bridge linking the outer and inner mitochondrial membranes. These latter data
show that it is most likely the bridging function of Mic60 that stimulates heme
biosynthesis. Ultimately, we uncovered that heme biosynthesis is stalled in Mic60deficient yeast by inefficient transport of heme precursors into mitochondria, a phenotype
that is amplified when Hem15 is overexpressed. The most probable proteins disrupted by
the absence of Mic60 in the heme biosynthetic pathway are mitochondrial porphyrin
transporters. To date, the mechanisms for mitochondrial porphyrin import are largely
unknown. Elucidating the factors involved and the fundamental mechanism behind this
process would provide a significant advancement in the field.
Next, we explored heme mobilization out of mitochondria. Using fluorescent
heme sensors, we found that heme is distributed to the nucleus quicker than to the cytosol
or mitochondrial matrix (14). Further analysis of these distribution dynamics revealed
that the initial enzyme in heme biosynthesis, aminolevulinic acid synthase
(ALAS/Hem1), negatively regulates heme trafficking to the nucleus while not affecting
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heme trafficking to the cytosol and mitochondrial matrix. Several conserved GTPases
related to mitochondrial dynamics (Mgm1 and Dnm1) and ER-mitochondria contact sites
(Gem1) were also shown to regulate heme trafficking to the nucleus (14). Mgm1 and
Dnm1 mediate mitochondrial fusion and fission, respectively (15). Just as they function
in dueling processes, Mgm1 and Dnm1 oppositely affect heme trafficking to the nucleus.
Mgm1, but no other mitochondrial fusion factor, positively regulates nuclear heme
localization, while Dnm1, but not other mitochondrial fission factor, negatively regulates
heme mobilization to the nucleus. It has been established that Gem1 negatively regulates
ER-mitochondria encounter sites (ERMES); however, we determined that Gem1 also
negatively regulates heme trafficking from mitochondria to the nucleus (14, 17, 18).
Interestingly, only Mgm1, Dnm1, and Gem1 are implicated in nuclear heme distribution,
while other factors involved in mitochondrial dynamics and ERMES regulation have no
effect on heme distribution. This poses the questions of how and why these specific
GTPases modulate heme localization to the nucleus and whether this new function is
linked to the established functions of these proteins. Furthermore, we also discovered that
heme regulates mitochondrial dynamics. When heme is depleted using the heme
biosynthesis inhibitor succinylacetone, mitochondria fragment in a mitochondria
membrane potential independent way. Altogether, these studies unveiled that heme
distribution and biosynthesis is tightly coupled to mitochondrial network behavior and
interorganellar interactions. These data were generated using the yeast Saccharomyces
cerevisiae model. Going forward, it will be interesting to determine if these conserved
pathways were also associated in higher order eukaryotes as well.
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Finally, we surveyed the mechanism behind Cu assembly into CcO. To analyze
this process, we specifically focused on the conserved Cu chaperones COX11 and SCO1
and SCO2, which load Cu into Cox1 and Cox2, respectively (19). In HEK293T cells, we
found that COX11 is dispensable for human CcO biogenesis, but its absence is
compensated for by the overexpression of the CcO assembly factor of unclear function
PET191. This is remarkable, because studies in yeast and bacteria showed that Cox11 is
exclusively involved in Cu metalation of Cox1, but our results indicate otherwise in
humans (20-23). We show that in mammalian mitochondria COX11 interacts with newly
synthesized Cox2 and that COX11 associates and cooperates with the metallochaperone
machinery involved in Cox2 metalation. In addition, we discovered that CcO assembly
factors previously earmarked for Cu-loading into CcO also maintain the proper redox
state and Cu-binding capacity of COX11, SCO1, and SCO2. Together, these data
represent a paradigm shift in how CcO maturation is understood. Previous studies in
yeast posited that the maturation of CcO subunits Cox1 and Cox2 occurred independently
and that the two proteins only associated with one another after assembly (19). However,
the work presented herein provides evidence that Cox1 and Cox2 assembly are closely
linked and cooperate with each other. There are still many outstanding questions
regarding CcO assembly. Although this work gave insight towards the role of PET91 in
Cu loading of Cox1 and Cox2, the mechanism of action for this small protein remains
elusive in both yeast and mammals. In addition to containing three Cu cofactors, CcO
also harbors two heme a prosthetic groups. To date, it is unclear how heme a is
transported to and inserted into Cox1.
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The topics and results discussed in this thesis provide significant insight into
heme biosynthesis and trafficking and Cu integration into CcO. The questions that were
answered herein are only the beginning to fully understanding these processes in
mitochondria. Thorough future investigation into mitochondrial heme and Cu metabolism
will further provide greater knowledge and understanding of mitochondrial function and
homeostasis.
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